Session » 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 542

‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story

9:00AM-11:00AM: Abstract Number: 492

‘It Felt Like I Was Walking on Rocks” Patients Share First Symptoms of RA

9:00AM-11:00AM: Abstract Number: 134

‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort

9:00AM-11:00AM: Abstract Number: 583

A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 511

A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 524

A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 219

A Fibromyalgia Assessment Screening Tool on a Multidimensional Health Assessment Questionnaire (MDHAQ) Which Does Not Include a Self-Report RADAI Painful Joint Count (RADAI), FAST3nJC, Recognizes Fibromyalgia Similarly to Other FAST3 Indices Which Include a RADAI

9:00AM-11:00AM: Abstract Number: 224

A Functional Exercise Program Improves Pain and Health Related Quality of Life in Patients with Fibromyalgia: A Randomized Controllel Trial

9:00AM-11:00AM: Abstract Number: 192

A Healthy Plant-Rich Diet and the Risk of Rheumatoid Arthritis in Women

9:00AM-11:00AM: Abstract Number: 646

A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody

9:00AM-11:00AM: Abstract Number: 54

A Metagenome-wide Association Study of Gut Microbiome Revealed Novel Etiology of Rheumatoid Arthritis in the Japanese Population

9:00AM-11:00AM: Abstract Number: 755

A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT

9:00AM-11:00AM: Abstract Number: 641

A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 424

A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index

9:00AM-11:00AM: Abstract Number: 6

A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 55

A Novel Subclass of Intravascular Non-classical, Tissue Resident Synovial Monocyte Is Critical for Rheumatoid Arthritis Pathogenesis

9:00AM-11:00AM: Abstract Number: 532

A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics

9:00AM-11:00AM: Abstract Number: 503

A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects

9:00AM-11:00AM: Abstract Number: 514

A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 220

A Positive Response to Nonpharmacological Therapies in Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 319

A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 155

A Prospective, Unblinded, Non-randomized Pilot Study Examining the Effect of a Musculoskeletal Immersion Curriculum for First Year Internal Medicine Residents

9:00AM-11:00AM: Abstract Number: 147

A Qualitative Study of Factors That Influence Interest in a Career in Pediatric Rheumatology

9:00AM-11:00AM: Abstract Number: 539

A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA

9:00AM-11:00AM: Abstract Number: 162

A Shared Mental Model for Teaching and Assessing Examination of the Hand, Wrist, and Elbow in the “Training Rheum” Continuing Professional Development Program

9:00AM-11:00AM: Abstract Number: 152

A Shoulder to Lean On: Differences in Shoulder Examinations Between Rheumatology Educators and Fellows

9:00AM-11:00AM: Abstract Number: 517

A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

9:00AM-11:00AM: Abstract Number: 504

A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 253

A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 731

A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)

9:00AM-11:00AM: Abstract Number: 705

A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries

9:00AM-11:00AM: Abstract Number: 200

A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records

9:00AM-11:00AM: Abstract Number: 756

A Volar Pattern of 18F-Fluorodeoxyglucose Uptake at the Hand on Whole Body PET/CT Predicts Glucocorticoid-Responsive Disease in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 30

Aberrant M1 Polarization of Macrophages in Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 32

Aberration of Histone Lysine Methylation in Adult-Onset Still’s Disease Are Novel Biomarker Candidates Associated with the Disease Activity

9:00AM-11:00AM: Abstract Number: 185

Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 190

Accuracy of Administrative Algorithms for Identifying Interstitial Lung Disease in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 450

ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography

9:00AM-11:00AM: Abstract Number: 389

ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis

9:00AM-11:00AM: Abstract Number: 53

Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis

9:00AM-11:00AM: Abstract Number: 222

Acupuncture for Chronic Musculoskeletal Pain: A Review of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 330

Acute Gout Attacks Among Patients Admitted Due to Heart Failure: Analysis of NIS Database

9:00AM-11:00AM: Abstract Number: 135

Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations

9:00AM-11:00AM: Abstract Number: 158

Addressing the Pediatric Rheumatology Physician Shortage: Does Early Exposure Matter?

9:00AM-11:00AM: Abstract Number: 248

Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel

9:00AM-11:00AM: Abstract Number: 324

Adherence to Guideline Directed Management of Gout Among VA Providers

9:00AM-11:00AM: Abstract Number: 321

Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 691

Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina

9:00AM-11:00AM: Abstract Number: 120

Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 328

Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events

9:00AM-11:00AM: Abstract Number: 674

Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 639

African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup

9:00AM-11:00AM: Abstract Number: 257

Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data

9:00AM-11:00AM: Abstract Number: 581

Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 353

Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study

9:00AM-11:00AM: Abstract Number: 25

Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis

9:00AM-11:00AM: Abstract Number: 27

Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 66

Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

9:00AM-11:00AM: Abstract Number: 725

Amniotic Membrane Dressings Provide an Effective Treatment for Systemic Sclerosis Digital Ulcers

9:00AM-11:00AM: Abstract Number: 4

AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine

9:00AM-11:00AM: Abstract Number: 166

An Analysis of Inpatient Rheumatology Consults at an Academic Military Medical Center over 16 Years: Do Consults Requests Accurately Reflect the Curriculum and Prepare Fellows for Board Certification and Future Practice?

9:00AM-11:00AM: Abstract Number: 421

An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 632

An Observational Analysis of the Co-existence of Brugada Syndrome in Patients with Spondyloarthritis; A Potentially Important Link

9:00AM-11:00AM: Abstract Number: 307

ANA-lysis: Utility of Repeated Antinuclear Antibody Testing in a Single Center

9:00AM-11:00AM: Abstract Number: 561

Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)

9:00AM-11:00AM: Abstract Number: 768

Angiographic Patterns and Changes in Arterial Lesions in Patients with Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 70

Angiotensin Receptor Blockers Prevent Loss of Dendritic Complexity in a Lupus Mouse Model of Cognitive Impairment

9:00AM-11:00AM: Abstract Number: 610

Ankylosing Spondylitis-associated Killer Immunoglobin-like Receptors Are Strongly Expressed on γδ T Cells

9:00AM-11:00AM: Abstract Number: 452

Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients

9:00AM-11:00AM: Abstract Number: 405

Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature

9:00AM-11:00AM: Abstract Number: 131

Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population

9:00AM-11:00AM: Abstract Number: 132

Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 455

Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use

9:00AM-11:00AM: Abstract Number: 133

Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 126

Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS

9:00AM-11:00AM: Abstract Number: 482

Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis

9:00AM-11:00AM: Abstract Number: 142

Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities

9:00AM-11:00AM: Abstract Number: 660

Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease

9:00AM-11:00AM: Abstract Number: 139

Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE

9:00AM-11:00AM: Abstract Number: 144

Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype

9:00AM-11:00AM: Abstract Number: 409

Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment

9:00AM-11:00AM: Abstract Number: 765

Application of Different Sets of Classification/diagnostic Criteria for Polymyalgia Rheumatica: Single Center Study of 100 Patients

9:00AM-11:00AM: Abstract Number: 784

Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease

9:00AM-11:00AM: Abstract Number: 799

Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital

9:00AM-11:00AM: Abstract Number: 654

Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 744

Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica?

9:00AM-11:00AM: Abstract Number: 603

Are the Modified New York and ASAS Criteria Interchangeable in the Classification of Patients with Spondyloarthritis with Radiographic Sacroiliitis?

9:00AM-11:00AM: Abstract Number: 762

Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study

9:00AM-11:00AM: Abstract Number: 626

Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas

9:00AM-11:00AM: Abstract Number: 620

Arterial Elasticity by 2 Dimensional Circumferential Strain and Beta Stiffness Index in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 564

ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 198

Assessing Care Quality in Rheumatology Services

9:00AM-11:00AM: Abstract Number: 428

Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 655

Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 630

Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database

9:00AM-11:00AM: Abstract Number: 333

Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients

9:00AM-11:00AM: Abstract Number: 295

Assessing the Vascularization of Salivary Glands in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Group Reliability Exercise

9:00AM-11:00AM: Abstract Number: 496

Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort

9:00AM-11:00AM: Abstract Number: 528

Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 420

Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials

9:00AM-11:00AM: Abstract Number: 743

Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-a(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations

9:00AM-11:00AM: Abstract Number: 670

Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan

9:00AM-11:00AM: Abstract Number: 643

Association Between Neutrophil to Lymphocyte, Monocyte to Lymphocyte, and Platelet to Lymphocyte Ratios and Lupus Disease Activity and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 635

Association Between Radiographic Progression and Cardiovascular Risk in Spondyloarthritis: Data from CoSpaR REGISTRY

9:00AM-11:00AM: Abstract Number: 686

Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort

9:00AM-11:00AM: Abstract Number: 616

Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort

9:00AM-11:00AM: Abstract Number: 645

Association of Co-positivity for Anti-dsDNA, -Nucleosome, and -Histone Antibodies and Disease Activity in Patients with Lupus Nephritis: Results from the KORNET Registry

9:00AM-11:00AM: Abstract Number: 580

Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study

9:00AM-11:00AM: Abstract Number: 701

Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 661

Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 175

Associations Between Circulating Cytokines and Incident Inflammatory Arthritis in an Anti-citrullinated Protein Antibody Positive Population

9:00AM-11:00AM: Abstract Number: 210

Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease

9:00AM-11:00AM: Abstract Number: 474

Associations of Plasma Extravesicular (EV) MicroRNA Levels in Seropositive and Seronegative Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 191

Associations of Self-Reported Inhalant Exposures with Autoantibodies and Disease Severity in U.S. Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 345

Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey

9:00AM-11:00AM: Abstract Number: 625

Associations of Work-Related Abilities with Disability in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 186

Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 269

Attitudes and Beliefs About Opioid Medications: Determining Treatment Use in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 404

Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis

9:00AM-11:00AM: Abstract Number: 52

Autophagy Protein Microtubule-associated Protein 1 Light chain-3B (LC3B) Regulates Joint Inflammation and Destruction in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 38

Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 47

Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity

9:00AM-11:00AM: Abstract Number: 430

Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients

9:00AM-11:00AM: Abstract Number: 624

Axial Spondyloarthritis: Knowledge, Screening and Referral Practices Amongst Primary Care Providers

9:00AM-11:00AM: Abstract Number: 609

Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort

9:00AM-11:00AM: Abstract Number: 2

Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 720

Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 45

bDMARD-experienced Filgotinib-treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population

9:00AM-11:00AM: Abstract Number: 22

Beta-2 Glycoprotein I as a DNA- and NET-binding Protein

9:00AM-11:00AM: Abstract Number: 167

Bioethics for the Rheumatologist: A Needs-Assessment, Curriculum Development, and Knowledge Assessment of Bioethical Topics for Rheumatology Trainees

9:00AM-11:00AM: Abstract Number: 110

Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 683

Biologic Differences Between Type 1 and 2 Lupus

9:00AM-11:00AM: Abstract Number: 11

Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy

9:00AM-11:00AM: Abstract Number: 724

Biomechanical Properties of Skin for Assessment of Scleroderma: A Systemic Review

9:00AM-11:00AM: Abstract Number: 123

Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope

9:00AM-11:00AM: Abstract Number: 694

Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE

9:00AM-11:00AM: Abstract Number: 273

Bone Health in Lupus: Findings from the Southern California Lupus Registry

9:00AM-11:00AM: Abstract Number: 364

Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series

9:00AM-11:00AM: Abstract Number: 483

Can a Single Question on Functional Impairments Facilitate the Diagnosis of Early Inflammatory Arthritis? A Cross-Sectional Derivation and Validation Study in Two Early Arthritis Recognition Clinics

9:00AM-11:00AM: Abstract Number: 613

Can Fecal Calprotectin Predict Future Development of Inflammatory Bowel Disease in Axial Spondyloarthritis Patients? – TReasure Real-Life Preliminary Data

9:00AM-11:00AM: Abstract Number: 790

Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?

9:00AM-11:00AM: Abstract Number: 283

Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD

9:00AM-11:00AM: Abstract Number: 802

Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 745

Cardiac Involvements Are Related to Poor Prognosis in Patients with Takayasu’s Arteritis in China

9:00AM-11:00AM: Abstract Number: 326

Cardiac Sarcoidosis Awareness: Are We Underdiagnosing?

9:00AM-11:00AM: Abstract Number: 349

Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study

9:00AM-11:00AM: Abstract Number: 687

CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race

9:00AM-11:00AM: Abstract Number: 101

CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 65

CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE

9:00AM-11:00AM: Abstract Number: 115

CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues

9:00AM-11:00AM: Abstract Number: 84

Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 448

Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory

9:00AM-11:00AM: Abstract Number: 546

Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX

9:00AM-11:00AM: Abstract Number: 780

Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation

9:00AM-11:00AM: Abstract Number: 797

Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 714

Characteristics of Patients with Systemic Sclerosis in the Rheumatology Informatics System for Effectiveness (RISE) Registry

9:00AM-11:00AM: Abstract Number: 529

Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators

9:00AM-11:00AM: Abstract Number: 96

Characterizing the Brain T Cell Receptor Repertoire in Neuropsychiatric Lupus

9:00AM-11:00AM: Abstract Number: 9

Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 749

Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort

9:00AM-11:00AM: Abstract Number: 746

Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK

9:00AM-11:00AM: Abstract Number: 56

Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly

9:00AM-11:00AM: Abstract Number: 773

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation

9:00AM-11:00AM: Abstract Number: 402

Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy

9:00AM-11:00AM: Abstract Number: 256

Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States

9:00AM-11:00AM: Abstract Number: 51

Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)

9:00AM-11:00AM: Abstract Number: 50

Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 488

Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis

9:00AM-11:00AM: Abstract Number: 7

Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 8

CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling

9:00AM-11:00AM: Abstract Number: 365

Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 494

Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective

9:00AM-11:00AM: Abstract Number: 143

Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 675

Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease

9:00AM-11:00AM: Abstract Number: 684

Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 673

Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center

9:00AM-11:00AM: Abstract Number: 397

Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia

9:00AM-11:00AM: Abstract Number: 302

Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center

9:00AM-11:00AM: Abstract Number: 396

Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflamatory Myopathies: Data from the REMICAM Registry

9:00AM-11:00AM: Abstract Number: 174

Clinical Presentation and Disease Course Evaluation of Mono- and Bilateral Knee Arthritis: Results from the Leiden Early Arthritis Clinic Cohort

9:00AM-11:00AM: Abstract Number: 652

Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody

9:00AM-11:00AM: Abstract Number: 515

Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

9:00AM-11:00AM: Abstract Number: 791

Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 676

Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments

9:00AM-11:00AM: Abstract Number: 360

Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis

9:00AM-11:00AM: Abstract Number: 245

Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015

9:00AM-11:00AM: Abstract Number: 20

Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation

9:00AM-11:00AM: Abstract Number: 355

Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol

9:00AM-11:00AM: Abstract Number: 241

Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise

9:00AM-11:00AM: Abstract Number: 540

Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar

9:00AM-11:00AM: Abstract Number: 557

Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

9:00AM-11:00AM: Abstract Number: 182

Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts

9:00AM-11:00AM: Abstract Number: 279

Comparison of Carotid Ultrasound and Coronary Artery Calcium Score in Cardiovascular Risk Stratification of Patients with Inflammatory Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 485

Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis

9:00AM-11:00AM: Abstract Number: 150

Comparison of Debate vs. Lecture to Teach Medical Students Pediatric Rheumatology

9:00AM-11:00AM: Abstract Number: 602

Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 433

Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 688

Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort

9:00AM-11:00AM: Abstract Number: 669

Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria

9:00AM-11:00AM: Abstract Number: 642

Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 787

Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 323

Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients

9:00AM-11:00AM: Abstract Number: 243

Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment

9:00AM-11:00AM: Abstract Number: 429

Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results

9:00AM-11:00AM: Abstract Number: 464

Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage

9:00AM-11:00AM: Abstract Number: 417

Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 223

Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia

9:00AM-11:00AM: Abstract Number: 427

Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD

9:00AM-11:00AM: Abstract Number: 682

Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population

9:00AM-11:00AM: Abstract Number: 692

Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker

9:00AM-11:00AM: Abstract Number: 23

Covalent High Molecular Weight HMGB1 Complexes in Muscle Regeneration: Implications in Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 444

Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration

9:00AM-11:00AM: Abstract Number: 800

Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience

9:00AM-11:00AM: Abstract Number: 775

Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin

9:00AM-11:00AM: Abstract Number: 534

CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 15

CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment

9:00AM-11:00AM: Abstract Number: 543

Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 560

Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort

9:00AM-11:00AM: Abstract Number: 769

Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up

9:00AM-11:00AM: Abstract Number: 644

Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis

9:00AM-11:00AM: Abstract Number: 476

Decreased Muscle Mass, a Novel Predicting Indicator for One-year Radiographic Progression in Rheumatoid Arthritis: A Real-world Cohort Study

9:00AM-11:00AM: Abstract Number: 116

Defective EZH2 Expression Attenuates Treg Differentiation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 299

Definition of New Ultrasound Enthesophytes Score: Application in a Consecutive Series of IBD Patients

9:00AM-11:00AM: Abstract Number: 717

Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities

9:00AM-11:00AM: Abstract Number: 178

Depression: A Common Comorbidity in Rheumatic Diseases. a Case-Control Study

9:00AM-11:00AM: Abstract Number: 339

Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate

9:00AM-11:00AM: Abstract Number: 67

Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model

9:00AM-11:00AM: Abstract Number: 259

Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty

9:00AM-11:00AM: Abstract Number: 255

Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers

9:00AM-11:00AM: Abstract Number: 237

Determination of Muscle Pressure in Patients with Fibromyalgia by Two Examiners; The Examiners Get Similar Results

9:00AM-11:00AM: Abstract Number: 747

Detrimental Factors Affecting the First-year Clinical Response in Korean Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 267

Develop Risk Prediction Model and Drug Withdrawl Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 168

Development and Usability Testing of Take Charge: An Email Series to Increase Knowledge of Self-Management Skills in People with Lupus

9:00AM-11:00AM: Abstract Number: 341

Development of a Multivariable Improvement Measure for Gout

9:00AM-11:00AM: Abstract Number: 562

Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 601

Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis – Data from the OptiRef Study

9:00AM-11:00AM: Abstract Number: 798

Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model

9:00AM-11:00AM: Abstract Number: 145

Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results

9:00AM-11:00AM: Abstract Number: 718

Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions

9:00AM-11:00AM: Abstract Number: 723

Diagnosis of Systemic Sclerosis: How and When

9:00AM-11:00AM: Abstract Number: 633

Diagnostic Delay in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 491

Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 559

Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 193

Diet as a Risk Factor for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 89

Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis

9:00AM-11:00AM: Abstract Number: 783

Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients

9:00AM-11:00AM: Abstract Number: 425

Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN

9:00AM-11:00AM: Abstract Number: 697

Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients

9:00AM-11:00AM: Abstract Number: 726

Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 659

Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity

9:00AM-11:00AM: Abstract Number: 521

Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 36

Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers

9:00AM-11:00AM: Abstract Number: 440

Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome

9:00AM-11:00AM: Abstract Number: 502

Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 658

Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study

9:00AM-11:00AM: Abstract Number: 719

Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth

9:00AM-11:00AM: Abstract Number: 385

Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 786

Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 493

Diversity Analysis of Intestinal Flora in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 789

DNASE1L3 Variant in Hypocomplementemic Urticarial Vasculitis Syndrome Identifies a Different Clinical Phenotype

9:00AM-11:00AM: Abstract Number: 604

Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort

9:00AM-11:00AM: Abstract Number: 311

Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 205

Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 739

Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?

9:00AM-11:00AM: Abstract Number: 216

Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies

9:00AM-11:00AM: Abstract Number: 432

Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 289

Doppler in Entheses: A Potential Useful Outcome in Active Spondyloarthritis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 586

Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial

9:00AM-11:00AM: Abstract Number: 752

Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 231

Duloxetine for Chronic Pain Management in a Tertiary Care Rheumatology Practice: How Patients Are Doing in the Real World

9:00AM-11:00AM: Abstract Number: 754

Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naïve and Treated Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 83

Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5

9:00AM-11:00AM: Abstract Number: 140

Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis

9:00AM-11:00AM: Abstract Number: 387

Early Mortality in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 572

Early Recognition of Patients with Axial Spondyloarthritis by Using a Practical Referral System – Evaluation of the Recently Proposed 2-step Strategy

9:00AM-11:00AM: Abstract Number: 177

Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal

9:00AM-11:00AM: Abstract Number: 468

Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C – Reactive Protein Levels with the Body’s Inflammatory Status

9:00AM-11:00AM: Abstract Number: 76

Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

9:00AM-11:00AM: Abstract Number: 571

Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry

9:00AM-11:00AM: Abstract Number: 338

Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults

9:00AM-11:00AM: Abstract Number: 585

Effect of Testosterone on Spinal Ankylosis in Ankylosing Spondylitis : in Vivo and in Vitro

9:00AM-11:00AM: Abstract Number: 381

Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 484

Effectiveness of Platelet-derived Microparticles for the Diagnosis and Clinical Evaluation of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 276

Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 606

Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 211

Effects of Deep Haptic Massage in Fibromyalgia (pilot Study)

9:00AM-11:00AM: Abstract Number: 615

Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 207

Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 218

Effects of Tai Chi versus Aerobic Exercise on Mindfulness in Fibromyalgia

9:00AM-11:00AM: Abstract Number: 363

Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout

9:00AM-11:00AM: Abstract Number: 548

Efficacy and Safety of a Novel Subcutaneous Formulation of CT-P13 over the 1-year Treatment Period and After Switching from Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 506

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results

9:00AM-11:00AM: Abstract Number: 531

Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 512

Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY

9:00AM-11:00AM: Abstract Number: 520

Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA

9:00AM-11:00AM: Abstract Number: 537

Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA

9:00AM-11:00AM: Abstract Number: 277

Efficacy of a Counselling Program to Promote Physical Activity in People with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 519

Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components

9:00AM-11:00AM: Abstract Number: 206

Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study

9:00AM-11:00AM: Abstract Number: 310

Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biossimilar CT-P13 of All Patients with Inflamatory Arthritis from a Single Center

9:00AM-11:00AM: Abstract Number: 127

Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 125

Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 412

Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 640

Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers

9:00AM-11:00AM: Abstract Number: 358

Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients

9:00AM-11:00AM: Abstract Number: 343

Emergency Department Length of Stay in Patients with Acute Gout

9:00AM-11:00AM: Abstract Number: 221

Emergency Department Utilization for Fibromyalgia Patients

9:00AM-11:00AM: Abstract Number: 57

Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 730

Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma

9:00AM-11:00AM: Abstract Number: 594

Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort

9:00AM-11:00AM: Abstract Number: 154

Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting

9:00AM-11:00AM: Abstract Number: 695

Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis

9:00AM-11:00AM: Abstract Number: 187

Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort

9:00AM-11:00AM: Abstract Number: 553

Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 501

EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies

9:00AM-11:00AM: Abstract Number: 170

Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 225

Evaluating Fibromyalgia Symptoms in Transgender Patients

9:00AM-11:00AM: Abstract Number: 288

Evaluating the Performance of a Single-site Musculoskeletal Ultrasound Clinic Associated with an Academic Rheumatology Practice: Diagnostic and Therapeutic Impact on Patient Care and Survey of Patient and Physician Satisfaction

9:00AM-11:00AM: Abstract Number: 160

Evaluation of ACGME Competencies in a Rheumatology Observed Structured Clinical Examination

9:00AM-11:00AM: Abstract Number: 354

Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis

9:00AM-11:00AM: Abstract Number: 59

Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA

9:00AM-11:00AM: Abstract Number: 249

Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity

9:00AM-11:00AM: Abstract Number: 623

Evaluation of the Early Cervical Structural Changes in Patients with Non-Radiographic Axial Spondyloarthropathy

9:00AM-11:00AM: Abstract Number: 681

Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population

9:00AM-11:00AM: Abstract Number: 554

Evidence to Guide Glucocorticoid Tapering Is Lacking in RA

9:00AM-11:00AM: Abstract Number: 565

Evidence-Based Recommendations for the Management of Enteropathic Arthritis: A Rheumatology – Gastroenterology Collaborative Initiative

9:00AM-11:00AM: Abstract Number: 486

Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 329

Excessive Alcohol Intake Is Associated with Tophi Formation in Gout Patients

9:00AM-11:00AM: Abstract Number: 275

Exercise Is Medicine® in Primary Care Practice: Provider Characteristics and Physical Activity Counseling for Patients with Arthritis, DocStyles, 2018

9:00AM-11:00AM: Abstract Number: 107

Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium

9:00AM-11:00AM: Abstract Number: 607

Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 375

Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center

9:00AM-11:00AM: Abstract Number: 535

Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA

9:00AM-11:00AM: Abstract Number: 183

Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry

9:00AM-11:00AM: Abstract Number: 750

Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort

9:00AM-11:00AM: Abstract Number: 575

Facet Joint Ankylosis on Whole Spine Low-Dose CT in Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 618

Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 525

Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 344

Factors Associated with the Disappearance of Calcifications Following Ultrasound Guided Percutaneous Lavage of Rotator Cuff Calcific Tendinopathy: A Post Hoc Analysis of a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 291

Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound

9:00AM-11:00AM: Abstract Number: 526

Factors Influencing Discontinuation in Long-term RA Treatment

9:00AM-11:00AM: Abstract Number: 293

False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign

9:00AM-11:00AM: Abstract Number: 460

Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels

9:00AM-11:00AM: Abstract Number: 217

Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis

9:00AM-11:00AM: Abstract Number: 77

Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells

9:00AM-11:00AM: Abstract Number: 325

Frailty and Sarcopenia in Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 558

Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center

9:00AM-11:00AM: Abstract Number: 411

Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies

9:00AM-11:00AM: Abstract Number: 361

Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares

9:00AM-11:00AM: Abstract Number: 408

Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome

9:00AM-11:00AM: Abstract Number: 600

Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)

9:00AM-11:00AM: Abstract Number: 265

Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline

9:00AM-11:00AM: Abstract Number: 281

Frequency of Ultrasound Features of Knee Osteoarthritis and Their Association with Radiographic Features and Symptoms in a Community-Based Cohort

9:00AM-11:00AM: Abstract Number: 264

Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort

9:00AM-11:00AM: Abstract Number: 577

Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients

9:00AM-11:00AM: Abstract Number: 629

Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting

9:00AM-11:00AM: Abstract Number: 776

Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma

9:00AM-11:00AM: Abstract Number: 416

Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review

9:00AM-11:00AM: Abstract Number: 228

Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients

9:00AM-11:00AM: Abstract Number: 356

Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study

9:00AM-11:00AM: Abstract Number: 337

Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study

9:00AM-11:00AM: Abstract Number: 331

Gout Management in the Medical Community: A Claims-Based Analysis

9:00AM-11:00AM: Abstract Number: 33

GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes

9:00AM-11:00AM: Abstract Number: 693

Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 232

Hand Digital Thermography Findings in Patients with Primary Fibromyalgia

9:00AM-11:00AM: Abstract Number: 247

Health Literacy, Adherence, and Quality of Life of Uveitis Patients

9:00AM-11:00AM: Abstract Number: 263

Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France

9:00AM-11:00AM: Abstract Number: 258

Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 803

Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment

9:00AM-11:00AM: Abstract Number: 165

Heterogeneity of Strategies and Methods for Assessment of Competences in Rheumatology Training: Results of a Systematic Literature Review to Inform EULAR Points to Consider

9:00AM-11:00AM: Abstract Number: 446

High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire

9:00AM-11:00AM: Abstract Number: 597

High Prevalence of Sacroiliac Bone Marrow Edema on MRI in Post Partum Women: A Temporary Phenomenom

9:00AM-11:00AM: Abstract Number: 463

High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis

9:00AM-11:00AM: Abstract Number: 91

Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 637

How Often Should SLE Patients Be Tested for Lupus Anticoagulant?

9:00AM-11:00AM: Abstract Number: 214

How Well Do Visual Analogue Scales Used in the Fibromyalgia Impact Questionnaire (FIQ) Correlate with Other Measures of Pain, Fatigue, Sleep, Sleep Disturbance, Anxiety and Depression in Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 62

Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway

9:00AM-11:00AM: Abstract Number: 320

Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

9:00AM-11:00AM: Abstract Number: 322

Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population

9:00AM-11:00AM: Abstract Number: 226

Hypersensitivity Beyond Pain: Hyperacusis and Hyperalgesia of Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 774

Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 573

Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years – Evaluation of Data from a Large Community Study

9:00AM-11:00AM: Abstract Number: 201

Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies

9:00AM-11:00AM: Abstract Number: 598

Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 180

Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 136

Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients

9:00AM-11:00AM: Abstract Number: 386

Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain

9:00AM-11:00AM: Abstract Number: 95

IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE

9:00AM-11:00AM: Abstract Number: 286

Imaging Neoangiogenesis in Rheumatoid Arthritis (INIRA): Whole-Body Synovial Uptake of a 99mTc-Labelled RGD Peptide Is Highly Correlated with Power Doppler Ultrasound

9:00AM-11:00AM: Abstract Number: 715

Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 21

Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody

9:00AM-11:00AM: Abstract Number: 479

Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 516

Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib

9:00AM-11:00AM: Abstract Number: 284

Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in Rheumatoid Arthritis : Multicenter and Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 533

Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients

9:00AM-11:00AM: Abstract Number: 359

Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge

9:00AM-11:00AM: Abstract Number: 112

Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 261

Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 316

Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA

9:00AM-11:00AM: Abstract Number: 151

Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients

9:00AM-11:00AM: Abstract Number: 439

Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection

9:00AM-11:00AM: Abstract Number: 708

Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences

9:00AM-11:00AM: Abstract Number: 278

Improving a SLE-Quality Indicator Tool in an Outpatient Tertiary Care Setting

9:00AM-11:00AM: Abstract Number: 317

Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative

9:00AM-11:00AM: Abstract Number: 704

Improving Patient-Centered Care by Utilizing Lupus Wellness Program

9:00AM-11:00AM: Abstract Number: 318

Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 315

Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire

9:00AM-11:00AM: Abstract Number: 298

In CCP Positive “At Risk of Rheumatoid Arthritis” Individuals, the Presence of Sub-clinical Synovitis in 4-10joints Universally Results in Clinical Synovitis

9:00AM-11:00AM: Abstract Number: 290

In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?

9:00AM-11:00AM: Abstract Number: 58

In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets

9:00AM-11:00AM: Abstract Number: 552

In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients

9:00AM-11:00AM: Abstract Number: 113

In Vitro Characterization of the Effect of Cenerimod, a Potent and Selective Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulator, on S1P1 Receptor Expression, Receptor Internalization, and Migration of Primary Human T Cells in the Presence or Absence of Glucocorticoids

9:00AM-11:00AM: Abstract Number: 121

In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition

9:00AM-11:00AM: Abstract Number: 68

Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 332

Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis

9:00AM-11:00AM: Abstract Number: 453

Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status

9:00AM-11:00AM: Abstract Number: 340

Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels

9:00AM-11:00AM: Abstract Number: 587

Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study

9:00AM-11:00AM: Abstract Number: 26

Increased Sodium Accumulation Detected by 23Na-Magnetic Resonance Imaging in Inflamed Knees of Patients with Autoimmune Joint Disease

9:00AM-11:00AM: Abstract Number: 106

Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects

9:00AM-11:00AM: Abstract Number: 309

Increasing Capacity and Reducing Costs of Rituximab Administration

9:00AM-11:00AM: Abstract Number: 40

Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 477

Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients

9:00AM-11:00AM: Abstract Number: 306

Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders

9:00AM-11:00AM: Abstract Number: 19

Inhibition of IkB Kinase-IKK Complex of Canonical NF-κB Pathway in Antiphospholipid Antibody-Mediated Endothelial Cell Activation

9:00AM-11:00AM: Abstract Number: 507

Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan

9:00AM-11:00AM: Abstract Number: 122

Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis

9:00AM-11:00AM: Abstract Number: 71

Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival

9:00AM-11:00AM: Abstract Number: 547

Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 753

Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 233

Intensive CBT Is Effective in the Treatment of Significant Functional Impairment and Psychological Distress Found in Fibromyalgia: But Can We Improve Depressive Symptoms?

9:00AM-11:00AM: Abstract Number: 5

Interferon Kappa Promotes the Development of Psoriasis

9:00AM-11:00AM: Abstract Number: 93

Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis

9:00AM-11:00AM: Abstract Number: 777

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI

9:00AM-11:00AM: Abstract Number: 758

Interleukin-6 May Predict Disease Relapse During Long-term Follow-up in Takayasu’s Arteritis in a Han Chinese Population

9:00AM-11:00AM: Abstract Number: 1

Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 254

Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population

9:00AM-11:00AM: Abstract Number: 37

Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 12

Intraarticular and Circulatory Cytokine Responses to Chlamydia Trachomatis: A Clinical Study in Reactive Arthritis/ Undifferentiated Spondyloarthropathy Patients

9:00AM-11:00AM: Abstract Number: 770

Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 647

Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?

9:00AM-11:00AM: Abstract Number: 781

Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?

9:00AM-11:00AM: Abstract Number: 229

Is Fibromyalgia Associated with Structural or Functional Abnormalities in Skeletal Muscle?

9:00AM-11:00AM: Abstract Number: 292

Is Shoulder Involvement an Early Feature of Rheumatoid Arthritis in Clinically Suspect Arthralgia? A Longitudinal Ultrasound Study

9:00AM-11:00AM: Abstract Number: 172

Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014

9:00AM-11:00AM: Abstract Number: 795

Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 579

Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?

9:00AM-11:00AM: Abstract Number: 437

Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?

9:00AM-11:00AM: Abstract Number: 130

Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting

9:00AM-11:00AM: Abstract Number: 434

Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 209

Joint Overuse in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 46

Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs

9:00AM-11:00AM: Abstract Number: 87

KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 668

Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population

9:00AM-11:00AM: Abstract Number: 268

LARS Study: Latin American Rheumatologist Survey

9:00AM-11:00AM: Abstract Number: 164

Learner Practice Gaps in Osteoporosis: Piloting a Metabolic Bone Disease Curriculum Within a Fracture Liaison Service Framework

9:00AM-11:00AM: Abstract Number: 74

LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies

9:00AM-11:00AM: Abstract Number: 41

Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations

9:00AM-11:00AM: Abstract Number: 574

Localization and Morphology of Magnetic Resonance Imaging Features of Pathologic Changes in the Sacroiliac Joints Suggestive of Axial Spondyloarthritis – a Systematic Comparison of Patients and Controls with Chronic Back Pain

9:00AM-11:00AM: Abstract Number: 469

Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 757

Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 251

Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US

9:00AM-11:00AM: Abstract Number: 376

Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 538

Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

9:00AM-11:00AM: Abstract Number: 508

Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

9:00AM-11:00AM: Abstract Number: 591

Longitudinal Assessment of MRI of the Sacroiliac Joints in the ASAS Classification Cohort: Evolution of Diagnostic Features and Predictive Utility for Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 679

Longitudinal Changes in Manifestations of SLE

9:00AM-11:00AM: Abstract Number: 438

Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?

9:00AM-11:00AM: Abstract Number: 638

Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 357

Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification

9:00AM-11:00AM: Abstract Number: 716

Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 97

Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 505

Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission

9:00AM-11:00AM: Abstract Number: 61

Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency

9:00AM-11:00AM: Abstract Number: 605

Macrophage Migration Inhibitory Factor Is a Critical Regulator in a Mouse Model of Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 392

Management of Idiopathic Inflammatory Myopathies Using Intravenous Immunoglobulin Therapy: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 35

Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 99

Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis

9:00AM-11:00AM: Abstract Number: 461

Maximal Improvement in Fatigue Lags Behind Achievement of Sustained Remission in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 698

Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 266

Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada: Stand up and Be Counted Too (2)!

9:00AM-11:00AM: Abstract Number: 227

Metabolomic and Symptom Comparison in Women With/without Fibromyalgia: A Pilot Study

9:00AM-11:00AM: Abstract Number: 128

Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis

9:00AM-11:00AM: Abstract Number: 627

Metabolomics Screening in Axial Spondyloarthritis: Identifying Potential Biomarkers

9:00AM-11:00AM: Abstract Number: 362

Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries

9:00AM-11:00AM: Abstract Number: 369

Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review

9:00AM-11:00AM: Abstract Number: 75

Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

9:00AM-11:00AM: Abstract Number: 119

Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model

9:00AM-11:00AM: Abstract Number: 729

Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 545

Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study

9:00AM-11:00AM: Abstract Number: 16

Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway

9:00AM-11:00AM: Abstract Number: 727

Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 672

Mouse SLE Studies Do Not Describe Human SLE

9:00AM-11:00AM: Abstract Number: 60

mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA

9:00AM-11:00AM: Abstract Number: 108

Mucosal Associated Invariant T Cells in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 541

Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 442

Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care

9:00AM-11:00AM: Abstract Number: 441

Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain

9:00AM-11:00AM: Abstract Number: 778

Multiple Genetic Diagnoses in a Cohort of Patients with Cryopyrin Associated Periodic Syndrome (CAPS)

9:00AM-11:00AM: Abstract Number: 599

Muscle Physical Properties in Young Adult Axial Spondyloarthritis Patients, the MyoSpA Study

9:00AM-11:00AM: Abstract Number: 238

Muscle Pressure as Measured by a Manometer Correlates with Dolorimetry in Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 235

Muscle Pressure Correlates with Pain Levels in Fibromyalgia Patients and Muscle Tension May Be the Cause of Their Pain

9:00AM-11:00AM: Abstract Number: 794

Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma

9:00AM-11:00AM: Abstract Number: 475

Myopenia in Elderly Female Patients with Rheumatoid Arthritis Is Associated with Severe Joint Damage: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 406

Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort

9:00AM-11:00AM: Abstract Number: 664

Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 447

Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage

9:00AM-11:00AM: Abstract Number: 728

Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 305

Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing

9:00AM-11:00AM: Abstract Number: 92

Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls

9:00AM-11:00AM: Abstract Number: 713

NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity

9:00AM-11:00AM: Abstract Number: 382

Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis

9:00AM-11:00AM: Abstract Number: 706

Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments

9:00AM-11:00AM: Abstract Number: 379

Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group

9:00AM-11:00AM: Abstract Number: 685

Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 653

Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 184

No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA

9:00AM-11:00AM: Abstract Number: 480

Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database

9:00AM-11:00AM: Abstract Number: 377

Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition

9:00AM-11:00AM: Abstract Number: 28

Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction

9:00AM-11:00AM: Abstract Number: 104

Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders

9:00AM-11:00AM: Abstract Number: 199

Obesity and Incident Opioid Use in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 470

Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 612

Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients

9:00AM-11:00AM: Abstract Number: 782

Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion

9:00AM-11:00AM: Abstract Number: 555

Oncostatin M Receptor (OSMR) Underexpression in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 215

Opioid Treatment Pattern in a Community Based Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 272

Osteoporosis Management Outcomes in a Southern California County Health System

9:00AM-11:00AM: Abstract Number: 767

Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains

9:00AM-11:00AM: Abstract Number: 270

Outcomes of a Fracture Liaison Service at an Academic Health Center

9:00AM-11:00AM: Abstract Number: 262

Outpatient Healthcare Utilization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1988-2016)

9:00AM-11:00AM: Abstract Number: 234

Oxytocin Attenuates Tactile Allodynia in Experimental Fibromyalgia Rats

9:00AM-11:00AM: Abstract Number: 628

Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 153

Palliative Care Curriculum in Rheumatology: Teaching Serious Illness Conversations

9:00AM-11:00AM: Abstract Number: 301

PANLAR Ultrasound Study Group Recommendations for the Use of Imaging in the Management of Patients with Gout

9:00AM-11:00AM: Abstract Number: 3

Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss

9:00AM-11:00AM: Abstract Number: 274

Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis

9:00AM-11:00AM: Abstract Number: 423

Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 648

Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity

9:00AM-11:00AM: Abstract Number: 680

Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort

9:00AM-11:00AM: Abstract Number: 230

Patients with Fibromyalgia Associated with Rheumatoid Arthritis and Patients with Primary Fibromyalgia Differ in Depression, Anxiety, Stress-related Disorders and Events: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 570

Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up of Ankylosing Spondylitis (AS) Patients with a Rheumatologist-patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China

9:00AM-11:00AM: Abstract Number: 347

Patterns and Clinico-Radiological Correlates of Symptomatic Atlantoaxial Joint Involvement in Patients with Calcium Pyrophosphate Deposition Disease

9:00AM-11:00AM: Abstract Number: 689

Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 348

Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry

9:00AM-11:00AM: Abstract Number: 171

Performance of 2010 ACR/EULAR and 1987 ACR Criteria for Classification of Rheumatoid Arthritis in a Population-based Incidence Cohort, 2010-2014

9:00AM-11:00AM: Abstract Number: 401

Performance of EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies in a Real-life Cohort of Adult Patients

9:00AM-11:00AM: Abstract Number: 677

Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery

9:00AM-11:00AM: Abstract Number: 657

Performance of the “Do You Know What I Mean” Questionnaire in the Assessment of Disease Knowledge in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 593

Performance of the ASAS Classification Criteria Presenting with Undiagnosed Back Pain: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort

9:00AM-11:00AM: Abstract Number: 678

Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease

9:00AM-11:00AM: Abstract Number: 400

Performance of the European League Against Rheumatism/American College of Rheumatology Idiopathic Inflammatory Myopathies Classification Criteria in a Myositis Cohort from Argentina

9:00AM-11:00AM: Abstract Number: 413

Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 650

Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients

9:00AM-11:00AM: Abstract Number: 536

PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis

9:00AM-11:00AM: Abstract Number: 372

Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience

9:00AM-11:00AM: Abstract Number: 663

Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 617

Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort

9:00AM-11:00AM: Abstract Number: 671

Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study

9:00AM-11:00AM: Abstract Number: 451

Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores

9:00AM-11:00AM: Abstract Number: 114

Persistent Synovial Resident Memory T Cells Mediate Arthritis Flares

9:00AM-11:00AM: Abstract Number: 530

Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay

9:00AM-11:00AM: Abstract Number: 48

Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients

9:00AM-11:00AM: Abstract Number: 118

Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 759

Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?

9:00AM-11:00AM: Abstract Number: 742

Polymyalgia Rheumatica: New Therapeutic Strategy Based on Low Dose Metrotexate Plus Local Infiltration with Corticosteroids

9:00AM-11:00AM: Abstract Number: 761

Polymyalgia Rheumatica: Winter Is Coming

9:00AM-11:00AM: Abstract Number: 436

Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 73

Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 649

Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study

9:00AM-11:00AM: Abstract Number: 368

Practice Patterns in Bone Health and Vitamin D Management in Sarcoidosis: A Survey of Physicians Who Manage Sarcoidosis

9:00AM-11:00AM: Abstract Number: 495

Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years

9:00AM-11:00AM: Abstract Number: 314

Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data

9:00AM-11:00AM: Abstract Number: 194

Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data

9:00AM-11:00AM: Abstract Number: 466

Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 766

Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 651

Predictors of Renal Damage in Systemic Lupus Erythematosus Patients from Latin America

9:00AM-11:00AM: Abstract Number: 785

Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience

9:00AM-11:00AM: Abstract Number: 141

Pregnancy in Antiphospholipid Syndrome: Outcomes and Risk Factors – Data from a Portuguese Multidisclinary Unit

9:00AM-11:00AM: Abstract Number: 751

Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group

9:00AM-11:00AM: Abstract Number: 801

Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing

9:00AM-11:00AM: Abstract Number: 390

Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 760

Prescribing Methotrexate in Polymyalgia Rheumatica: A Missed Opportunity?

9:00AM-11:00AM: Abstract Number: 327

Presentation Order Bias in Rheumatology Journals: A Content Analysis

9:00AM-11:00AM: Abstract Number: 384

Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease

9:00AM-11:00AM: Abstract Number: 296

Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study

9:00AM-11:00AM: Abstract Number: 410

Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review

9:00AM-11:00AM: Abstract Number: 608

Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls

9:00AM-11:00AM: Abstract Number: 181

Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population

9:00AM-11:00AM: Abstract Number: 352

Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 454

Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study

9:00AM-11:00AM: Abstract Number: 703

Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics

9:00AM-11:00AM: Abstract Number: 481

Production of IL17A in Synovial Tissue Correlates with MRI RAMRIS Scores in ACPA Positive Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 465

Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review

9:00AM-11:00AM: Abstract Number: 373

Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 300

Proliferative Globular Synovitis, an Ultrasound Pattern Associated with Seropositive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 596

Prostaglandin Receptor EP4 Drives Pathogenic Th17 Cell Development in Ankylosing Spondylitis and Is a New Marker of Disease Activity

9:00AM-11:00AM: Abstract Number: 431

Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 308

Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays

9:00AM-11:00AM: Abstract Number: 473

RA Presents in Disease Patterns Impacting Treatment Response

9:00AM-11:00AM: Abstract Number: 64

Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice

9:00AM-11:00AM: Abstract Number: 82

Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice

9:00AM-11:00AM: Abstract Number: 584

Radiographic Association of Hip and SI Joints in Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 350

Rapid Reduction in Uric Acid Is Associated with Recurrent Cardiovascular Events

9:00AM-11:00AM: Abstract Number: 244

Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review

9:00AM-11:00AM: Abstract Number: 419

Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study

9:00AM-11:00AM: Abstract Number: 204

Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US

9:00AM-11:00AM: Abstract Number: 203

Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures

9:00AM-11:00AM: Abstract Number: 631

Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral

9:00AM-11:00AM: Abstract Number: 736

Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders

9:00AM-11:00AM: Abstract Number: 31

Regulation of Neutrophil Extracellular Traps by Apremilast (phosphodiesterase 4 Inhibition)

9:00AM-11:00AM: Abstract Number: 619

Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty

9:00AM-11:00AM: Abstract Number: 213

Relationship Between a History of Abuse and Fibromyalgia Symptoms and Severity: Data from the Cleveland Clinic Fibromyalgia Registry

9:00AM-11:00AM: Abstract Number: 710

Relationship Between High-Resolution Computer Tomography and FVC% Predicted for Classification of Pulmonary Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 138

Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 335

Renal Transplant Complications in Patients with and Without Gout

9:00AM-11:00AM: Abstract Number: 236

Repeat Muscle Pressures Measured in Fibromyalgia Patients and Compared with Pain Scores

9:00AM-11:00AM: Abstract Number: 592

Replacement of Radiographic Sacroilitis by MRI Structural Lesions: What Is the Impact on Classification of Axial Spondyloarthritis in the ASAS Classification Cohort?

9:00AM-11:00AM: Abstract Number: 578

Restricted Work Participation Relates to High Disease Activity in Spondyloarthritis Patients

9:00AM-11:00AM: Abstract Number: 611

Retina of Ankylosing Spondylitis Patients Shows Early Signs of Atherosclerotic Disease in Comparison with Healthy Controls

9:00AM-11:00AM: Abstract Number: 383

Retroperitoneal Fibrosis- a Single Center Experience

9:00AM-11:00AM: Abstract Number: 699

Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity

9:00AM-11:00AM: Abstract Number: 582

Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?

9:00AM-11:00AM: Abstract Number: 260

Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014

9:00AM-11:00AM: Abstract Number: 550

Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 342

Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout

9:00AM-11:00AM: Abstract Number: 734

Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 202

Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies

9:00AM-11:00AM: Abstract Number: 351

Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City

9:00AM-11:00AM: Abstract Number: 732

Risk of Heart Valve Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 196

Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 793

Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients

9:00AM-11:00AM: Abstract Number: 740

Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 371

Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 39

Role of Sialic Acid in the Aggressive Phenotype of RA FLS

9:00AM-11:00AM: Abstract Number: 24

Role of Trained Immunity in the Pathogenesis of Erdheim-Chester Disease

9:00AM-11:00AM: Abstract Number: 10

Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs

9:00AM-11:00AM: Abstract Number: 489

S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 527

Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks

9:00AM-11:00AM: Abstract Number: 712

Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics

9:00AM-11:00AM: Abstract Number: 509

Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

9:00AM-11:00AM: Abstract Number: 569

Sarcopenia, Segmental Muscle Strength and Body Composition in Young Axial Spondylarthritis Patients: Results from MyoSpA Study

9:00AM-11:00AM: Abstract Number: 313

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

9:00AM-11:00AM: Abstract Number: 399

Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 380

Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution

9:00AM-11:00AM: Abstract Number: 398

Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong

9:00AM-11:00AM: Abstract Number: 702

Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort

9:00AM-11:00AM: Abstract Number: 14

Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 98

Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 85

Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model

9:00AM-11:00AM: Abstract Number: 208

Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 666

Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort

9:00AM-11:00AM: Abstract Number: 103

Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells

9:00AM-11:00AM: Abstract Number: 102

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)

9:00AM-11:00AM: Abstract Number: 656

Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 467

Serum Long-chain n-3 and -6 Fatty Acids Are Associated with Disease Feature at Onset and with 6-month Disease Activity in Early RA: Results from the ESPOIR Cohort

9:00AM-11:00AM: Abstract Number: 457

Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity

9:00AM-11:00AM: Abstract Number: 366

Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 707

Severity and Evolution over Time of Gastro-Intestinal Involvement in Patients with Systemic Sclerosis in Two Large and Independent Cohorts

9:00AM-11:00AM: Abstract Number: 394

Sexual Health in 39 Female Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 498

Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?

9:00AM-11:00AM: Abstract Number: 146

Simulated Rheumatology Clinic: Bridging Basic Science and Clinical Application

9:00AM-11:00AM: Abstract Number: 403

Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome

9:00AM-11:00AM: Abstract Number: 90

SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation

9:00AM-11:00AM: Abstract Number: 700

Sleep Quality Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 472

Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms

9:00AM-11:00AM: Abstract Number: 246

Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus

9:00AM-11:00AM: Abstract Number: 589

Smoking, Alcohol Intake and Body Mass Index in Prediction of Disease Activity over Time in Early Axial Spondyloarthritis – Results from the SPondyloArthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 792

Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 576

Spinal Bone Formation as Assessed by Low-Dose CT Scan in Patients with Radiographic Axial Spondyloarthritis – Comparison of the Progression Observed in Vertebrae and Facet Joints

9:00AM-11:00AM: Abstract Number: 173

Statin Use Is Associated with Increased Risk of RA in US Population: Results from a Large Nationwide Study

9:00AM-11:00AM: Abstract Number: 804

STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 709

Structural Abnormalities of the Optic Nerve Head and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 42

Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis

9:00AM-11:00AM: Abstract Number: 346

Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016

9:00AM-11:00AM: Abstract Number: 129

Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile

9:00AM-11:00AM: Abstract Number: 393

Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody

9:00AM-11:00AM: Abstract Number: 378

Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years

9:00AM-11:00AM: Abstract Number: 738

Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features: Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis

9:00AM-11:00AM: Abstract Number: 748

Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center

9:00AM-11:00AM: Abstract Number: 614

Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data

9:00AM-11:00AM: Abstract Number: 634

Targeted 1H NMR Based Metabolomics Analysis Revealed Significantly Higher Synovial Phe/Tyr Ratio in Reactive Arthritis and Undifferentiated Spondyloarthropathy

9:00AM-11:00AM: Abstract Number: 109

Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis

9:00AM-11:00AM: Abstract Number: 100

Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells

9:00AM-11:00AM: Abstract Number: 149

Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon

9:00AM-11:00AM: Abstract Number: 566

Temporal Relationship Between Enteropathic Spondylitis Symptoms/diagnosis and Inflammatory Bowel Diseases Diagnosis: HUR-BIO Real Life Results

9:00AM-11:00AM: Abstract Number: 622

Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 294

Tendons Involvement at Early Onset of Gouty Arthritis, Ultrasonographic Study

9:00AM-11:00AM: Abstract Number: 304

The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017

9:00AM-11:00AM: Abstract Number: 391

The Beneficial Effects of Rituximab Treatment in Myositis May Be Due to the Binding of a Non B-Cell Protein, SMPDL3B, in Skeletal Muscle

9:00AM-11:00AM: Abstract Number: 179

The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry

9:00AM-11:00AM: Abstract Number: 764

The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years

9:00AM-11:00AM: Abstract Number: 137

The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-11:00AM: Abstract Number: 195

The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 148

The Combat Rheumatologist: Long Term Professional Outcomes of Graduates from a Tri-Service Military Rheumatology Fellowship Program

9:00AM-11:00AM: Abstract Number: 556

The Correlation of Bone Bridge and Low Bone Mineral Density Measured by Quantitative Computed Tomography in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 449

The Course of Disability Related to Function of the Upper Extremities in Early Rheumatoid Arthritis over 10 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 105

The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3

9:00AM-11:00AM: Abstract Number: 500

The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 13

The Effect of Estrogen and Interferon γ on the Immunobiology of Minor Salivary Gland Mesenchymal Stromal Cells

9:00AM-11:00AM: Abstract Number: 242

The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences

9:00AM-11:00AM: Abstract Number: 459

The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA – ANSWER Longitudinal Cohort Study –

9:00AM-11:00AM: Abstract Number: 462

The Endogenous Plasma Small RNAome of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 176

The Epidemiology of Rheumatoid Arthritis in the Czech Republic

9:00AM-11:00AM: Abstract Number: 499

The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthiritis: A Systematic Literature Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 588

The Gut Enthesis Axis Coming into Focus with the Description of Enriched Entheseal Resident Mucosal Associated Invariant T-cells (MAITs) Capable of IL17A and TNF Production

9:00AM-11:00AM: Abstract Number: 422

The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 43

The Impact of Air Pollution on Extracellular Vesicles as a Potential Pro-inflammatory Stimulus in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 563

The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 156

The Impact of Spaced Education and Reciprocal Peer Teaching on Rheumatology Fellows’ Long-term Recall from Core Curriculum

9:00AM-11:00AM: Abstract Number: 523

The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 188

The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood

9:00AM-11:00AM: Abstract Number: 374

The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 117

The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 478

The Influence of Gender on Composite Disease Activity Indices for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 458

The Influence of Mediterranean Diet in Rheumatoid Arthritis: A Monocenter Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 779

The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants

9:00AM-11:00AM: Abstract Number: 722

The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 737

The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 696

The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy

9:00AM-11:00AM: Abstract Number: 667

The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity

9:00AM-11:00AM: Abstract Number: 735

The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 197

The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application

9:00AM-11:00AM: Abstract Number: 334

The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout

9:00AM-11:00AM: Abstract Number: 80

The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model

9:00AM-11:00AM: Abstract Number: 34

The Role of NFAT5-p65 Complex Enhanceosome in the Inflammatory Responses of Rheumatoid Arthritis Synovial Fibroblasts via TLR4 Signaling

9:00AM-11:00AM: Abstract Number: 63

The Role of the Intestinal Microbiota in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 239

The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia

9:00AM-11:00AM: Abstract Number: 72

The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease

9:00AM-11:00AM: Abstract Number: 772

The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)

9:00AM-11:00AM: Abstract Number: 111

The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles

9:00AM-11:00AM: Abstract Number: 621

The Use of Microbial Flow Cytometry to Analyze the Intestinal and Oral Microbiota

9:00AM-11:00AM: Abstract Number: 29

Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro

9:00AM-11:00AM: Abstract Number: 285

Thermal Imaging in Rheumatoid Arthritis: A Comparative Analysis with Ultrasonography and Clinical Joint Assessment

9:00AM-11:00AM: Abstract Number: 487

Third Generation Anti-cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Second Generation Anti-cyclic Citrullinated Peptide Positive Subjects at Risk of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 86

THOR-809: An IL-2 Engineered from an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders

9:00AM-11:00AM: Abstract Number: 426

Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo

9:00AM-11:00AM: Abstract Number: 312

Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity

9:00AM-11:00AM: Abstract Number: 544

Tolerance, Survival, and Adherence to Methotrexate Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 49

Towards a Single Cell Portrait of Rheumatoid Arthritis – Development of a Single Cell Multiomics Pipeline for Phase 2 of the Accelerating Medicine Partnership (AMP) – RA Network

9:00AM-11:00AM: Abstract Number: 17

Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis

9:00AM-11:00AM: Abstract Number: 414

Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 336

Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease

9:00AM-11:00AM: Abstract Number: 388

Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity

9:00AM-11:00AM: Abstract Number: 763

Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 69

Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ

9:00AM-11:00AM: Abstract Number: 250

Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US

9:00AM-11:00AM: Abstract Number: 252

Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 124

Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 510

Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels

9:00AM-11:00AM: Abstract Number: 522

Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 94

Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells

9:00AM-11:00AM: Abstract Number: 788

Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 88

Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets

9:00AM-11:00AM: Abstract Number: 297

Ultrasound and Magnetic Resonance Imaging Evaluation of the Fingers’ Joints of Psoriatic Arthritis Patients – Interim Analysis

9:00AM-11:00AM: Abstract Number: 287

Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review

9:00AM-11:00AM: Abstract Number: 711

Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints

9:00AM-11:00AM: Abstract Number: 282

Ultrasound Is More Sensitive Compared to Conventional Radiography to Detect Joint Erosions in ACPA-positive Patients with Musculoskeletal Pain

9:00AM-11:00AM: Abstract Number: 721

Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 280

Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial

9:00AM-11:00AM: Abstract Number: 78

Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells

9:00AM-11:00AM: Abstract Number: 796

Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 568

Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility

9:00AM-11:00AM: Abstract Number: 367

Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience

9:00AM-11:00AM: Abstract Number: 435

Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower

9:00AM-11:00AM: Abstract Number: 18

Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution

9:00AM-11:00AM: Abstract Number: 79

Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice

9:00AM-11:00AM: Abstract Number: 513

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks

9:00AM-11:00AM: Abstract Number: 518

Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks

9:00AM-11:00AM: Abstract Number: 551

Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 690

Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment

9:00AM-11:00AM: Abstract Number: 549

US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey

9:00AM-11:00AM: Abstract Number: 161

Use of a Systematic Consensus Process to Inform Development of the Veterans Health Affairs Simulation Learning, Education and Research Network (SimLEARN) Musculoskeletal Clinician Course

9:00AM-11:00AM: Abstract Number: 370

Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 662

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 407

Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 212

Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry

9:00AM-11:00AM: Abstract Number: 303

Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission

9:00AM-11:00AM: Abstract Number: 665

Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia

9:00AM-11:00AM: Abstract Number: 81

UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury

9:00AM-11:00AM: Abstract Number: 159

VA Musculoskeletal “Master Educator” Faculty Development Program for Health Professions Educators: Follow-Up on Changes in Educational Duties and Perceptions of Program Content

9:00AM-11:00AM: Abstract Number: 636

Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire

9:00AM-11:00AM: Abstract Number: 443

Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 415

Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials

9:00AM-11:00AM: Abstract Number: 189

Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 44

Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis

9:00AM-11:00AM: Abstract Number: 490

Validation of Risk Scores for Predicting Progression in Individuals “At Risk of Rheumatoid Arthritis”

9:00AM-11:00AM: Abstract Number: 741

Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 456

Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 771

Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma

9:00AM-11:00AM: Abstract Number: 733

Vonoprazan, a Novel Potassium-competitive Acid Blocker, for Treatment of Proton Pump Inhibitor-resistant Reflux Esophagitis in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 157

We Can Do Better: Evaluating Inpatient Pediatric Rheumatology Inpatient/Consult Service Performance

9:00AM-11:00AM: Abstract Number: 445

What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 595

What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study

9:00AM-11:00AM: Abstract Number: 590

What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?

9:00AM-11:00AM: Abstract Number: 471

When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA

9:00AM-11:00AM: Abstract Number: 271

Who Prescribed Which Osteoporosis Medication to Whom

9:00AM-11:00AM: Abstract Number: 240

Whom Do Patients with Fibromyalgia Turn to for Emotional Support?

9:00AM-11:00AM: Abstract Number: 169

Wikipedia as a Source of Health Information for the Public: Systematic Analysis of Quality and Readability of 8 Common Rheumatic Diseases Articles

9:00AM-11:00AM: Abstract Number: 497

Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population

9:00AM-11:00AM: Abstract Number: 418

Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 163

Workforce Survey: Career Trends of Combined Adult and Pediatric Rheumatology Fellowship Graduates

9:00AM-11:00AM: Abstract Number: 567

Worse Outcomes for Female Patients with Axial Spondyloarthropathy

9:00AM-11:00AM: Abstract Number: 395

Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis

11:00AM-12:30PM: Abstract Number: 806

A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease

11:00AM-12:30PM: Abstract Number: 807

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

11:00AM-12:30PM: Abstract Number: 808

Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial

11:00AM-12:30PM: Abstract Number: 805

Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities

11:00AM-12:30PM: Abstract Number: 809

TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)

11:30AM-1:30PM: Abstract Number: PP06

Art for Arthritis: A New Approach

11:30AM-1:30PM: Abstract Number: PP03

Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine

11:30AM-1:30PM: Abstract Number: PP07

Coming to Terms with Lupus: How Learning to Listen to My Body and Letting it Tell Me What to Do Improved My Quality of Life

11:30AM-1:30PM: Abstract Number: PP08

Framework for Enhancing Patient-Physician Communication in the Context of Rare Disease

11:30AM-1:30PM: Abstract Number: PP01

From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving

11:30AM-1:30PM: Abstract Number: PP09

Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius

11:30AM-1:30PM: Abstract Number: PP02

Living and Adjusting to a Diagnosis of Rheumatoid Arthritis (RA) with an Interdisciplinary Team

11:30AM-1:30PM: Abstract Number: PP05

Race for Relapsing Polychondritis Drives Awareness, Accelerates Research, and Improves the Quality of My Life: How Motorsports Help Me Overcome the Hopelessness of an Incurable, Rare Disease

11:30AM-1:30PM: Abstract Number: PP04

Reclaiming Medical Autonomy Through Healthcare Advocacy

11:30AM-1:30PM: Abstract Number: PP10

The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 876

“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study

2:30PM-4:00PM: Abstract Number: 828

A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)

2:30PM-4:00PM: Abstract Number: 827

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

2:30PM-4:00PM: Abstract Number: 858

Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE

2:30PM-4:00PM: Abstract Number: 871

ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

2:30PM-4:00PM: Abstract Number: 838

Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?

2:30PM-4:00PM: Abstract Number: 851

Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort

2:30PM-4:00PM: Abstract Number: 864

Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

2:30PM-4:00PM: Abstract Number: 822

Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis

2:30PM-4:00PM: Abstract Number: 869

Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort

2:30PM-4:00PM: Abstract Number: 874

Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features

2:30PM-4:00PM: Abstract Number: 845

Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions

2:30PM-4:00PM: Abstract Number: 861

Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE

2:30PM-4:00PM: Abstract Number: 832

Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria

2:30PM-4:00PM: Abstract Number: 829

Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia

2:30PM-4:00PM: Abstract Number: 839

Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 820

Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 854

Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort

2:30PM-4:00PM: Abstract Number: 837

Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

2:30PM-4:00PM: Abstract Number: 833

Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial

2:30PM-4:00PM: Abstract Number: 875

Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial

2:30PM-4:00PM: Abstract Number: 860

Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations

2:30PM-4:00PM: Abstract Number: 841

Elevation of Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Onset and Risks for Developing Chronic Obstructive Pulmonary Disease or Asthma

2:30PM-4:00PM: Abstract Number: 817

Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 879

Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study

2:30PM-4:00PM: Abstract Number: 866

Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease

2:30PM-4:00PM: Abstract Number: 815

Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis

2:30PM-4:00PM: Abstract Number: 862

First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study

2:30PM-4:00PM: Abstract Number: 872

Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry

2:30PM-4:00PM: Abstract Number: 835

High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network

2:30PM-4:00PM: Abstract Number: 843

High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope

2:30PM-4:00PM: Abstract Number: 852

Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients

2:30PM-4:00PM: Abstract Number: 826

Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death

2:30PM-4:00PM: Abstract Number: 844

Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial

2:30PM-4:00PM: Abstract Number: 834

Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges

2:30PM-4:00PM: Abstract Number: 814

Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases

2:30PM-4:00PM: Abstract Number: 859

Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis

2:30PM-4:00PM: Abstract Number: 846

MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

2:30PM-4:00PM: Abstract Number: 831

Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain

2:30PM-4:00PM: Abstract Number: 857

Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients

2:30PM-4:00PM: Abstract Number: 813

Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome

2:30PM-4:00PM: Abstract Number: 811

Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model

2:30PM-4:00PM: Abstract Number: 842

Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease

2:30PM-4:00PM: Abstract Number: 856

MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?

2:30PM-4:00PM: Abstract Number: 870

Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

2:30PM-4:00PM: Abstract Number: 836

Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results

2:30PM-4:00PM: Abstract Number: 824

Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients

2:30PM-4:00PM: Abstract Number: 877

Rheumatoid Arthritis Patients’ Perspectives on Tapering of Biologics: A Qualitative Study

2:30PM-4:00PM: Abstract Number: 849

Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database

2:30PM-4:00PM: Abstract Number: 848

Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 867

Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial

2:30PM-4:00PM: Abstract Number: 865

Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

2:30PM-4:00PM: Abstract Number: 850

Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 847

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis

2:30PM-4:00PM: Abstract Number: 818

Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 812

Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism

2:30PM-4:00PM: Abstract Number: 810

Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase

2:30PM-4:00PM: Abstract Number: 873

Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database

2:30PM-4:00PM: Abstract Number: 825

Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades

2:30PM-4:00PM: Abstract Number: 878

The Association of Serum Magnesium with Chondrocalcinosis and Osteoarthritis

2:30PM-4:00PM: Abstract Number: 868

The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study

2:30PM-4:00PM: Abstract Number: 830

The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis

2:30PM-4:00PM: Abstract Number: 816

The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts

2:30PM-4:00PM: Abstract Number: 819

The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts

2:30PM-4:00PM: Abstract Number: 823

The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study

2:30PM-4:00PM: Abstract Number: 863

Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial

2:30PM-4:00PM: Abstract Number: 840

Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015

2:30PM-4:00PM: Abstract Number: 821

Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)

2:30PM-4:00PM: Abstract Number: 853

Two-Year Progression of Facet Joint Ankylosis on Whole Spine Low-Dose CT in Patients with Radiographic Axial Spondyloarthritis

2:30PM-4:00PM: Abstract Number: 855

Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?

4:30PM-6:00PM: Abstract Number: 943

A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

4:30PM-6:00PM: Abstract Number: 939

A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis

4:30PM-6:00PM: Abstract Number: 942

A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus

4:30PM-6:00PM: Abstract Number: 895

A Spatial-temporal Analysis of Organ-specific Lupus Flares in Relation to Fine Particulate Matter Pollution and Temperature

4:30PM-6:00PM: Abstract Number: 905

A Third of Relapsing Polychondritis Patients with Ear Involvement at Presentation Had Airway Involvement at the Last Follow-up with a High Mortality Rate

4:30PM-6:00PM: Abstract Number: 890

Adenosine A2A Receptor Signaling Activates FoxO1 and FoxO3 and Promotes Cartilage Autophagy

4:30PM-6:00PM: Abstract Number: 920

Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome

4:30PM-6:00PM: Abstract Number: 955

Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study

4:30PM-6:00PM: Abstract Number: 892

Adverse Childhood Experiences Are Associated with Systemic Lupus Erythematosus in a Clinical Population from Bronx, New York

4:30PM-6:00PM: Abstract Number: 949

Assessment of Femoral Vein Wall Thickness with Doppler Ultrasound Can Be a Diagnostic Tool for Behcet’s Disease

4:30PM-6:00PM: Abstract Number: 881

Auto-antibodies Targeting Components of Sarcolemma Repair: A Pathogenic Mechanism in Human Inflammatory Myopathies

4:30PM-6:00PM: Abstract Number: 951

Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences

4:30PM-6:00PM: Abstract Number: 883

B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus

4:30PM-6:00PM: Abstract Number: 904

Bone Manifestations in Gaucher Disease: A Monocentric Study of 128 Patients

4:30PM-6:00PM: Abstract Number: 912

Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials

4:30PM-6:00PM: Abstract Number: 945

Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease

4:30PM-6:00PM: Abstract Number: 887

Critical Role of the Cholinergic System Involvement in Osteoarthritis

4:30PM-6:00PM: Abstract Number: 913

Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis

4:30PM-6:00PM: Abstract Number: 916

Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

4:30PM-6:00PM: Abstract Number: 915

Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis

4:30PM-6:00PM: Abstract Number: 880

Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development

4:30PM-6:00PM: Abstract Number: 937

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

4:30PM-6:00PM: Abstract Number: 936

Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes

4:30PM-6:00PM: Abstract Number: 944

Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study

4:30PM-6:00PM: Abstract Number: 932

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 929

Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

4:30PM-6:00PM: Abstract Number: 927

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results

4:30PM-6:00PM: Abstract Number: 908

Epidemiology and Presentation of Sarcoidosis with and Without HIV Infection

4:30PM-6:00PM: Abstract Number: 923

First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?

4:30PM-6:00PM: Abstract Number: 919

Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

4:30PM-6:00PM: Abstract Number: 894

Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015

4:30PM-6:00PM: Abstract Number: 924

Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 896

Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 889

Identification of Genetic Variants Associated with Erosive Hand Osteoarthritis Using Pedigrees from a State-Wide Population-Based Cohort

4:30PM-6:00PM: Abstract Number: 922

Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study

4:30PM-6:00PM: Abstract Number: 946

Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study

4:30PM-6:00PM: Abstract Number: 925

Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database

4:30PM-6:00PM: Abstract Number: 921

Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms

4:30PM-6:00PM: Abstract Number: 884

Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice

4:30PM-6:00PM: Abstract Number: 909

Is Long-term High-intensity Strength Training Beneficial or Harmful for Knee Osteoarthritis Patients? The Strength Training and Arthritis Trial (START)

4:30PM-6:00PM: Abstract Number: 910

Is There Any Role for Opioids in the Management of OA?

4:30PM-6:00PM: Abstract Number: 899

Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout

4:30PM-6:00PM: Abstract Number: 891

Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

4:30PM-6:00PM: Abstract Number: 950

Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease

4:30PM-6:00PM: Abstract Number: 886

Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development

4:30PM-6:00PM: Abstract Number: 926

Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification

4:30PM-6:00PM: Abstract Number: 888

Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models

4:30PM-6:00PM: Abstract Number: 928

Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks

4:30PM-6:00PM: Abstract Number: 897

Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients

4:30PM-6:00PM: Abstract Number: 918

Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation

4:30PM-6:00PM: Abstract Number: 907

Musculoskeletal Sarcoidosis: Characterization and Clinical Expression of 129 Patients with Granulomatous Infiltration of Bones And/or Muscles

4:30PM-6:00PM: Abstract Number: 930

Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator

4:30PM-6:00PM: Abstract Number: 911

Perfusion in Bone Marrow Lesions Assessed on Dynamic Contrast-enhanced MRI and Its Association with Pain in Knee Osteoarthritis: A Cross-sectional Study

4:30PM-6:00PM: Abstract Number: 954

Physical Therapy and Opioid Use in Knee Osteoarthritis

4:30PM-6:00PM: Abstract Number: 934

Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondylarthritis

4:30PM-6:00PM: Abstract Number: 903

Prevalence of Atopic Features in Classic Autoinflammatory Diseases

4:30PM-6:00PM: Abstract Number: 952

Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population

4:30PM-6:00PM: Abstract Number: 935

Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

4:30PM-6:00PM: Abstract Number: 948

Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study

4:30PM-6:00PM: Abstract Number: 940

Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis

4:30PM-6:00PM: Abstract Number: 906

Sarcoidosis as a Systemic Disease. Clinical and Epidemiological Characterization of Systemic Phenotype in 1521 Patients

4:30PM-6:00PM: Abstract Number: 901

Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study

4:30PM-6:00PM: Abstract Number: 882

Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis

4:30PM-6:00PM: Abstract Number: 900

Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults

4:30PM-6:00PM: Abstract Number: 917

Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors

4:30PM-6:00PM: Abstract Number: 902

The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate

4:30PM-6:00PM: Abstract Number: 914

The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older U.S. Adults

4:30PM-6:00PM: Abstract Number: 956

The Impact of Psychiatric Comorbidity on Health Care Utilization and Preventive Health Care in Rheumatoid Arthritis: A Population Based Study

4:30PM-6:00PM: Abstract Number: 893

The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome

4:30PM-6:00PM: Abstract Number: 885

TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses

4:30PM-6:00PM: Abstract Number: 947

TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2

4:30PM-6:00PM: Abstract Number: 938

TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity

4:30PM-6:00PM: Abstract Number: 941

Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity

4:30PM-6:00PM: Abstract Number: 953

Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data

4:30PM-6:00PM: Abstract Number: 933

Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study

4:30PM-6:00PM: Abstract Number: 931

Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial

4:30PM-6:00PM: Abstract Number: 898

Ultrasound Demonstrates Rapid Reduction of Crystal Depositions During a Treat-to-target Approach in Gout Patients: Two-year Results from a Longitudinal, Observational Study (NOR-GOUT)

9:00AM-11:00AM: Abstract Number: 1157

#WomeninRheumatology: Is There a Speaker Gender Gap at ACR Meetings?

9:00AM-11:00AM: Abstract Number: 1071

A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1355

A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1354

A Comparison of Convergent Validity and Sensitivity to Change of the Conventional Scoring Method to Alternative Scoring Methods of the Health Assessment Questionnaire in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1126

A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients

9:00AM-11:00AM: Abstract Number: 1215

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1227

A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout

9:00AM-11:00AM: Abstract Number: 1166

A New Risk Factor for Predicting the Long-term Outcome of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Pulmonary Artery Size Measured by Chest Computed Tomography

9:00AM-11:00AM: Abstract Number: 959

A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting

9:00AM-11:00AM: Abstract Number: 1536

A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 982

A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice

9:00AM-11:00AM: Abstract Number: 1307

A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain

9:00AM-11:00AM: Abstract Number: 1207

A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1190

A Quality Improvement Project to Increase Documentation Efficiency in an Academic Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1298

A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1240

A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study

9:00AM-11:00AM: Abstract Number: 1498

A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions

9:00AM-11:00AM: Abstract Number: 1675

A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1254

A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States

9:00AM-11:00AM: Abstract Number: 1213

A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology

9:00AM-11:00AM: Abstract Number: 1751

A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1065

Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1292

Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1516

Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast

9:00AM-11:00AM: Abstract Number: 1347

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies

9:00AM-11:00AM: Abstract Number: 1535

Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 1435

Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1679

Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 1372

Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 981

Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models

9:00AM-11:00AM: Abstract Number: 1721

Adult Primary Central Nervous System Vasculitis Treatment and Course: A Long-term Follow-up Study

9:00AM-11:00AM: Abstract Number: 1271

Adult-Onset Still’s Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment

9:00AM-11:00AM: Abstract Number: 1247

Adult-Onset Still’s Disease and Spondyloarthritis: Overlapping Syndrome or Incidental Association? A Series of 5 Cases

9:00AM-11:00AM: Abstract Number: 1364

Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients

9:00AM-11:00AM: Abstract Number: 1266

AGBL3 as a Novel Gene Associated with Hereditary Hypocomplementemic Urticarial Vasculitis and Favorable Response to Rituximab

9:00AM-11:00AM: Abstract Number: 1586

All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database

9:00AM-11:00AM: Abstract Number: 1531

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1294

Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 957

Alterations in Cholesterol Homeostasis Regulate Autoimmunity/Age-associated B Cells

9:00AM-11:00AM: Abstract Number: 963

Alterations of Memory and Naive B Cell Subsets Associate with Reduced IFNα and TNFRII in ANA+ Healthy Individuals

9:00AM-11:00AM: Abstract Number: 1701

Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road

9:00AM-11:00AM: Abstract Number: 1367

An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1243

Anakinra Treatment in Recurrent Pericarditis: Single Center Experience

9:00AM-11:00AM: Abstract Number: 1436

Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan

9:00AM-11:00AM: Abstract Number: 1054

Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis

9:00AM-11:00AM: Abstract Number: 1369

Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy

9:00AM-11:00AM: Abstract Number: 987

Anti-citrullinated Protein Antibodies Induce Subclinical Inflammation, Bone Loss and Pain in Mice

9:00AM-11:00AM: Abstract Number: 1021

Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice

9:00AM-11:00AM: Abstract Number: 1287

Anti-mitochondrial Autoantibodies in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1591

Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide

9:00AM-11:00AM: Abstract Number: 1652

Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1289

Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features

9:00AM-11:00AM: Abstract Number: 1191

Application of the Systemic Lupus Erythematosus (SLE) Quality Indicators in Patients Attending a Young Adult Transition Program

9:00AM-11:00AM: Abstract Number: 1695

Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases

9:00AM-11:00AM: Abstract Number: 1012

Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis

9:00AM-11:00AM: Abstract Number: 1224

AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile

9:00AM-11:00AM: Abstract Number: 1229

AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial

9:00AM-11:00AM: Abstract Number: 1753

Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?

9:00AM-11:00AM: Abstract Number: 1107

Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?

9:00AM-11:00AM: Abstract Number: 1149

Are There Country Differences in Disease Activity and Life Impact of Psoriatic Arthritis? An Analysis of 436 Patients from 14 Countries

9:00AM-11:00AM: Abstract Number: 1345

Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 1201

Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?

9:00AM-11:00AM: Abstract Number: 1597

Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes

9:00AM-11:00AM: Abstract Number: 1079

Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018

9:00AM-11:00AM: Abstract Number: 1596

Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1565

Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1631

Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1663

Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1394

Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study

9:00AM-11:00AM: Abstract Number: 1386

Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study

9:00AM-11:00AM: Abstract Number: 1433

Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1606

Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1401

Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis

9:00AM-11:00AM: Abstract Number: 960

Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins

9:00AM-11:00AM: Abstract Number: 1323

Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma

9:00AM-11:00AM: Abstract Number: 1642

Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns

9:00AM-11:00AM: Abstract Number: 1708

Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease

9:00AM-11:00AM: Abstract Number: 1455

B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 1416

B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 971

B Cell ROCK1 Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity

9:00AM-11:00AM: Abstract Number: 1407

Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1142

Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 1453

Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1626

Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1650

Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)

9:00AM-11:00AM: Abstract Number: 1189

Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation

9:00AM-11:00AM: Abstract Number: 1059

BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo

9:00AM-11:00AM: Abstract Number: 1002

Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model

9:00AM-11:00AM: Abstract Number: 1540

Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey

9:00AM-11:00AM: Abstract Number: 1693

Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients

9:00AM-11:00AM: Abstract Number: 1272

Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study

9:00AM-11:00AM: Abstract Number: 1080

Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience

9:00AM-11:00AM: Abstract Number: 1490

Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 1627

Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure

9:00AM-11:00AM: Abstract Number: 974

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

9:00AM-11:00AM: Abstract Number: 967

Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression

9:00AM-11:00AM: Abstract Number: 1008

C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility

9:00AM-11:00AM: Abstract Number: 1567

Cachexia in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1194

Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?

9:00AM-11:00AM: Abstract Number: 1250

Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?

9:00AM-11:00AM: Abstract Number: 1570

Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?

9:00AM-11:00AM: Abstract Number: 1714

Can We Predict Early Relapses in Adult IgA Vasculitis?

9:00AM-11:00AM: Abstract Number: 1082

Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea

9:00AM-11:00AM: Abstract Number: 1683

Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort

9:00AM-11:00AM: Abstract Number: 1078

Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1089

Causes of Death in ANCA-Associated Vasculitis According to ANCA Type

9:00AM-11:00AM: Abstract Number: 1574

Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India

9:00AM-11:00AM: Abstract Number: 1072

CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis

9:00AM-11:00AM: Abstract Number: 1064

CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy

9:00AM-11:00AM: Abstract Number: 1069

CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1403

CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1507

Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1508

Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1273

Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study

9:00AM-11:00AM: Abstract Number: 1641

Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1285

Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course

9:00AM-11:00AM: Abstract Number: 1162

Changes in Novel Composite Scores of Disease Activity and Cumulative Damage Are Prognostic of Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 1081

Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries

9:00AM-11:00AM: Abstract Number: 1027

Characterization of Antibody Secreting Cells in Patients with Active Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1710

Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1661

Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1034

Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 968

Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1068

Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures

9:00AM-11:00AM: Abstract Number: 1590

Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1700

Clinical Characteristics and the Level Disease Activity of Behcet´s Disease in China: A Study Based on Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1480

Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1467

Clinical Characteristics of Primary Sjögren’s Syndrome in Adult Patients Diagnosed at Age Less Than or Equal to 35 Years versus Those over 35 Years of Age

9:00AM-11:00AM: Abstract Number: 1262

Clinical Features of Elderly-onset Adult Still’s Disease

9:00AM-11:00AM: Abstract Number: 1248

Clinical Manifestations and Management of US Patients with SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, a Retrospective Study

9:00AM-11:00AM: Abstract Number: 1719

Clinical Phenotypes in Relapsing Polychondritis in a Prospective Cohort

9:00AM-11:00AM: Abstract Number: 1449

Clinical Phenotyping of Patients with Primary Sjögren’s Syndrome Using Salivary Gland Ultrasonograhpy

9:00AM-11:00AM: Abstract Number: 1299

Clinical Significance of Magnetic Resonance Imaging Derived Femur Bone Shape in Young Adults

9:00AM-11:00AM: Abstract Number: 1160

Clinical Trials in Rheumatoid Arthritis Have Inadequate Racial/Ethnic, Gender and Age Diversity: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1178

Clinical Utility of DECT in the Diagnosis of Gout at Mayo Clinic in Florida

9:00AM-11:00AM: Abstract Number: 1735

Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1552

Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study

9:00AM-11:00AM: Abstract Number: 1048

Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1736

Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies

9:00AM-11:00AM: Abstract Number: 1622

Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1754

Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain

9:00AM-11:00AM: Abstract Number: 1397

Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis

9:00AM-11:00AM: Abstract Number: 1496

Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study

9:00AM-11:00AM: Abstract Number: 1645

Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillarscopy for Microvascular Assessment in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1452

Comparison of Clinical Phenotype, Serological Characteristics and Histologic Features Between Males and Females Patients with Primary Sjögren’s Syndrome (pSS)

9:00AM-11:00AM: Abstract Number: 1634

Comparison of Different Pulmonary Hypertension Screening Algorithms in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1475

Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies

9:00AM-11:00AM: Abstract Number: 1256

Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over

9:00AM-11:00AM: Abstract Number: 1409

Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1669

Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1427

Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic

9:00AM-11:00AM: Abstract Number: 1442

Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1437

Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1447

Comparison of Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands and Conventional Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome Assessment

9:00AM-11:00AM: Abstract Number: 1041

Computational Methods for Drug Repositioning of Systemic Sclerosis Using Gene Fold-Change and Network Analyses

9:00AM-11:00AM: Abstract Number: 1537

Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study

9:00AM-11:00AM: Abstract Number: 1309

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 977

Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice

9:00AM-11:00AM: Abstract Number: 1180

Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study

9:00AM-11:00AM: Abstract Number: 1391

Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study

9:00AM-11:00AM: Abstract Number: 1365

Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States

9:00AM-11:00AM: Abstract Number: 1630

Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1635

Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1359

Correlation of Ultrasound Guided Synovial Biopsies and Surgical Synovial Biopsies in Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1170

Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1419

Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1371

Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1640

Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease

9:00AM-11:00AM: Abstract Number: 1047

CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage

9:00AM-11:00AM: Abstract Number: 1410

Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis

9:00AM-11:00AM: Abstract Number: 1705

Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?

9:00AM-11:00AM: Abstract Number: 1070

Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1277

Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1356

DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1561

Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation

9:00AM-11:00AM: Abstract Number: 1159

Deep Learning Social Media Analysis Demonstrated Gender-Specific Disparity in Side Effects from Rheumatoid Medications

9:00AM-11:00AM: Abstract Number: 1358

Defining Minimal Clinically Important Changes for the Patient Activity Scale-II

9:00AM-11:00AM: Abstract Number: 1592

Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype

9:00AM-11:00AM: Abstract Number: 1187

Delayed Gadolinium-enhanced MR Imaging of Cartilage – A Pilot Study to Measure the Effect of Adalimumab Plus MTX versus Placebo Plus MTX on Cartilage in Early RA Patients (CAR-ERA-Study)

9:00AM-11:00AM: Abstract Number: 1741

Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1680

Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 1176

Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Structural Damage Score in a 5-year Longitudinal Study of Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 990

Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1101

Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database

9:00AM-11:00AM: Abstract Number: 1580

Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1698

Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1109

Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1156

Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1268

Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?

9:00AM-11:00AM: Abstract Number: 1129

Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States

9:00AM-11:00AM: Abstract Number: 1598

Disability Among Subtypes of SLE

9:00AM-11:00AM: Abstract Number: 1438

Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study

9:00AM-11:00AM: Abstract Number: 1385

Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

9:00AM-11:00AM: Abstract Number: 965

Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1612

Disease Activity and Cognitive Function in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1588

Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?

9:00AM-11:00AM: Abstract Number: 1726

Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study

9:00AM-11:00AM: Abstract Number: 1725

Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 1699

Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation

9:00AM-11:00AM: Abstract Number: 1724

Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 972

Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease

9:00AM-11:00AM: Abstract Number: 1057

Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma

9:00AM-11:00AM: Abstract Number: 1038

Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1711

Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study

9:00AM-11:00AM: Abstract Number: 1465

Diversity Analysis of Intestinal Flora in Patients with Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1030

DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients

9:00AM-11:00AM: Abstract Number: 1616

Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?

9:00AM-11:00AM: Abstract Number: 1230

Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank

9:00AM-11:00AM: Abstract Number: 1088

Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration

9:00AM-11:00AM: Abstract Number: 1676

Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?

9:00AM-11:00AM: Abstract Number: 1662

Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?

9:00AM-11:00AM: Abstract Number: 1551

Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration

9:00AM-11:00AM: Abstract Number: 1153

Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population

9:00AM-11:00AM: Abstract Number: 1687

Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis

9:00AM-11:00AM: Abstract Number: 1555

Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry

9:00AM-11:00AM: Abstract Number: 1548

Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors

9:00AM-11:00AM: Abstract Number: 1511

Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients

9:00AM-11:00AM: Abstract Number: 1713

Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase

9:00AM-11:00AM: Abstract Number: 1458

Dual Analysis with Nerve Ultrasound and Skin Biopsy in Painful Neuropathy Associated with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1384

Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort

9:00AM-11:00AM: Abstract Number: 1025

Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity

9:00AM-11:00AM: Abstract Number: 1066

Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1349

Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada

9:00AM-11:00AM: Abstract Number: 1541

Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1619

Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1192

Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital

9:00AM-11:00AM: Abstract Number: 1425

Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial

9:00AM-11:00AM: Abstract Number: 1636

Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial

9:00AM-11:00AM: Abstract Number: 1439

Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs

9:00AM-11:00AM: Abstract Number: 1517

Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

9:00AM-11:00AM: Abstract Number: 1483

Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study

9:00AM-11:00AM: Abstract Number: 1554

Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study

9:00AM-11:00AM: Abstract Number: 1608

Effect of the Metabolic Syndrome on Renal Function Decline in Four Rheumatic Diseases: An 8-year Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 1421

Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results

9:00AM-11:00AM: Abstract Number: 1415

Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1269

Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome

9:00AM-11:00AM: Abstract Number: 1546

Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry

9:00AM-11:00AM: Abstract Number: 1270

Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 1500

Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?

9:00AM-11:00AM: Abstract Number: 1063

Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1013

Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1258

Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial

9:00AM-11:00AM: Abstract Number: 1644

Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial

9:00AM-11:00AM: Abstract Number: 1468

Effects of Resistive Exercise on Fatigue and Disease Activity in Women with Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1352

Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1092

Efficacy and Safety of Dose Adjustment Based on Patients’ Body Size in Low Dose Intravenous CYC Treatment for Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1304

Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis

9:00AM-11:00AM: Abstract Number: 1643

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

9:00AM-11:00AM: Abstract Number: 1653

Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study

9:00AM-11:00AM: Abstract Number: 1526

Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1412

Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study

9:00AM-11:00AM: Abstract Number: 1697

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study

9:00AM-11:00AM: Abstract Number: 1245

Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 1704

Efficacy of Leflunomide for Treatment of Vasculitis

9:00AM-11:00AM: Abstract Number: 1408

Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1497

Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

9:00AM-11:00AM: Abstract Number: 1691

Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients

9:00AM-11:00AM: Abstract Number: 1413

Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy

9:00AM-11:00AM: Abstract Number: 1402

Efficacy, Safety and Continuation Rate of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis : The Comparative Observational Study

9:00AM-11:00AM: Abstract Number: 1193

EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1639

Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1585

Endothelial Dysfunction and Arterial Stiffness in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1223

Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1098

Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study

9:00AM-11:00AM: Abstract Number: 1267

Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study

9:00AM-11:00AM: Abstract Number: 1074

Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells

9:00AM-11:00AM: Abstract Number: 1029

Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis

9:00AM-11:00AM: Abstract Number: 1163

Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP

9:00AM-11:00AM: Abstract Number: 1654

Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1102

Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance

9:00AM-11:00AM: Abstract Number: 1742

Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort

9:00AM-11:00AM: Abstract Number: 1094

EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases

9:00AM-11:00AM: Abstract Number: 1732

Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 1466

Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1399

Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset

9:00AM-11:00AM: Abstract Number: 1322

Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain

9:00AM-11:00AM: Abstract Number: 1670

Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)

9:00AM-11:00AM: Abstract Number: 1015

Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals

9:00AM-11:00AM: Abstract Number: 1171

Evidence of Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Minimal Disease Activity – Interim Analysis

9:00AM-11:00AM: Abstract Number: 1632

Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1148

Examining Five Year Lupus Retention in Care in an Academic Cohort

9:00AM-11:00AM: Abstract Number: 1035

Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1745

Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1031

Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1110

Expanding Access to Research Using Tele-Health: Lupus and Informatics Feasibility Study

9:00AM-11:00AM: Abstract Number: 1492

Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study

9:00AM-11:00AM: Abstract Number: 1556

Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms

9:00AM-11:00AM: Abstract Number: 1405

Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab

9:00AM-11:00AM: Abstract Number: 1132

Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1584

Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort

9:00AM-11:00AM: Abstract Number: 1197

Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1618

Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity

9:00AM-11:00AM: Abstract Number: 1673

Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial

9:00AM-11:00AM: Abstract Number: 1150

Factors Associated with Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1614

Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1122

Factors Impacting Referral of Juvenile Idiopathic Arthritis Patients to a Tertiary Level Pediatric Rheumatology Center in North India

9:00AM-11:00AM: Abstract Number: 1578

Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1474

Factors Influencing the ESSPRI Index in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1337

Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy

9:00AM-11:00AM: Abstract Number: 983

Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection

9:00AM-11:00AM: Abstract Number: 1282

Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis

9:00AM-11:00AM: Abstract Number: 1182

Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach

9:00AM-11:00AM: Abstract Number: 1316

Frail Patients Have Less Pain After Total Hip Replacement

9:00AM-11:00AM: Abstract Number: 1317

Frail Patients Have Worse Function After Total Knee Replacement

9:00AM-11:00AM: Abstract Number: 1600

Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1168

Frequently Encountered Artifacts in Novel Application of Dual-Energy CT to Vascular Imaging: A Pilot Study

9:00AM-11:00AM: Abstract Number: 975

Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function

9:00AM-11:00AM: Abstract Number: 1241

Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children

9:00AM-11:00AM: Abstract Number: 1161

Gadolinium-Enhanced Magnetic Resonance Imaging in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1004

Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1050

Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1718

Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017

9:00AM-11:00AM: Abstract Number: 1379

Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study

9:00AM-11:00AM: Abstract Number: 1383

Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study

9:00AM-11:00AM: Abstract Number: 1665

Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections

9:00AM-11:00AM: Abstract Number: 1688

Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial

9:00AM-11:00AM: Abstract Number: 1446

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

9:00AM-11:00AM: Abstract Number: 1477

Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany

9:00AM-11:00AM: Abstract Number: 1087

Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)

9:00AM-11:00AM: Abstract Number: 1499

Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

9:00AM-11:00AM: Abstract Number: 1183

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study

9:00AM-11:00AM: Abstract Number: 1117

Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience

9:00AM-11:00AM: Abstract Number: 1668

Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry

9:00AM-11:00AM: Abstract Number: 1494

Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year

9:00AM-11:00AM: Abstract Number: 1712

Head and Neck Involvement of IgA Vasculitis: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1125

Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1756

Health-related Social Media Use by Parents of Children with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1656

Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial

9:00AM-11:00AM: Abstract Number: 1470

Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI

9:00AM-11:00AM: Abstract Number: 1123

Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics

9:00AM-11:00AM: Abstract Number: 1593

Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality

9:00AM-11:00AM: Abstract Number: 1566

HER2 as a Biomarker of Proliferative Lupus Nephritis in Children

9:00AM-11:00AM: Abstract Number: 1104

Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study

9:00AM-11:00AM: Abstract Number: 1420

Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)

9:00AM-11:00AM: Abstract Number: 1378

High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

9:00AM-11:00AM: Abstract Number: 1594

High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1568

High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls

9:00AM-11:00AM: Abstract Number: 1381

High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1154

Hispanic Patients with Rheumatoid Arthritis Have Greater Discordance Between Patient and Physician Global Estimates Than Other Ethnic Groups, Explained Largely by Fibromyalgia (FM) According to a FM Assessment Screening Tool 3 (FAST3)

9:00AM-11:00AM: Abstract Number: 1655

Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1451

Histological Characteristics in SICCA Syndrome – Clinical and Serological Association

9:00AM-11:00AM: Abstract Number: 1706

HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1605

Homocysteinemia Predicts Renal Insufficiency in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1671

Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1186

How Accurate Is Physical Joint Inflammation of the MTP-joints and What Can We Learn from Additional MRI on Forefoot Involvement in Early Arthritis?

9:00AM-11:00AM: Abstract Number: 1220

How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1233

Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout

9:00AM-11:00AM: Abstract Number: 1090

Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 991

Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides

9:00AM-11:00AM: Abstract Number: 992

Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1051

Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1016

Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis

9:00AM-11:00AM: Abstract Number: 1073

Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1290

Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1342

Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 958

Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1067

Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis

9:00AM-11:00AM: Abstract Number: 976

Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1746

Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers

9:00AM-11:00AM: Abstract Number: 964

Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1717

Identifying Patterns of Histopathologic Presentation in CNS Vasculitis

9:00AM-11:00AM: Abstract Number: 1284

Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?

9:00AM-11:00AM: Abstract Number: 1010

IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis

9:00AM-11:00AM: Abstract Number: 1707

IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors

9:00AM-11:00AM: Abstract Number: 1560

Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia

9:00AM-11:00AM: Abstract Number: 1376

Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1319

Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis

9:00AM-11:00AM: Abstract Number: 1509

Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies

9:00AM-11:00AM: Abstract Number: 1476

Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits

9:00AM-11:00AM: Abstract Number: 1489

Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study

9:00AM-11:00AM: Abstract Number: 1513

Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1523

Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis

9:00AM-11:00AM: Abstract Number: 1581

Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1553

Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1730

Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1221

Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab

9:00AM-11:00AM: Abstract Number: 1393

Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1353

Impact of Smartphone Application Based Management in Rheumatoid Arthritis: SMART- RA Study

9:00AM-11:00AM: Abstract Number: 1242

Impact of Smoking Status on Remission in Hidradenitis Suppurativa

9:00AM-11:00AM: Abstract Number: 1426

Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib

9:00AM-11:00AM: Abstract Number: 1487

Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)

9:00AM-11:00AM: Abstract Number: 1341

Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1348

Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1658

Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort

9:00AM-11:00AM: Abstract Number: 1406

Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

9:00AM-11:00AM: Abstract Number: 984

Important Role of CD11c+ Cells in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1231

Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase

9:00AM-11:00AM: Abstract Number: 1434

Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 1493

Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics

9:00AM-11:00AM: Abstract Number: 1414

Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab

9:00AM-11:00AM: Abstract Number: 1204

Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial

9:00AM-11:00AM: Abstract Number: 1136

Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate

9:00AM-11:00AM: Abstract Number: 1755

Improving Adolescent Health Care Transition: Piloting the Transition Readiness Assessment Questionnaire

9:00AM-11:00AM: Abstract Number: 1211

Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1749

Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center

9:00AM-11:00AM: Abstract Number: 1113

Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool

9:00AM-11:00AM: Abstract Number: 1199

Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus

9:00AM-11:00AM: Abstract Number: 1318

In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms

9:00AM-11:00AM: Abstract Number: 1514

Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting

9:00AM-11:00AM: Abstract Number: 1573

Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort

9:00AM-11:00AM: Abstract Number: 1076

Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1748

Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood

9:00AM-11:00AM: Abstract Number: 1646

Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution

9:00AM-11:00AM: Abstract Number: 1234

Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?

9:00AM-11:00AM: Abstract Number: 994

Increased Antibody and T-cell Responses Following Treatment of Collagen-Induced Arthritis in C57Bl/6 Mice with Organic Dust Inhalants

9:00AM-11:00AM: Abstract Number: 1344

Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study

9:00AM-11:00AM: Abstract Number: 1297

Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1703

Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 1296

Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema

9:00AM-11:00AM: Abstract Number: 1320

Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort

9:00AM-11:00AM: Abstract Number: 1049

Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts

9:00AM-11:00AM: Abstract Number: 1729

Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India

9:00AM-11:00AM: Abstract Number: 1515

Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

9:00AM-11:00AM: Abstract Number: 1522

Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks

9:00AM-11:00AM: Abstract Number: 1486

Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1169

Influence of Steroid Treatment on 18F-FDG PET/CT Accuracy to Detect Vascular and Musculoeskeletal Involvement in Patients with Polymyalgia Reumatica

9:00AM-11:00AM: Abstract Number: 1200

Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital

9:00AM-11:00AM: Abstract Number: 985

Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis

9:00AM-11:00AM: Abstract Number: 995

Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 1058

Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis

9:00AM-11:00AM: Abstract Number: 1685

Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014

9:00AM-11:00AM: Abstract Number: 1278

Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States

9:00AM-11:00AM: Abstract Number: 1682

Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States

9:00AM-11:00AM: Abstract Number: 1026

Interferon Lambda Promotes Age-Associated B Cells

9:00AM-11:00AM: Abstract Number: 1678

Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 1563

Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?

9:00AM-11:00AM: Abstract Number: 1127

Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology

9:00AM-11:00AM: Abstract Number: 1303

Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA

9:00AM-11:00AM: Abstract Number: 1158

Investigating Health Literacy and Numeracy in an Academic Center Lupus Cohort

9:00AM-11:00AM: Abstract Number: 1441

Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1752

Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?

9:00AM-11:00AM: Abstract Number: 1255

Is Exon 2 Associated with FMF or a New Disease?

9:00AM-11:00AM: Abstract Number: 1696

Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?

9:00AM-11:00AM: Abstract Number: 1550

Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 1488

Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1510

Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1547

Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials

9:00AM-11:00AM: Abstract Number: 1521

Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores

9:00AM-11:00AM: Abstract Number: 1545

Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)

9:00AM-11:00AM: Abstract Number: 1501

Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors

9:00AM-11:00AM: Abstract Number: 1280

JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1338

Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

9:00AM-11:00AM: Abstract Number: 1709

Juvenile-Onset IgG4-Related Disease: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1739

Kawasaki Disease Shock Syndrome – More Common Than We Think: Our Experience at Chandigarh, North India

9:00AM-11:00AM: Abstract Number: 1743

Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre

9:00AM-11:00AM: Abstract Number: 1312

Knee Morphology Associates with Tibio-Femoral and Patello-Femoral Osteoarthritis: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1613

LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1096

Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks

9:00AM-11:00AM: Abstract Number: 1357

Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity

9:00AM-11:00AM: Abstract Number: 1139

Lifetime Direct Medical and Indirect Cost of Knee Osteoarthritis: Impact of Pain and Structural Severity

9:00AM-11:00AM: Abstract Number: 978

Light Mediated Therapeutics in Arthritis

9:00AM-11:00AM: Abstract Number: 1527

Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program

9:00AM-11:00AM: Abstract Number: 1225

Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound

9:00AM-11:00AM: Abstract Number: 1659

Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1288

Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 989

Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1032

Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation

9:00AM-11:00AM: Abstract Number: 1667

Long Term Outcome of Hydralazine-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1491

Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial

9:00AM-11:00AM: Abstract Number: 1542

Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry

9:00AM-11:00AM: Abstract Number: 1417

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry

9:00AM-11:00AM: Abstract Number: 1543

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry

9:00AM-11:00AM: Abstract Number: 1692

Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1733

Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort

9:00AM-11:00AM: Abstract Number: 1534

Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 1520

Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status

9:00AM-11:00AM: Abstract Number: 1506

Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results

9:00AM-11:00AM: Abstract Number: 1363

Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?

9:00AM-11:00AM: Abstract Number: 1131

Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?

9:00AM-11:00AM: Abstract Number: 1734

Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1387

Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab

9:00AM-11:00AM: Abstract Number: 1152

Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy

9:00AM-11:00AM: Abstract Number: 1628

Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

9:00AM-11:00AM: Abstract Number: 1028

Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits

9:00AM-11:00AM: Abstract Number: 1111

Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients

9:00AM-11:00AM: Abstract Number: 1062

Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1575

Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change

9:00AM-11:00AM: Abstract Number: 1024

Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells

9:00AM-11:00AM: Abstract Number: 1173

Magnetic Resonance Imaging in Patients in Clinical Remission: Tenosynovitis and Osteitis Are Independent Predictors of Radiographic and MRI Damage Progression

9:00AM-11:00AM: Abstract Number: 1281

Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?

9:00AM-11:00AM: Abstract Number: 1666

Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems

9:00AM-11:00AM: Abstract Number: 1677

Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?

9:00AM-11:00AM: Abstract Number: 1265

Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients

9:00AM-11:00AM: Abstract Number: 1033

Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus

9:00AM-11:00AM: Abstract Number: 1077

Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications

9:00AM-11:00AM: Abstract Number: 1134

Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1133

Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1007

Memory ex-Th17 Cells Contribute to Synovial Inflammation in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 961

Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody

9:00AM-11:00AM: Abstract Number: 966

Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients

9:00AM-11:00AM: Abstract Number: 1460

Minor Salivary Gland Biopsy and Dry Ocular Tests to Detect Occult Sjögren Syndrome in Patients with Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 1722

Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy

9:00AM-11:00AM: Abstract Number: 1723

Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients

9:00AM-11:00AM: Abstract Number: 1108

Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)

9:00AM-11:00AM: Abstract Number: 1039

Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE

9:00AM-11:00AM: Abstract Number: 1238

Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter

9:00AM-11:00AM: Abstract Number: 1218

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients

9:00AM-11:00AM: Abstract Number: 1235

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients

9:00AM-11:00AM: Abstract Number: 1623

Mortality in a SLE Inception Cohort of Hispanic Patients

9:00AM-11:00AM: Abstract Number: 1351

Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort

9:00AM-11:00AM: Abstract Number: 1377

MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome

9:00AM-11:00AM: Abstract Number: 1479

Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study

9:00AM-11:00AM: Abstract Number: 1651

Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers

9:00AM-11:00AM: Abstract Number: 1293

Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2

9:00AM-11:00AM: Abstract Number: 1649

Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II

9:00AM-11:00AM: Abstract Number: 1045

Myocardial Involvement in SSc: Key Role of Lin-gp38+ Stromal Cells in the Onset of Fibrosis and Defects of the Conduction System

9:00AM-11:00AM: Abstract Number: 1276

Myositis Specific Antibodies and Clinical Features in Patients from Argentina

9:00AM-11:00AM: Abstract Number: 1177

Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare

9:00AM-11:00AM: Abstract Number: 1457

Neurological Involvement in a Cohort of Primary Sjogren’s Syndrome Patients: Results of a Multicenter Italian Study

9:00AM-11:00AM: Abstract Number: 1226

Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity

9:00AM-11:00AM: Abstract Number: 1023

Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals

9:00AM-11:00AM: Abstract Number: 1469

New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice

9:00AM-11:00AM: Abstract Number: 1274

New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody

9:00AM-11:00AM: Abstract Number: 1185

New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission

9:00AM-11:00AM: Abstract Number: 970

New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction

9:00AM-11:00AM: Abstract Number: 1020

NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1331

No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab

9:00AM-11:00AM: Abstract Number: 1330

No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years

9:00AM-11:00AM: Abstract Number: 1116

Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data

9:00AM-11:00AM: Abstract Number: 1370

Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1164

Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1253

Novel Nonsense Variant and Entire Deletion of TNFAIP3 Cause Haploinsufficiency of A20 Clinically Distinct from Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1188

Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls

9:00AM-11:00AM: Abstract Number: 1689

Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa

9:00AM-11:00AM: Abstract Number: 1368

One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk

9:00AM-11:00AM: Abstract Number: 1100

Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1135

Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1001

Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis

9:00AM-11:00AM: Abstract Number: 1740

Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention

9:00AM-11:00AM: Abstract Number: 1609

Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1310

Osteoarthritis: What’s in a Name?

9:00AM-11:00AM: Abstract Number: 1295

Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells

9:00AM-11:00AM: Abstract Number: 1138

Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

9:00AM-11:00AM: Abstract Number: 1208

Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic

9:00AM-11:00AM: Abstract Number: 1587

Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1053

Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo

9:00AM-11:00AM: Abstract Number: 1462

Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study

9:00AM-11:00AM: Abstract Number: 1380

Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

9:00AM-11:00AM: Abstract Number: 1350

Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

9:00AM-11:00AM: Abstract Number: 1196

Patient Preference for an Electronic MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/ Routine Assessment of Patient Index Data), Which Gives Similar Results Compared to a Paper Version

9:00AM-11:00AM: Abstract Number: 1083

Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1209

Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project

9:00AM-11:00AM: Abstract Number: 1423

Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study

9:00AM-11:00AM: Abstract Number: 1375

Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1314

Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 1286

Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1252

Pattern of Arthropathy in Patients with Cystic Fibrosis

9:00AM-11:00AM: Abstract Number: 1334

Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1119

Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry

9:00AM-11:00AM: Abstract Number: 1340

Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1009

PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease

9:00AM-11:00AM: Abstract Number: 1750

Pediatric Sjögren Syndrome: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 1249

Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain

9:00AM-11:00AM: Abstract Number: 1720

Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome

9:00AM-11:00AM: Abstract Number: 1373

Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1206

Performance of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Item Profile in a Cohort of Australians with RA, OA and Other Inflammatory Arthritic Conditions

9:00AM-11:00AM: Abstract Number: 1175

Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA

9:00AM-11:00AM: Abstract Number: 1396

Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 1505

Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis

9:00AM-11:00AM: Abstract Number: 1602

Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1572

Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors

9:00AM-11:00AM: Abstract Number: 1728

Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 993

pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1694

Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1217

Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development

9:00AM-11:00AM: Abstract Number: 1128

Physician-Patient Interaction and Medication Adherence in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1061

PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis

9:00AM-11:00AM: Abstract Number: 1216

Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare

9:00AM-11:00AM: Abstract Number: 1617

Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 979

Platelet Derived Growth Factor Receptor Alpha (PDGFRα) Blockade Inhibits Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 1471

Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren´s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study

9:00AM-11:00AM: Abstract Number: 1329

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1569

Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1716

Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study

9:00AM-11:00AM: Abstract Number: 1343

Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1463

Positive Rate of Small Intestinal Bacterial Overgrowth Test (SIBO) Was Significant Correlations to Disease Activity of Primary Sjogren’s Syndrome (pSS)

9:00AM-11:00AM: Abstract Number: 1411

Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy

9:00AM-11:00AM: Abstract Number: 1346

Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1147

Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients

9:00AM-11:00AM: Abstract Number: 1198

Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents

9:00AM-11:00AM: Abstract Number: 1747

Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease

9:00AM-11:00AM: Abstract Number: 1445

Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States

9:00AM-11:00AM: Abstract Number: 1084

Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1519

Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)

9:00AM-11:00AM: Abstract Number: 1390

Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels

9:00AM-11:00AM: Abstract Number: 1610

Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index

9:00AM-11:00AM: Abstract Number: 1300

Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1715

Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis

9:00AM-11:00AM: Abstract Number: 1137

Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database

9:00AM-11:00AM: Abstract Number: 1430

Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1544

Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 1418

Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 1579

Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race

9:00AM-11:00AM: Abstract Number: 1576

Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis

9:00AM-11:00AM: Abstract Number: 1120

Prevalence of Burnout in Rheumatology Professionals

9:00AM-11:00AM: Abstract Number: 1589

Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery

9:00AM-11:00AM: Abstract Number: 1103

Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US

9:00AM-11:00AM: Abstract Number: 1601

Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1174

Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI

9:00AM-11:00AM: Abstract Number: 1311

Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study

9:00AM-11:00AM: Abstract Number: 1549

Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab

9:00AM-11:00AM: Abstract Number: 1472

Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up

9:00AM-11:00AM: Abstract Number: 1085

Probiotic Use and Psoriatic Arthritis Disease Activity

9:00AM-11:00AM: Abstract Number: 1056

Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway

9:00AM-11:00AM: Abstract Number: 1583

Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1624

Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients

9:00AM-11:00AM: Abstract Number: 1040

Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity

9:00AM-11:00AM: Abstract Number: 1055

Proteomic and Transcriptomic Analysis of Human Eosinophilic Fasciitis Fibroblasts

9:00AM-11:00AM: Abstract Number: 1086

Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis

9:00AM-11:00AM: Abstract Number: 1212

Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1203

Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review

9:00AM-11:00AM: Abstract Number: 1461

Pulmonary Cysts: Very Common Finding on Computed Tomography of the Chest of Asymptomatic Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1305

Quality Improvement in Diagnostic and Therapeutic Arthrocentesis in the Flexed Knee Using Pneumatic Compression of the Suprapatellar Bursa

9:00AM-11:00AM: Abstract Number: 1264

Quality of Life in Patients with SAPHO Syndrome: A Single-center Survey of 588 Patients

9:00AM-11:00AM: Abstract Number: 1195

Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?

9:00AM-11:00AM: Abstract Number: 1143

Racial Disparities in Factors Associated with SLICC Damage Score Among Patients with SLE

9:00AM-11:00AM: Abstract Number: 1141

Racial Disparities in Lupus Medication Adherence

9:00AM-11:00AM: Abstract Number: 1301

Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts

9:00AM-11:00AM: Abstract Number: 1313

Readmissions After Staged vs Simultaneous Bilateral Total Knee Replacements (TKR)

9:00AM-11:00AM: Abstract Number: 1495

Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients

9:00AM-11:00AM: Abstract Number: 1400

Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1530

Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe

9:00AM-11:00AM: Abstract Number: 1443

Real World Switching Patterns of Etanercept Original and Biosilmilar in Germany

9:00AM-11:00AM: Abstract Number: 1431

Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study

9:00AM-11:00AM: Abstract Number: 1374

Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US

9:00AM-11:00AM: Abstract Number: 1205

Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)

9:00AM-11:00AM: Abstract Number: 1481

Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

9:00AM-11:00AM: Abstract Number: 1257

Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 1664

Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial

9:00AM-11:00AM: Abstract Number: 1422

Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA

9:00AM-11:00AM: Abstract Number: 1014

Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients

9:00AM-11:00AM: Abstract Number: 1315

Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study

9:00AM-11:00AM: Abstract Number: 1440

Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1362

Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device

9:00AM-11:00AM: Abstract Number: 1633

Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1105

Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1222

Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration

9:00AM-11:00AM: Abstract Number: 1684

Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual

9:00AM-11:00AM: Abstract Number: 1564

Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1018

Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans

9:00AM-11:00AM: Abstract Number: 1528

Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1279

Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

9:00AM-11:00AM: Abstract Number: 1179

Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1429

Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1512

Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results

9:00AM-11:00AM: Abstract Number: 1757

Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions

9:00AM-11:00AM: Abstract Number: 1184

Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments

9:00AM-11:00AM: Abstract Number: 1112

Rheumatologists’ Opinions and Use of Telemedicine in the Southwestern U.S

9:00AM-11:00AM: Abstract Number: 1607

Risk Factors for Avascular Necrosis in SLE: A Multivariate Model

9:00AM-11:00AM: Abstract Number: 1306

Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?

9:00AM-11:00AM: Abstract Number: 1283

Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 1395

Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab

9:00AM-11:00AM: Abstract Number: 1339

Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1091

Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry

9:00AM-11:00AM: Abstract Number: 1686

Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers

9:00AM-11:00AM: Abstract Number: 1000

RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis

9:00AM-11:00AM: Abstract Number: 1036

RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery

9:00AM-11:00AM: Abstract Number: 1595

Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1559

Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE

9:00AM-11:00AM: Abstract Number: 1525

Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial

9:00AM-11:00AM: Abstract Number: 1503

Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials

9:00AM-11:00AM: Abstract Number: 1326

Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1325

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA

9:00AM-11:00AM: Abstract Number: 1450

Salivary Gland Hypofunction in a Mouse Model for Sjögren’s Syndrome Is Strongly Associated with Hyperglycemia

9:00AM-11:00AM: Abstract Number: 1657

Sarcopenia in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1398

Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1557

Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network

9:00AM-11:00AM: Abstract Number: 1485

Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study

9:00AM-11:00AM: Abstract Number: 1482

Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1366

Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?

9:00AM-11:00AM: Abstract Number: 980

Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis

9:00AM-11:00AM: Abstract Number: 1291

Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study

9:00AM-11:00AM: Abstract Number: 1660

Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?

9:00AM-11:00AM: Abstract Number: 973

Serum IgG4 Concentrations Differ According to Race and Sex

9:00AM-11:00AM: Abstract Number: 1744

Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1625

Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities

9:00AM-11:00AM: Abstract Number: 1638

Sexual Health in 60 Female Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1558

Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?

9:00AM-11:00AM: Abstract Number: 1629

Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience

9:00AM-11:00AM: Abstract Number: 1011

Single Cell RNA Sequencing of Patients with Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 1022

Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages

9:00AM-11:00AM: Abstract Number: 1454

Sjӧgren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms

9:00AM-11:00AM: Abstract Number: 1228

Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout

9:00AM-11:00AM: Abstract Number: 1275

Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity

9:00AM-11:00AM: Abstract Number: 969

ß-adrenergic Receptor Activation: A Way to Enhance CD4 T Cell Suppression by Improving Regulatory B Cell Function

9:00AM-11:00AM: Abstract Number: 998

Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis

9:00AM-11:00AM: Abstract Number: 1603

Stroke Clusters in SLE by Lupus Autoantibodies

9:00AM-11:00AM: Abstract Number: 997

Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis

9:00AM-11:00AM: Abstract Number: 1236

Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1504

Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years

9:00AM-11:00AM: Abstract Number: 1302

Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

9:00AM-11:00AM: Abstract Number: 1308

Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1114

Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative

9:00AM-11:00AM: Abstract Number: 1674

Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience

9:00AM-11:00AM: Abstract Number: 1115

Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)

9:00AM-11:00AM: Abstract Number: 1473

Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1259

Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series

9:00AM-11:00AM: Abstract Number: 1336

Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1478

Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials

9:00AM-11:00AM: Abstract Number: 1106

Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock

9:00AM-11:00AM: Abstract Number: 1611

Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?

9:00AM-11:00AM: Abstract Number: 1459

Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients

9:00AM-11:00AM: Abstract Number: 1648

Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression

9:00AM-11:00AM: Abstract Number: 1737

Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1620

T-cell Exhaustion in Prolonged Remission SLE Patients

9:00AM-11:00AM: Abstract Number: 1432

Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –

9:00AM-11:00AM: Abstract Number: 1702

Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study

9:00AM-11:00AM: Abstract Number: 999

Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy

9:00AM-11:00AM: Abstract Number: 1005

Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1202

Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies

9:00AM-11:00AM: Abstract Number: 1044

TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?

9:00AM-11:00AM: Abstract Number: 1121

The Association Between Physician Sex and Faculty Rank Among Academic Rheumatologists in the United States

9:00AM-11:00AM: Abstract Number: 1388

The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM

9:00AM-11:00AM: Abstract Number: 1239

The Association Between Urate and CSF Markers of Alzheimer’s Disease in a Population-Based Sample of 70-Year-Olds

9:00AM-11:00AM: Abstract Number: 1562

The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1582

The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy

9:00AM-11:00AM: Abstract Number: 1681

The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)

9:00AM-11:00AM: Abstract Number: 1637

The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy

9:00AM-11:00AM: Abstract Number: 1647

The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices

9:00AM-11:00AM: Abstract Number: 1333

The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea

9:00AM-11:00AM: Abstract Number: 1124

The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review

9:00AM-11:00AM: Abstract Number: 1060

The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients

9:00AM-11:00AM: Abstract Number: 1424

The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial

9:00AM-11:00AM: Abstract Number: 1046

The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1502

The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1615

The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement

9:00AM-11:00AM: Abstract Number: 1538

The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1214

The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?

9:00AM-11:00AM: Abstract Number: 1529

The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry

9:00AM-11:00AM: Abstract Number: 1382

The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1251

The Impact of Aging on Familial Mediterranean Fever Patients

9:00AM-11:00AM: Abstract Number: 1599

The Impact of Body Mass Index Variability in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1621

The Impact of Disease Activity and Related Factors on Cognitive Dysfunction in SLE

9:00AM-11:00AM: Abstract Number: 1151

The Impact of Gender on Time to Rheumatoid Arthritis Classification

9:00AM-11:00AM: Abstract Number: 1075

The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1577

The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1484

The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1456

The Increased Ratio of Blood CD56bright to CD56dim NK Cells Is a Distinguishing Feature of Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1017

The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus

9:00AM-11:00AM: Abstract Number: 1690

The Long-term Outcome of Patients with Arthritis of Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1043

The Metabolic Intermediate Alpha-Ketoglutarate Suppresses the TGFβ-driven Profibrotic Responses of Dermal Fibroblasts

9:00AM-11:00AM: Abstract Number: 1327

The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

9:00AM-11:00AM: Abstract Number: 1464

The Oral Microbiome as a Risk Factor for Benign or Pathologic Autoimmunity Associated with Anti-SSA/Ro Positivity and Mimicry for Von Willebrand Factor Type a Domain Protein (vWFA) of L. Mirabilis

9:00AM-11:00AM: Abstract Number: 1328

The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1533

The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1052

The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 962

The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1263

The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center

9:00AM-11:00AM: Abstract Number: 1392

The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes

9:00AM-11:00AM: Abstract Number: 1172

The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging

9:00AM-11:00AM: Abstract Number: 1145

The Representation of Skin Tones in Images of Patients with Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1130

The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 996

The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages

9:00AM-11:00AM: Abstract Number: 1095

The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1099

The Safety of Pulse Therapy- Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1140

The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients

9:00AM-11:00AM: Abstract Number: 1155

The Status of Latin-American Women in Rheumatology

9:00AM-11:00AM: Abstract Number: 1260

The Study of Peripheral Blood Lymphocyte Subsets and CD4+T Subsets in Recurrent Polychondritis

9:00AM-11:00AM: Abstract Number: 1604

The Systemic Lupus Erythematosus Cardiovascular Risk Equation

9:00AM-11:00AM: Abstract Number: 1261

The Time Lag – the Race in Diagnosis and Management of Hemophagocytic Lymphohistiocytosis

9:00AM-11:00AM: Abstract Number: 1093

The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)

9:00AM-11:00AM: Abstract Number: 1146

Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity

9:00AM-11:00AM: Abstract Number: 1042

Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis

9:00AM-11:00AM: Abstract Number: 1524

Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study

9:00AM-11:00AM: Abstract Number: 1428

Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1003

TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study

9:00AM-11:00AM: Abstract Number: 1167

To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?

9:00AM-11:00AM: Abstract Number: 1244

Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children

9:00AM-11:00AM: Abstract Number: 1181

Tocilizumab in Aortitis: A Multicenter Study of 79 Patients

9:00AM-11:00AM: Abstract Number: 986

Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1444

Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials

9:00AM-11:00AM: Abstract Number: 1738

Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging

9:00AM-11:00AM: Abstract Number: 988

Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1389

Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry

9:00AM-11:00AM: Abstract Number: 1237

Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans

9:00AM-11:00AM: Abstract Number: 1404

Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea

9:00AM-11:00AM: Abstract Number: 1097

Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study

9:00AM-11:00AM: Abstract Number: 1335

Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study

9:00AM-11:00AM: Abstract Number: 1518

Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases

9:00AM-11:00AM: Abstract Number: 1019

Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts

9:00AM-11:00AM: Abstract Number: 1448

Ultrasonography of Major Salivary Glands in Primary Sjögren’s Syndrome: Identification of Distinct Evolving Patterns in the Long-Term Follow-up

9:00AM-11:00AM: Abstract Number: 1360

Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1144

Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis

9:00AM-11:00AM: Abstract Number: 1332

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization

9:00AM-11:00AM: Abstract Number: 1219

Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population

9:00AM-11:00AM: Abstract Number: 1037

Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1118

US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation

9:00AM-11:00AM: Abstract Number: 1672

Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018

9:00AM-11:00AM: Abstract Number: 1246

Using PROMIS Data to Assess Activity of Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1539

Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 1165

Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review

9:00AM-11:00AM: Abstract Number: 1361

Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1210

Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity

9:00AM-11:00AM: Abstract Number: 1731

Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1571

Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1006

Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients

9:00AM-11:00AM: Abstract Number: 1324

Visceral Fat Deposition Associated with Pain in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1321

What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 1232

Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation

9:00AM-11:00AM: Abstract Number: 1532

Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study

9:00AM-11:00AM: Abstract Number: 1727

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care

11:00AM-12:30PM: Abstract Number: 1763

A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

11:00AM-12:30PM: Abstract Number: 1758

Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study

11:00AM-12:30PM: Abstract Number: 1759

Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial

11:00AM-12:30PM: Abstract Number: 1760

Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial

11:00AM-12:30PM: Abstract Number: 1761

The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block

11:00AM-12:30PM: Abstract Number: 1762

UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent

2:30PM-4:00PM: Abstract Number: 1822

6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

2:30PM-4:00PM: Abstract Number: 1768

A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation

2:30PM-4:00PM: Abstract Number: 1782

A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model

2:30PM-4:00PM: Abstract Number: 1847

A National Needs Assessment of Males with SLE: Assessing Medical, Psychosocial, Support & Coping Needs

2:30PM-4:00PM: Abstract Number: 1809

A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience

2:30PM-4:00PM: Abstract Number: 1829

Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients

2:30PM-4:00PM: Abstract Number: 1794

An Evaluation of Burnout Among U.S. Rheumatology Fellows: A National Survey

2:30PM-4:00PM: Abstract Number: 1788

Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 1791

Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

2:30PM-4:00PM: Abstract Number: 1817

Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change

2:30PM-4:00PM: Abstract Number: 1828

Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 1767

Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 1776

Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study

2:30PM-4:00PM: Abstract Number: 1764

CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion

2:30PM-4:00PM: Abstract Number: 1775

Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis

2:30PM-4:00PM: Abstract Number: 1772

Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice

2:30PM-4:00PM: Abstract Number: 1779

CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation

2:30PM-4:00PM: Abstract Number: 1827

Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 1836

Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial

2:30PM-4:00PM: Abstract Number: 1820

Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient

2:30PM-4:00PM: Abstract Number: 1792

Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)

2:30PM-4:00PM: Abstract Number: 1811

Commonly Used Drugs in Rheumatology May Alter Anti-Tumoral Response to Immune Checkpoint Inhibitors

2:30PM-4:00PM: Abstract Number: 1801

Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

2:30PM-4:00PM: Abstract Number: 1825

Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis

2:30PM-4:00PM: Abstract Number: 1818

Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study

2:30PM-4:00PM: Abstract Number: 1781

Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis

2:30PM-4:00PM: Abstract Number: 1789

Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation

2:30PM-4:00PM: Abstract Number: 1812

Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 1826

Describing Intra-Individual Cognitive Function Course over Time in Lupus Patients: Persistent and Fluctuating Cognitive Impairment, Affected Cognitive Domains, and Severity

2:30PM-4:00PM: Abstract Number: 1793

Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

2:30PM-4:00PM: Abstract Number: 1839

Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis

2:30PM-4:00PM: Abstract Number: 1846

Does Cartilage Loss Cause Pain in Osteoarthritis?

2:30PM-4:00PM: Abstract Number: 1795

Education of Rheumatology Faculty: Evaluation of an Interactive Team Based Approach versus Traditional Didactic Teaching

2:30PM-4:00PM: Abstract Number: 1833

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial

2:30PM-4:00PM: Abstract Number: 1778

Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis

2:30PM-4:00PM: Abstract Number: 1770

Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation

2:30PM-4:00PM: Abstract Number: 1835

Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients

2:30PM-4:00PM: Abstract Number: 1766

GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries

2:30PM-4:00PM: Abstract Number: 1796

Identifying Educational Themes and Knowledge Gaps Through Analysis of Electronic Consultation (eConsult) Communication Between Primary Care Physicians and Rheumatologists

2:30PM-4:00PM: Abstract Number: 1808

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation

2:30PM-4:00PM: Abstract Number: 1806

Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy: A Distinct Clinical Entity and Immunologic Phenotype

2:30PM-4:00PM: Abstract Number: 1765

Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 1814

Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era

2:30PM-4:00PM: Abstract Number: 1823

Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity

2:30PM-4:00PM: Abstract Number: 1780

Microbiome in Offspring of Ankylosing Spondylitis Patients

2:30PM-4:00PM: Abstract Number: 1771

MyD88 S209R Enhances Inflammation in Mouse Models of Arthritis

2:30PM-4:00PM: Abstract Number: 1769

Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response

2:30PM-4:00PM: Abstract Number: 1813

New Medications Are Needed for Children with Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 1842

Patients and Relatives Coping with Inflammatory Arthritis: Impact of Communication, Social Support and Relatives Burden on Patients Perceived Health

2:30PM-4:00PM: Abstract Number: 1824

Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 1803

Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina

2:30PM-4:00PM: Abstract Number: 1805

Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study

2:30PM-4:00PM: Abstract Number: 1845

Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 1774

Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 1843

Predictors of Mortality Among Black Women with Systemic Lupus Erythematosus: The Black Women’s Experiences Living with Lupus (BeWELL) Study

2:30PM-4:00PM: Abstract Number: 1816

Psoriasis Associated with Anti-Tumor Necrosis Factor-Alpha Therapies in Children with Inflammatory Bowel Disease, Juvenile Idiopathic Arthritis, and Chronic Noninfectious Osteomyelitis

2:30PM-4:00PM: Abstract Number: 1832

Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis

2:30PM-4:00PM: Abstract Number: 1841

Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study

2:30PM-4:00PM: Abstract Number: 1783

Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis

2:30PM-4:00PM: Abstract Number: 1810

Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study

2:30PM-4:00PM: Abstract Number: 1797

Rheumatology Mechanism Madness: A Pilot Collaborative Learning Activity for Rheumatology Trainees

2:30PM-4:00PM: Abstract Number: 1840

Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone

2:30PM-4:00PM: Abstract Number: 1800

Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)

2:30PM-4:00PM: Abstract Number: 1804

Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients

2:30PM-4:00PM: Abstract Number: 1834

Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease

2:30PM-4:00PM: Abstract Number: 1830

Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease

2:30PM-4:00PM: Abstract Number: 1784

Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions

2:30PM-4:00PM: Abstract Number: 1815

Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials

2:30PM-4:00PM: Abstract Number: 1831

Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes

2:30PM-4:00PM: Abstract Number: 1786

Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury

2:30PM-4:00PM: Abstract Number: 1807

Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease

2:30PM-4:00PM: Abstract Number: 1819

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index

2:30PM-4:00PM: Abstract Number: 1773

The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice

2:30PM-4:00PM: Abstract Number: 1844

The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE

2:30PM-4:00PM: Abstract Number: 1777

The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis

2:30PM-4:00PM: Abstract Number: 1790

The Epidemiology of the Antiphospholipid Syndrome in the UK, 1990 – 2016

2:30PM-4:00PM: Abstract Number: 1787

The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE

2:30PM-4:00PM: Abstract Number: 1785

The Pathogenic Potential of Choroid Plexus T Cells in Neuropsychiatric Lupus

2:30PM-4:00PM: Abstract Number: 1821

Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain

2:30PM-4:00PM: Abstract Number: 1798

Time to Bridge the Gap in Rheumatology Education: Interactive Team Based Learning Is Most Effective in Increasing Internal Medicine Residents’ Knowledge

2:30PM-4:00PM: Abstract Number: 1838

Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial

2:30PM-4:00PM: Abstract Number: 1837

Ustekinumab for the Treatment of Giant Cell Arteritis

2:30PM-4:00PM: Abstract Number: 1802

Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics

2:30PM-4:00PM: Abstract Number: 1799

Wellness and Resiliency Among Recent Rheumatology Fellowship Graduates: A Qualitative Study

4:30PM-6:00PM: Abstract Number: 1885

A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia

4:30PM-6:00PM: Abstract Number: 1907

Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial

4:30PM-6:00PM: Abstract Number: 1882

Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1887

Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1886

Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors

4:30PM-6:00PM: Abstract Number: 1900

Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies

4:30PM-6:00PM: Abstract Number: 1924

Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom

4:30PM-6:00PM: Abstract Number: 1892

Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery

4:30PM-6:00PM: Abstract Number: 1881

Association of Pain Centralization with DMARD Response in Active RA

4:30PM-6:00PM: Abstract Number: 1913

Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis

4:30PM-6:00PM: Abstract Number: 1884

Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1880

Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

4:30PM-6:00PM: Abstract Number: 1858

Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1895

Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques

4:30PM-6:00PM: Abstract Number: 1889

Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up

4:30PM-6:00PM: Abstract Number: 1867

Body Composition in Myositis Patients Is Negatively Changed Compared to Healthy Controls and the Changes Are Associated with Disease Activity and Duration, Skeletal Muscle Involvement and Physical Activity and Nutritional Status

4:30PM-6:00PM: Abstract Number: 1896

Breastfeeding in Women with Rheumatic Diseases

4:30PM-6:00PM: Abstract Number: 1903

BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years

4:30PM-6:00PM: Abstract Number: 1868

Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis

4:30PM-6:00PM: Abstract Number: 1852

Community-level Deprivation Index: Impact on Discharge Destination After Elective Hip Replacement

4:30PM-6:00PM: Abstract Number: 1849

Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

4:30PM-6:00PM: Abstract Number: 1919

Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis

4:30PM-6:00PM: Abstract Number: 1923

Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials

4:30PM-6:00PM: Abstract Number: 1925

Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis

4:30PM-6:00PM: Abstract Number: 1876

Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids

4:30PM-6:00PM: Abstract Number: 1883

Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients

4:30PM-6:00PM: Abstract Number: 1855

Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout

4:30PM-6:00PM: Abstract Number: 1874

Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial

4:30PM-6:00PM: Abstract Number: 1864

Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry

4:30PM-6:00PM: Abstract Number: 1873

Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap

4:30PM-6:00PM: Abstract Number: 1866

Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues

4:30PM-6:00PM: Abstract Number: 1912

High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 1857

High-resolution MRI Assessment of Flexor Tendon Pulleys in Psoriatic Arthritis for Disease Monitoring and Differentiation from Rheumatoid Arthritis Using a 16-channel Hand Coil

4:30PM-6:00PM: Abstract Number: 1891

Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1904

IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients

4:30PM-6:00PM: Abstract Number: 1922

Improvement in Hepatitis B Screening Prior to Initiation of Biologic Therapy in the Pediatric Rheumatology Clinic

4:30PM-6:00PM: Abstract Number: 1865

Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

4:30PM-6:00PM: Abstract Number: 1863

Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients

4:30PM-6:00PM: Abstract Number: 1914

Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature

4:30PM-6:00PM: Abstract Number: 1910

Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow

4:30PM-6:00PM: Abstract Number: 1859

Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients

4:30PM-6:00PM: Abstract Number: 1890

Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)

4:30PM-6:00PM: Abstract Number: 1909

miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients

4:30PM-6:00PM: Abstract Number: 1869

Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders

4:30PM-6:00PM: Abstract Number: 1871

Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury

4:30PM-6:00PM: Abstract Number: 1850

Needs Assessment of Rheumatology Fellowship Program Directors on the Need for a Health Disparities Curriculum for Our Fellowship Programs

4:30PM-6:00PM: Abstract Number: 1870

NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis

4:30PM-6:00PM: Abstract Number: 1921

Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

4:30PM-6:00PM: Abstract Number: 1908

Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis

4:30PM-6:00PM: Abstract Number: 1878

Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice

4:30PM-6:00PM: Abstract Number: 1853

Racial Differences in Highly Effective Contraceptive Use Among Medicaid Beneficiaries with SLE

4:30PM-6:00PM: Abstract Number: 1848

Racial Disparities in Septic and Aseptic Total Knee Replacement Revision Risk: A Study Using Four State-wide Inpatient Databases

4:30PM-6:00PM: Abstract Number: 1916

Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis

4:30PM-6:00PM: Abstract Number: 1898

Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study

4:30PM-6:00PM: Abstract Number: 1894

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study

4:30PM-6:00PM: Abstract Number: 1877

Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial

4:30PM-6:00PM: Abstract Number: 1920

School Nurse Education for Juvenile Idiopathic Arthritis

4:30PM-6:00PM: Abstract Number: 1901

Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib

4:30PM-6:00PM: Abstract Number: 1888

Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA

4:30PM-6:00PM: Abstract Number: 1897

Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story

4:30PM-6:00PM: Abstract Number: 1899

sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia

4:30PM-6:00PM: Abstract Number: 1905

Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)

4:30PM-6:00PM: Abstract Number: 1893

Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1875

Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study

4:30PM-6:00PM: Abstract Number: 1902

Systems Biology in 874 Patients with Primary Sjögren’s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA

4:30PM-6:00PM: Abstract Number: 1911

Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements

4:30PM-6:00PM: Abstract Number: 1856

Tenosynovial Aspiration by Ultrasound Guidance: Correlation and Diagnostic Implications of Tenosynovial Analysis and Ultrasound Doppler Signal

4:30PM-6:00PM: Abstract Number: 1851

The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus

4:30PM-6:00PM: Abstract Number: 1879

The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

4:30PM-6:00PM: Abstract Number: 1854

The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis

4:30PM-6:00PM: Abstract Number: 1862

Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making

4:30PM-6:00PM: Abstract Number: 1917

Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis

4:30PM-6:00PM: Abstract Number: 1918

Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis

4:30PM-6:00PM: Abstract Number: 1861

Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy

4:30PM-6:00PM: Abstract Number: 1860

Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study

4:30PM-6:00PM: Abstract Number: 1906

Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)

4:30PM-6:00PM: Abstract Number: 1915

Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis

4:30PM-6:00PM: Abstract Number: 1872

Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014

9:00AM-11:00AM: Abstract Number: 2600

‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2193

“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial

9:00AM-11:00AM: Abstract Number: 2218

1,25D3 Promotes Mineralization of Osteoblasts by Activating C/EBPβ-DKK1 Axis

9:00AM-11:00AM: Abstract Number: 2409

24-hour Activity Profiling in People Living with Arthritis: Habits Matter

9:00AM-11:00AM: Abstract Number: 2524

24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States

9:00AM-11:00AM: Abstract Number: 2585

A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2012

A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1968

A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2630

A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2184

A Flexion Contracture Is a Risk Factor for Radiographic Progression and Earlier Need for Arthroplasty in Knee Osteoarthritis: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2443

A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1966

A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2187

A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment

9:00AM-11:00AM: Abstract Number: L09

A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial

9:00AM-11:00AM: Abstract Number: 2290

A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2176

A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2559

A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2417

A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2270

A Pilot Study of the Psychosocial Impact of Undifferentiated Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2408

A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2263

A Qualitative Study Evaluating Near-Patient Tools Including a Mobile Application for Earlier RA Referral; Potential to Reduce Chronic Disease Burden

9:00AM-11:00AM: Abstract Number: 2512

A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2095

A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients

9:00AM-11:00AM: Abstract Number: 2579

A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity

9:00AM-11:00AM: Abstract Number: 2167

A Randomised Controlled Clinical Trial Comparing the Effectiveness of 6 and 12 Weeks of a Shoulder Specific Exercise Programme for Patients with Rotator Cuff Related Shoulder Pain

9:00AM-11:00AM: Abstract Number: 2718

A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1964

A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)

9:00AM-11:00AM: Abstract Number: L07

A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2622

A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2661

A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta

9:00AM-11:00AM: Abstract Number: 2220

Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2548

Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity

9:00AM-11:00AM: Abstract Number: 2345

Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients

9:00AM-11:00AM: Abstract Number: 2029

Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2623

Abnormality of Percentages and Absolute Numbers of CD4+ Memory and Regulatory T Subset Cells in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2635

Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2503

Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2353

ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices

9:00AM-11:00AM: Abstract Number: 2082

Activity in Work and Life: The Association Between Physical Activity and Employment Status with Future Slow Walking in Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2133

Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016

9:00AM-11:00AM: Abstract Number: 2700

Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry

9:00AM-11:00AM: Abstract Number: 1992

Adenosine A2A Receptor (A2AR) Stimulation Mitigates Mitochondrial Inflammaging, Enhances Mitochondrial Metabolism and Reduces Reactive Oxygen Species-Mediated Mitochondrial Injury In Vitro and In Vivo in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1967

Adenosine A2A Receptor Signals Through AMPK and SIRT1 to Increase Chondrocyte Homeostasis

9:00AM-11:00AM: Abstract Number: 2564

Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2255

Adherence to Subcutaneous Anti-tnf Therapies in Chronic Inflammatory Rheumatism and Therapeutic Education

9:00AM-11:00AM: Abstract Number: 2653

Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2403

Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings

9:00AM-11:00AM: Abstract Number: 1957

Aggregation of Functional Variants in NOTCH4 Gene Increases SSc Risk

9:00AM-11:00AM: Abstract Number: 2723

Alagille Syndrome and Chronic Arthritis: An International Case Series

9:00AM-11:00AM: Abstract Number: 2069

Alcohol Consumption Is Not an Independent Predictor of Fatigue Severity over Time

9:00AM-11:00AM: Abstract Number: 1984

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model but Not in A2A KO Mice

9:00AM-11:00AM: Abstract Number: 2416

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2419

An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2096

An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2542

An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1939

Analysis of Discoid Lupus Erythematosus (DLE) Gene Expression Reveals Dysregulation of Pathogenic Pathways Associated with Infiltrating Immune/Inflammatory Cells

9:00AM-11:00AM: Abstract Number: 2022

Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms

9:00AM-11:00AM: Abstract Number: 1930

Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells

9:00AM-11:00AM: Abstract Number: 2634

ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

9:00AM-11:00AM: Abstract Number: 2642

ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA

9:00AM-11:00AM: Abstract Number: 2025

Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients

9:00AM-11:00AM: Abstract Number: 2609

Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy

9:00AM-11:00AM: Abstract Number: 2000

Anti-inflammatory Effect of Novel Spleen Tyrosine Kinase Inhibitor, SKI-O-592, on Fibroblast-like Synoviocyte in Rheumatoid Arthritis and THP-1 Cell

9:00AM-11:00AM: Abstract Number: 2003

Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5

9:00AM-11:00AM: Abstract Number: 2618

Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2103

Anti-TNF Therapy in Patients with HIV Infection

9:00AM-11:00AM: Abstract Number: 2297

Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System

9:00AM-11:00AM: Abstract Number: 2128

Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality

9:00AM-11:00AM: Abstract Number: 2038

Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2526

Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2555

Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients

9:00AM-11:00AM: Abstract Number: 2355

Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2356

Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1950

Apolipoprotein L1 Variant-Carrying Monocytes Exhibit Mitochondrial Respiration Defects

9:00AM-11:00AM: Abstract Number: 2230

Applicability of FRAX in Clinical Practice: 10-year Results

9:00AM-11:00AM: Abstract Number: 2109

Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study

9:00AM-11:00AM: Abstract Number: 2651

Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?

9:00AM-11:00AM: Abstract Number: 2319

Are Vitamin D Metabolite Levels at Time of Diagnosis Associated with Long-term Severe Cardiovascular Events in Early Diagnosed Rheumatoid Arthritis Patients, Aggressively Treated During 10 Year Follow Up? Post-hoc Analyses of Observational Data from the CIMESTRA Cohort

9:00AM-11:00AM: Abstract Number: 2086

Arthritis-Attributable Work Limitation Variation by U.S. County Classifications and Selected Characteristics, 2017

9:00AM-11:00AM: Abstract Number: 2062

Arthritis, Physical Function, and Disability Among Older Mexican Americans over 20-Years of Follow-up

9:00AM-11:00AM: Abstract Number: 2063

Arthritis, Upper-Lower Extremity Functional Limitations, and Disability in American Older Adults: Findings from the National Health and Aging Trends Study (NHATS)

9:00AM-11:00AM: Abstract Number: 2449

Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort

9:00AM-11:00AM: Abstract Number: 2214

Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 2296

Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 2065

Association Between Anemia and Hyperuricemia: Korean National Health and Nutrition Survey 2016-2017

9:00AM-11:00AM: Abstract Number: 2621

Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis

9:00AM-11:00AM: Abstract Number: 2648

Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy: A Retrospective, Single Center Experience over a 21 Years’ Period

9:00AM-11:00AM: Abstract Number: 2614

Association of Body Composition in Scleroderma Patients with Disease Activity, Serum Levels of Inflammatory Cytokines and Parameters of Nutrition and Lipid Metabolism

9:00AM-11:00AM: Abstract Number: 2706

Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry

9:00AM-11:00AM: Abstract Number: 1954

Association of Functional (GA)n Microsatellite Polymorphism in the FLI1 Gene with Susceptibility to Human Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2050

Association of Gout with Vitamin D: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2061

Association of Periodontitis with Rheumatological Disorders: NHANES III Analysis

9:00AM-11:00AM: Abstract Number: 2315

Association of Rheumatic Autoimmune Disease, Including Rheumatoid Arthritis, with Post-Traumatic Stress Disorder but Not Traumatic Brain Injury in Veterans

9:00AM-11:00AM: Abstract Number: 2331

Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2342

Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study

9:00AM-11:00AM: Abstract Number: 2311

Association of Sexual Dysfunction and Depression in Rheumatoid Arthritis Female Patients

9:00AM-11:00AM: Abstract Number: 1955

Association of TERT and DSP Polymorphisms with Susceptibility to Myeloperoxidase-ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2052

Association of Traumatic Knee Injury with Knee Function, Symptoms, and Radiographic Osteoarthritis in Military Officers

9:00AM-11:00AM: Abstract Number: 2627

Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2594

Associations Between Antibodies to the Angiotensin II Type 1 Receptor and Endothelian-1 Type a Receptor and the Incidence of Vascular Complications in Early Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2178

Associations Between Baseline and Longitudinal Quantitative Joint Space Width and Incident Hip Osteoarthritis: The Johnston County Osteoarthritis Project

9:00AM-11:00AM: Abstract Number: 2362

Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort

9:00AM-11:00AM: Abstract Number: 2595

Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2223

Attenuated Association Between Proton Pump Inhibitor Use and Fracture Risk After Consideration of Chronic Comorbidities

9:00AM-11:00AM: Abstract Number: 2437

Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253

9:00AM-11:00AM: Abstract Number: 2438

Autoantibody Mediated Salivary Gland Hypofunction in Sjögren’s Syndrome Involves Activation of Innate Immunity and Endothelial Cells

9:00AM-11:00AM: Abstract Number: 2074

Automated Diagnosis Extraction from Electronic Medical Records with Machine Learning Classifiers

9:00AM-11:00AM: Abstract Number: 2726

Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis

9:00AM-11:00AM: Abstract Number: 2381

Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

9:00AM-11:00AM: Abstract Number: 2040

BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes

9:00AM-11:00AM: Abstract Number: 2545

Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients

9:00AM-11:00AM: Abstract Number: 2017

Beyond Genes—a Multi-omic Analysis of Monozygotic Twins Discordant for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2113

Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever

9:00AM-11:00AM: Abstract Number: 2009

Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2115

BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants

9:00AM-11:00AM: Abstract Number: 2195

BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel

9:00AM-11:00AM: Abstract Number: 2463

Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2599

Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2068

Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications

9:00AM-11:00AM: Abstract Number: 2222

Bone Health: An Independent Predictor of Coronary Artery Disease

9:00AM-11:00AM: Abstract Number: 2221

Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2304

Bone Microstructure of Patients with Rheumatoid Arthritis: A HR-pQCT Study

9:00AM-11:00AM: Abstract Number: 2207

Bone Mineral Density and Microarchitecture Among Chinese Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2440

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study

9:00AM-11:00AM: Abstract Number: 2216

Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis

9:00AM-11:00AM: Abstract Number: 1996

Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast

9:00AM-11:00AM: Abstract Number: 2477

Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

9:00AM-11:00AM: Abstract Number: 2295

Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data

9:00AM-11:00AM: Abstract Number: 2505

Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina

9:00AM-11:00AM: Abstract Number: 2227

Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?

9:00AM-11:00AM: Abstract Number: 2327

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies

9:00AM-11:00AM: Abstract Number: L04

Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease

9:00AM-11:00AM: Abstract Number: 2439

Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2136

Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology

9:00AM-11:00AM: Abstract Number: 2332

Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients

9:00AM-11:00AM: Abstract Number: 2676

Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study

9:00AM-11:00AM: Abstract Number: 2411

Casting a Wide Net: Comparing Strategies for Recruiting 18-35-year-olds with Rheumatic Disease as Study Participants

9:00AM-11:00AM: Abstract Number: 2258

Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1987

CCN3 Regulates Macrophage Function in MSU-induced Inflammation

9:00AM-11:00AM: Abstract Number: 1971

CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis

9:00AM-11:00AM: Abstract Number: 2626

Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2519

Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE

9:00AM-11:00AM: Abstract Number: 2602

Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2399

Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis

9:00AM-11:00AM: Abstract Number: 2632

Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 2162

Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)

9:00AM-11:00AM: Abstract Number: 2447

Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment

9:00AM-11:00AM: Abstract Number: 1926

Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome

9:00AM-11:00AM: Abstract Number: 1956

Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood

9:00AM-11:00AM: Abstract Number: 2157

Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival

9:00AM-11:00AM: Abstract Number: 2421

Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular Inflammation in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2005

Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2586

Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome

9:00AM-11:00AM: Abstract Number: 2641

Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 2576

Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE

9:00AM-11:00AM: Abstract Number: 2725

Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study

9:00AM-11:00AM: Abstract Number: 2123

Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2581

Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2665

Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 2461

Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement

9:00AM-11:00AM: Abstract Number: 2309

Clinical Study of Peripheral Blood Lymphocyte Subsets in Patients with Rheumatoid Arthritis Complicated with Osteoporosis

9:00AM-11:00AM: Abstract Number: 2674

Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2066

Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience

9:00AM-11:00AM: Abstract Number: 2197

Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%

9:00AM-11:00AM: Abstract Number: 2546

Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial

9:00AM-11:00AM: Abstract Number: 2687

Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2636

Cluster Analysis for Classification of Japanese Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Subgroup Analysis of Nationwide Cohort Studies

9:00AM-11:00AM: Abstract Number: 2070

Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry

9:00AM-11:00AM: Abstract Number: 2664

Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience

9:00AM-11:00AM: Abstract Number: 2126

Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2287

Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion

9:00AM-11:00AM: Abstract Number: 1963

Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 2378

Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA

9:00AM-11:00AM: Abstract Number: L01

Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

9:00AM-11:00AM: Abstract Number: 2643

Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre

9:00AM-11:00AM: Abstract Number: 2253

Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2483

Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2302

Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2624

Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial

9:00AM-11:00AM: Abstract Number: 2652

Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up

9:00AM-11:00AM: Abstract Number: 2654

Comparison of Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair

9:00AM-11:00AM: Abstract Number: 2649

Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2494

Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2366

Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2067

Comparison of Medication New User Definitions in Multi-Specialty EMR Data

9:00AM-11:00AM: Abstract Number: 2639

Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2099

Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong

9:00AM-11:00AM: Abstract Number: 2107

Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database

9:00AM-11:00AM: Abstract Number: 2688

Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort

9:00AM-11:00AM: Abstract Number: 2132

Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2146

Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease

9:00AM-11:00AM: Abstract Number: 1931

Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq

9:00AM-11:00AM: Abstract Number: 2590

Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2386

Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2191

Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings

9:00AM-11:00AM: Abstract Number: 2523

Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2294

Contraception Documentation Rates in Women with Rheumatic Diseases on Teratogenic Medications in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1958

Contribution of MOCS on Xanthinuria Type III and Its Clinical Significance for Screening

9:00AM-11:00AM: Abstract Number: 2250

Contribution of Personality Traits, Psychological Factors and Health Related Quality of Life on Medication Adherence in Patients with RA

9:00AM-11:00AM: Abstract Number: 2692

Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden

9:00AM-11:00AM: Abstract Number: 2603

Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database

9:00AM-11:00AM: Abstract Number: 2057

Cross-sectional Associations of Multiple Joint Osteoarthritis in the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2075

Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2615

Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis

9:00AM-11:00AM: Abstract Number: 2500

Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox

9:00AM-11:00AM: Abstract Number: 2593

Cyclophosphamide for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2527

Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2435

Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas

9:00AM-11:00AM: Abstract Number: 2561

Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells

9:00AM-11:00AM: Abstract Number: 2172

Depression of Vitamin D Levels After Adult Primary Posterior Spinal Fusion: Are We Adding Insult to Injury?

9:00AM-11:00AM: Abstract Number: 2350

Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2497

Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain

9:00AM-11:00AM: Abstract Number: 2173

Descriptive Analysis of Patient-Reported Home Exercise and Physical Activity and Their Associations with Patient Baseline Characteristics Following Total Knee Replacement

9:00AM-11:00AM: Abstract Number: 2552

Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change

9:00AM-11:00AM: Abstract Number: 2430

Detection and Clinical Significance of Circulating M3 Muscarinic Acetylcholine Receptor Reactive Th17 Cells in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2310

Determinants of Cognitive Function in Rheumatoid Arthritis (RA) Patients

9:00AM-11:00AM: Abstract Number: 1965

Determining a Polygenic Risk Score in Pediatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2201

Developing a Comprehensive Patient-Specific Disease Progression Prediction Model for Knee Osteoarthritis Using Machine/Deep Learning Methods

9:00AM-11:00AM: Abstract Number: 2666

Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation

9:00AM-11:00AM: Abstract Number: 2516

Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2217

DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids

9:00AM-11:00AM: Abstract Number: 2127

Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics

9:00AM-11:00AM: Abstract Number: 2482

Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy

9:00AM-11:00AM: Abstract Number: 2489

Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe

9:00AM-11:00AM: Abstract Number: 2229

Differences in Fracture Risk Assessment (FRAX) and Osteoporosis Treatment Cutoffs with and Without Bone Mineral Density Are Greater in Anti-Cyclic Citrullinated Peptide Positive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2090

Differences in Stepping and Standing Based on Self-reported Exercise Identity in Persons Following Total Knee Replacement

9:00AM-11:00AM: Abstract Number: 2598

Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 2504

Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 2370

Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2515

Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis

9:00AM-11:00AM: Abstract Number: 2292

Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?

9:00AM-11:00AM: Abstract Number: 1980

Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice

9:00AM-11:00AM: Abstract Number: 2426

Distinct Clinical Characteristics of Anti-Ro/SSA Negative Primary Sjögren’s Syndrome: Data from a Cohort for Sjögren’s Syndrome in Korea

9:00AM-11:00AM: Abstract Number: 2098

Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas

9:00AM-11:00AM: Abstract Number: 2536

Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States

9:00AM-11:00AM: Abstract Number: 1985

Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2469

Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance

9:00AM-11:00AM: Abstract Number: 2395

DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment

9:00AM-11:00AM: Abstract Number: 2396

DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 2554

Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?

9:00AM-11:00AM: Abstract Number: 2329

Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium

9:00AM-11:00AM: Abstract Number: 2404

Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 2205

Dual Femur Bone Density Measurements with Novel Sonographic Approach – Radiofrequency Echographic Multi Spectrometry

9:00AM-11:00AM: Abstract Number: 2027

Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2571

Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2168

Early Start of Outpatient Physical Therapy After Knee Replacement Is Associated with More Objectively-measured Steps and Time Spent Upright

9:00AM-11:00AM: Abstract Number: 2361

Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico

9:00AM-11:00AM: Abstract Number: 2695

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2528

Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2391

Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2708

Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials

9:00AM-11:00AM: Abstract Number: 2459

Effect of Obesity and Surgical Weight Loss on Joint Surgery Hospitalizations in Psoriatic Arthritis: Data from National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 2578

Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2275

Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis

9:00AM-11:00AM: Abstract Number: 2532

Effect of Treatment on Antiphospholipid Antibodies in SLE

9:00AM-11:00AM: Abstract Number: 2620

Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model

9:00AM-11:00AM: Abstract Number: 2572

Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status

9:00AM-11:00AM: Abstract Number: 2414

Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

9:00AM-11:00AM: Abstract Number: 2385

Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study

9:00AM-11:00AM: Abstract Number: 2492

Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2092

Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials

9:00AM-11:00AM: Abstract Number: 2667

Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience

9:00AM-11:00AM: Abstract Number: 2118

Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2344

Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2633

Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis

9:00AM-11:00AM: Abstract Number: 2682

Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution

9:00AM-11:00AM: Abstract Number: L15

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2575

Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks

9:00AM-11:00AM: Abstract Number: 2318

Elevated Pro-inflammatory Lipid Mediators Associate with Low Paraoxonase 1 Activity in Patients with Rheumatoid Arthritis and Arthritic K/BxN Mice

9:00AM-11:00AM: Abstract Number: 2018

Elevated Serum Levels of Tie-1 in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2303

Emotional and Social Determinants of Health Increase Office Communication for Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2032

Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation

9:00AM-11:00AM: Abstract Number: 2401

Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate

9:00AM-11:00AM: Abstract Number: 2130

Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy

9:00AM-11:00AM: Abstract Number: 2478

Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan

9:00AM-11:00AM: Abstract Number: 2445

Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity

9:00AM-11:00AM: Abstract Number: 2054

Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database

9:00AM-11:00AM: Abstract Number: 2349

Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2041

Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease

9:00AM-11:00AM: Abstract Number: 2179

Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort

9:00AM-11:00AM: Abstract Number: 1988

Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSc) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk

9:00AM-11:00AM: Abstract Number: 1953

Estimating the Infiltration of Immune Cells in Synovium of Rheumatoid Arthritis Compared to Osteoarthritis and Healthy Control Using Transcriptomic Profiling

9:00AM-11:00AM: Abstract Number: 2242

Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2486

Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2213

Evaluation of Factors Associated with Bone Structure in an SLE Cohort Measured by Clinical 3T MRI and DEXA

9:00AM-11:00AM: Abstract Number: 2262

Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement

9:00AM-11:00AM: Abstract Number: 2094

Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination

9:00AM-11:00AM: Abstract Number: 2064

Evaluation of Methods to Account for Differential Follow-up When Comparing Clinical Trial Data to Observational Data

9:00AM-11:00AM: Abstract Number: 2415

Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients

9:00AM-11:00AM: Abstract Number: 2249

Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment

9:00AM-11:00AM: Abstract Number: 2466

Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2606

Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation

9:00AM-11:00AM: Abstract Number: 2156

Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome

9:00AM-11:00AM: Abstract Number: 2339

Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind

9:00AM-11:00AM: Abstract Number: 2016

Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2044

Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice

9:00AM-11:00AM: Abstract Number: 2134

Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2431

Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers

9:00AM-11:00AM: Abstract Number: 2330

Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2448

Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission

9:00AM-11:00AM: Abstract Number: 2560

Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

9:00AM-11:00AM: Abstract Number: 2685

Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers

9:00AM-11:00AM: Abstract Number: 2226

Factors Contributing to Fracture in Pernicious Anemia Patients Presenting with Symptomatic Subacute Vertebral Compression Fractures

9:00AM-11:00AM: Abstract Number: 2051

Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data

9:00AM-11:00AM: Abstract Number: 2724

Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA

9:00AM-11:00AM: Abstract Number: 2690

Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience

9:00AM-11:00AM: Abstract Number: 2433

Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)

9:00AM-11:00AM: Abstract Number: 2106

Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1975

Fibrates as Drugs with Senolytic and Autophagic Activity for Osteoarthritis Treatment

9:00AM-11:00AM: Abstract Number: 2341

Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease

9:00AM-11:00AM: Abstract Number: 2102

First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients

9:00AM-11:00AM: Abstract Number: 2647

Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study

9:00AM-11:00AM: Abstract Number: 2616

Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort

9:00AM-11:00AM: Abstract Number: 1969

FOXO1 Is Required for Human Osteoclast Differentiation

9:00AM-11:00AM: Abstract Number: 2204

Fragility Fractures in a Community Setting: Clinical Characteristics, Care Gaps, and Outcomes

9:00AM-11:00AM: Abstract Number: 2460

Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database

9:00AM-11:00AM: Abstract Number: 2142

Frailty in Systemic Rheumatic Diseases: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2522

Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE

9:00AM-11:00AM: Abstract Number: 2701

Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER

9:00AM-11:00AM: Abstract Number: 2150

Frequency of Polyautoimmunity in a Tertiary Hospital

9:00AM-11:00AM: Abstract Number: 1981

Functional Differences Between Osteoclasts and Osteoclast-like Cells Differentiated from Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2171

Functional Exercise for Adults with Chronic Nonspecific Low Back Pain

9:00AM-11:00AM: Abstract Number: 2237

Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies

9:00AM-11:00AM: Abstract Number: 2446

Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response

9:00AM-11:00AM: Abstract Number: 2484

Gender Influence on Treatment Effectiveness in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2023

Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways

9:00AM-11:00AM: Abstract Number: 1952

Genes Associated with Nucleotide Oligomerization Domain-Like Receptor Signaling Pathway Are Upregulated in Discoid Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1932

Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 2024

Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1942

Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2658

Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries

9:00AM-11:00AM: Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series

9:00AM-11:00AM: Abstract Number: 2659

Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study

9:00AM-11:00AM: Abstract Number: 1995

Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast

9:00AM-11:00AM: Abstract Number: L16

GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study

9:00AM-11:00AM: Abstract Number: 2562

Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018

9:00AM-11:00AM: Abstract Number: 2689

GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2569

Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

9:00AM-11:00AM: Abstract Number: L13

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

9:00AM-11:00AM: Abstract Number: 2317

Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2677

Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study

9:00AM-11:00AM: Abstract Number: 1994

Helicobacter Pylori Infection Among Korean Patients with Rheumatoid Arthritis and Its Interaction with Shared Epitope

9:00AM-11:00AM: Abstract Number: 2101

Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 2406

Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry

9:00AM-11:00AM: Abstract Number: 2359

High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2055

High Dietary Sodium Intake May Be Associated with Symptomatic Knee Osteoarthritis in a Korean Population: Korean National Health and Nutrition Examination Survey, 2010-2011

9:00AM-11:00AM: Abstract Number: 2379

High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2325

High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles

9:00AM-11:00AM: Abstract Number: 2180

High Molecular Weight Intraarticular Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2039

High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements (LINE-1) in SLE

9:00AM-11:00AM: Abstract Number: 2021

Higher Genetic Risk Load in Patients with More Diverse Manifestations in a Korean Systemic Lupus Erythematosus Cohort

9:00AM-11:00AM: Abstract Number: 2285

Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers

9:00AM-11:00AM: Abstract Number: 2233

Hip Fracture Incidence in a Teaching Hospital: Intervention for the Prevention of Second Hip Fracture

9:00AM-11:00AM: Abstract Number: 1997

Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network

9:00AM-11:00AM: Abstract Number: 2556

Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN

9:00AM-11:00AM: Abstract Number: 2008

Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 2591

Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)

9:00AM-11:00AM: Abstract Number: 2121

Hospitalization Trends for Bacterial Septic Arthritis in the United States from 1997 to 2014

9:00AM-11:00AM: Abstract Number: 2613

Hsp90 as a Potential Biomarker of Lung and Skin Involvement in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1978

HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2533

Hydroxychloroquine Increases Low C3 in SLE

9:00AM-11:00AM: Abstract Number: 2517

Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS

9:00AM-11:00AM: Abstract Number: 2573

Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels

9:00AM-11:00AM: Abstract Number: 1929

Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women

9:00AM-11:00AM: Abstract Number: 2487

Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement

9:00AM-11:00AM: Abstract Number: 1972

Identification of Distinct Lipidomic Profiles in Synovial Membranes from Inflammatory Arthritis by Mass Spectrometry Imaging

9:00AM-11:00AM: Abstract Number: 2034

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement

9:00AM-11:00AM: Abstract Number: 1928

Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis

9:00AM-11:00AM: Abstract Number: 2535

Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 2568

Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study

9:00AM-11:00AM: Abstract Number: 2493

IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2119

Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 2079

Impact of Eliminating the Bouted Minutes Requirement in the New 2018 Physical Activity Guidelines for Americans on Gender Disparity in Guideline Attainment for Persons with or at High Risk of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2455

Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey

9:00AM-11:00AM: Abstract Number: 2203

Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study

9:00AM-11:00AM: Abstract Number: 2540

Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt

9:00AM-11:00AM: Abstract Number: 2474

Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 2550

Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study

9:00AM-11:00AM: Abstract Number: 2117

Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2276

Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach

9:00AM-11:00AM: Abstract Number: 2720

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

9:00AM-11:00AM: Abstract Number: 2473

Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?

9:00AM-11:00AM: Abstract Number: 2538

Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 2314

Improved Anxiety, Depression, and Emotional Distress for Rheumatoid Arthritis Patients Following the Completion of an Online Mental Health Intervention

9:00AM-11:00AM: Abstract Number: 2707

Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study

9:00AM-11:00AM: Abstract Number: 2231

Improving Compliance with Screening for Osteoporosis in Elderly Women

9:00AM-11:00AM: Abstract Number: 2380

Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome

9:00AM-11:00AM: Abstract Number: 2283

Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients

9:00AM-11:00AM: Abstract Number: 2423

In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature

9:00AM-11:00AM: Abstract Number: 2328

In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use

9:00AM-11:00AM: Abstract Number: 2498

Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study

9:00AM-11:00AM: Abstract Number: 2582

Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test : A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2715

Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset

9:00AM-11:00AM: Abstract Number: 2013

Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux

9:00AM-11:00AM: Abstract Number: 2422

Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2457

Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study

9:00AM-11:00AM: Abstract Number: 2631

Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2693

Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 2010

Individual Functions of Histone-acetyltransferases CBP and p300 in Regulating Autophagy and Proteasomal Degradation in Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 2363

Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy

9:00AM-11:00AM: Abstract Number: 2537

Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 2028

Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1991

Inhibition of CD44 Intracellular Domain Production Suppresses Bovine Articular Chondrocyte De-differentiation Induced by Excessive Mechanical Stress Loading

9:00AM-11:00AM: Abstract Number: 1993

Inhibition of Choline Kinase Alpha Improves Synovitis and Cartilage Damage in Animal Models of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2704

Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications

9:00AM-11:00AM: Abstract Number: 2694

Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1986

Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles

9:00AM-11:00AM: Abstract Number: 1947

Integrating Genetic Risk Scores and Pre-Diagnostic Metabolomics to Infer Dysregulated Mechanisms in Rheumatoid Arthritis in Women

9:00AM-11:00AM: Abstract Number: 1941

Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk

9:00AM-11:00AM: Abstract Number: 2031

Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes

9:00AM-11:00AM: Abstract Number: L06

Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

9:00AM-11:00AM: Abstract Number: 2307

Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF

9:00AM-11:00AM: Abstract Number: 2346

Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors

9:00AM-11:00AM: Abstract Number: 2298

Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2042

Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice

9:00AM-11:00AM: Abstract Number: 2110

Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico

9:00AM-11:00AM: Abstract Number: 1940

Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis

9:00AM-11:00AM: Abstract Number: 2714

Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry

9:00AM-11:00AM: Abstract Number: 2033

IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells

9:00AM-11:00AM: Abstract Number: 2334

Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?

9:00AM-11:00AM: Abstract Number: 2199

Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?

9:00AM-11:00AM: Abstract Number: 2080

It Starts at Work: The Relationship Between Workplace Supports and Presenteeism Among Young Adults with Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 2468

JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target

9:00AM-11:00AM: Abstract Number: 2713

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis

9:00AM-11:00AM: Abstract Number: 2348

KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD

9:00AM-11:00AM: Abstract Number: 2320

Knowledge of Cardiovascular Disease Risk Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2243

Knowledge, Needs and Expectations Among Systemic Lupus Erythematosus: Preliminary Results from the INTEGRATE Pilot Project

9:00AM-11:00AM: Abstract Number: 2508

Large Joint and Lower Extremity Involvement Has Higher Impact on Disease Outcomes in Oligoarticular PsA

9:00AM-11:00AM: Abstract Number: 2043

Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation

9:00AM-11:00AM: Abstract Number: 2655

Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment

9:00AM-11:00AM: Abstract Number: 2248

Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease

9:00AM-11:00AM: Abstract Number: 2336

Levels of Proinflammatory Cytokines in Rheumatoid Arthritis Patients with Carotid Plaque: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 2716

Long Term Outcomes of Childhood Onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2696

Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2717

Long-term Outcome of Juvenile-onset Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2145

Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 2347

Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center

9:00AM-11:00AM: Abstract Number: 2592

Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care

9:00AM-11:00AM: Abstract Number: 2014

Loss-of-function of the DNA Repair Nuclease MRE11A Induces Mitochondrial Failure and Tissue Inflammation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2413

LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2531

Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship

9:00AM-11:00AM: Abstract Number: 2164

Lumbar Spinal Stenosis in Patients with Wild-type Transthyretin Cardiac Amyloidosis

9:00AM-11:00AM: Abstract Number: 2312

Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture

9:00AM-11:00AM: Abstract Number: 2196

Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)

9:00AM-11:00AM: Abstract Number: 2200

Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2663

Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: L11

Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

9:00AM-11:00AM: Abstract Number: 1998

Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use

9:00AM-11:00AM: Abstract Number: 2269

Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year

9:00AM-11:00AM: Abstract Number: 2584

Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2387

Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice

9:00AM-11:00AM: Abstract Number: 2488

MDA Versus DAPSA: Applicability in a Real World

9:00AM-11:00AM: Abstract Number: 1970

Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose

9:00AM-11:00AM: Abstract Number: 2208

Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis

9:00AM-11:00AM: Abstract Number: 2605

Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 2611

Mesenchymal Stem Cells in Scleroderma: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2543

Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE

9:00AM-11:00AM: Abstract Number: 2020

Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development

9:00AM-11:00AM: Abstract Number: 1946

Metabolic Regulation in Cybrids Obtained from Healthy and Osteoarthritic (OA) Patients: Impaired Metabolic Flexibility in OA Process

9:00AM-11:00AM: Abstract Number: 2324

Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity

9:00AM-11:00AM: Abstract Number: 2377

Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2357

Methotrexate Liver Toxicity in a Large Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2015

Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients

9:00AM-11:00AM: Abstract Number: 2026

MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27

9:00AM-11:00AM: Abstract Number: 2240

Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2612

Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 1961

Mitochondrial DNA Sub-haplogroup H1 Influences the Risk of Rapidly Progressive Osteoarthritis of the Knee: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2036

Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2286

Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?

9:00AM-11:00AM: Abstract Number: 2215

Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab

9:00AM-11:00AM: Abstract Number: 2376

Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1937

Mononuclear Leukocyte DNA Methylome Imprinting of Networked Signaling and Immunity Regulatory Pathways in Gout

9:00AM-11:00AM: Abstract Number: 2628

Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center

9:00AM-11:00AM: Abstract Number: 2374

MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy

9:00AM-11:00AM: Abstract Number: 2206

MRI-based Textural Analysis of Trabecular Bone: A Novel Method for the Opportunistic Screening of Bone Quality

9:00AM-11:00AM: Abstract Number: 2185

MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 2364

Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development

9:00AM-11:00AM: Abstract Number: 1935

Multi-Organ System Meta-Analytic Approach to Investigating Sarcoidosis

9:00AM-11:00AM: Abstract Number: 2190

Multi-vendor Multi-site T1ρ and T2 Quantification of Knee Cartilage

9:00AM-11:00AM: Abstract Number: 2464

Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results

9:00AM-11:00AM: Abstract Number: 2166

Multimodal Edema Management After Total Knee Arthroplasty: A Pilot Study

9:00AM-11:00AM: Abstract Number: 2305

Multimorbidity May Worsen Fatigue in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: L02

Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity

9:00AM-11:00AM: Abstract Number: 2148

Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2144

Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience

9:00AM-11:00AM: Abstract Number: 2147

Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events

9:00AM-11:00AM: Abstract Number: 2160

Myopenia Is an Independent Risk Factor for Rotator Cuff Tear and Shoulder Dysfunction in Elderly People : Data from NAMGARAM Cohort

9:00AM-11:00AM: Abstract Number: 2588

Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations

9:00AM-11:00AM: Abstract Number: 1999

NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion

9:00AM-11:00AM: Abstract Number: 2049

National Estimates of Pain Medication Use in Patients with Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2316

National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014

9:00AM-11:00AM: Abstract Number: 2181

Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1989

Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal

9:00AM-11:00AM: Abstract Number: 2143

Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center

9:00AM-11:00AM: Abstract Number: 2046

NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2120

No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study

9:00AM-11:00AM: Abstract Number: 2502

Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study

9:00AM-11:00AM: Abstract Number: 2011

Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)

9:00AM-11:00AM: Abstract Number: L03

NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 2153

Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre

9:00AM-11:00AM: Abstract Number: 2495

Oligoarticular Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2048

Opioid Prescription Use Among Patients with Rheumatic Disease: A Population Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2480

Opioid Use Surrounding Diagnosis of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2056

Opioids Use Among Medicare Beneficiaries with Knee Osteoarthritis: Prevalence and Correlates of Chronic Use

9:00AM-11:00AM: Abstract Number: 2291

Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2680

Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients

9:00AM-11:00AM: Abstract Number: 2234

Osteoporosis Screening in a Resident-Driven Clinic of a Large Academic Hospital

9:00AM-11:00AM: Abstract Number: 2235

Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough?

9:00AM-11:00AM: Abstract Number: 2122

Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions

9:00AM-11:00AM: Abstract Number: 2137

Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma

9:00AM-11:00AM: Abstract Number: 2159

Pachymeningitis in Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 2467

Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries

9:00AM-11:00AM: Abstract Number: 2604

Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2241

Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study

9:00AM-11:00AM: Abstract Number: 2224

Parkinson’s Disease and Risk of Fractures : A Meta Analysis of Cohort Studies

9:00AM-11:00AM: Abstract Number: 2257

Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial

9:00AM-11:00AM: Abstract Number: 2256

Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2388

Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort

9:00AM-11:00AM: Abstract Number: 2247

Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications

9:00AM-11:00AM: Abstract Number: 2539

Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 2151

Patient Reported Outcomes and Factors Predicting Clinical Disease Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2212

Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA

9:00AM-11:00AM: Abstract Number: 2313

Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2702

Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group

9:00AM-11:00AM: Abstract Number: 2260

Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 2712

Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2640

Performance of Berden’s Classification and ANCA Renal Risk Score for the Prediction of End-Stage Renal Disease in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2007

Periodontal Pockets as a Potential Source of Circulating TREM-1 and Its Ligand PGLYRP1 in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2161

Perioperative Glucocorticoid Management in Patients with Rheumatologic Diseases Undergoing Elective Joint Surgeries

9:00AM-11:00AM: Abstract Number: 2278

Perspectives About Contraception Among Reproductive-Aged Women with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2277

Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists

9:00AM-11:00AM: Abstract Number: 2671

PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2058

Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016

9:00AM-11:00AM: Abstract Number: 2565

Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2668

Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 2541

Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment

9:00AM-11:00AM: Abstract Number: 2580

Pharmacotherapies Targeting Type 2 SLE Symptoms

9:00AM-11:00AM: Abstract Number: 2259

Physical Challenges in RA: A Qualitative Study of an Online Patient Support Group

9:00AM-11:00AM: Abstract Number: 2563

PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease

9:00AM-11:00AM: Abstract Number: 1960

Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 1959

Pleiotropy of Systemic Lupus Erythematosus (SLE) Risk Alleles: Association with Increased Risk for Type 1 Diabetes (T1D) Complications Through a PTPN22 Polymorphism

9:00AM-11:00AM: Abstract Number: 1945

Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2245

Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective

9:00AM-11:00AM: Abstract Number: 2566

Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE

9:00AM-11:00AM: Abstract Number: 2077

Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained

9:00AM-11:00AM: Abstract Number: 2549

Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials

9:00AM-11:00AM: Abstract Number: 2261

Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2372

Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 1983

Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2499

Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2390

Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission

9:00AM-11:00AM: Abstract Number: 2335

Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models

9:00AM-11:00AM: Abstract Number: 2625

Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement

9:00AM-11:00AM: Abstract Number: 2491

Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 2719

Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers

9:00AM-11:00AM: Abstract Number: 2650

Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration

9:00AM-11:00AM: Abstract Number: 2458

Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation

9:00AM-11:00AM: Abstract Number: 2140

Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 2268

Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation

9:00AM-11:00AM: Abstract Number: 2293

Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy

9:00AM-11:00AM: Abstract Number: 2279

Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 2288

Pregnancy Outcomes in Women Exposed to Golimumab

9:00AM-11:00AM: Abstract Number: 2264

Prescribing Exercise: Facilitators and Barriers to the Successful Implementation of Physical Activity Guidelines in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2553

Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

9:00AM-11:00AM: Abstract Number: 2002

Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 2673

Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)

9:00AM-11:00AM: Abstract Number: 2597

Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2583

Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies

9:00AM-11:00AM: Abstract Number: 2398

Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions

9:00AM-11:00AM: Abstract Number: 2087

Prevalence of Corticosteroid Use in Incidental Vertebral or Hip Fractures

9:00AM-11:00AM: Abstract Number: 2475

Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 2163

Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014

9:00AM-11:00AM: Abstract Number: 2072

Prevalence of Thyroid Dysfunction with Therapeutic Indication in Patients with Rheumatological Diseases

9:00AM-11:00AM: Abstract Number: 2306

Prevalent and Incident Multimorbidity in Rheumatoid Arthritis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2149

Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2301

Profile of Renal Function in Patient Suffering from Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2705

Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis

9:00AM-11:00AM: Abstract Number: 2558

Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616

9:00AM-11:00AM: Abstract Number: 2289

Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells

9:00AM-11:00AM: Abstract Number: 2326

Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity

9:00AM-11:00AM: Abstract Number: 2587

Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2454

PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2567

Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

9:00AM-11:00AM: Abstract Number: 1973

Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies

9:00AM-11:00AM: Abstract Number: 2405

Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2004

Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2557

Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes – Case Control Study

9:00AM-11:00AM: Abstract Number: 2509

Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study

9:00AM-11:00AM: Abstract Number: 2006

Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2219

Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)

9:00AM-11:00AM: Abstract Number: 2451

Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database

9:00AM-11:00AM: Abstract Number: 2441

Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database

9:00AM-11:00AM: Abstract Number: 2660

Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling

9:00AM-11:00AM: Abstract Number: 2686

Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry

9:00AM-11:00AM: Abstract Number: 2112

Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 2684

Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement

9:00AM-11:00AM: Abstract Number: 2352

Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2444

Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies

9:00AM-11:00AM: Abstract Number: 2698

Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States

9:00AM-11:00AM: Abstract Number: 2485

Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy

9:00AM-11:00AM: Abstract Number: 2189

Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population

9:00AM-11:00AM: Abstract Number: 2471

Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study

9:00AM-11:00AM: Abstract Number: 1976

Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5

9:00AM-11:00AM: Abstract Number: 2183

Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2182

Relation of MRI-detected Structural Damage in the Knee to Anterior Knee Pain: The MOST Study

9:00AM-11:00AM: Abstract Number: 2610

Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography

9:00AM-11:00AM: Abstract Number: 2470

Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2210

Relationship Between Structural Spine Involvement and the Scanographic Bone Attenuation Coefficient of L1 in a Population of 73 Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2382

Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2514

Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2513

Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2465

Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2354

Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2169

Reporting of Adverse Events in Randomized Controlled Trials of Therapeutic Exercise for Knee Osteoarthritis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2282

Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population

9:00AM-11:00AM: Abstract Number: 2239

Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2280

Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention

9:00AM-11:00AM: Abstract Number: 2678

Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms

9:00AM-11:00AM: Abstract Number: 2617

Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial

9:00AM-11:00AM: Abstract Number: 2089

Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2232

Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis

9:00AM-11:00AM: Abstract Number: 2544

Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE

9:00AM-11:00AM: Abstract Number: 2125

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

9:00AM-11:00AM: Abstract Number: 2158

Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 2138

Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population

9:00AM-11:00AM: Abstract Number: 2139

Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases

9:00AM-11:00AM: Abstract Number: 2228

Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients

9:00AM-11:00AM: Abstract Number: 2114

Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2170

Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?

9:00AM-11:00AM: Abstract Number: 2108

Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2300

Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty

9:00AM-11:00AM: Abstract Number: 2365

Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 2368

Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study

9:00AM-11:00AM: Abstract Number: 2333

Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance

9:00AM-11:00AM: Abstract Number: 2434

Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database

9:00AM-11:00AM: Abstract Number: 2371

Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database

9:00AM-11:00AM: Abstract Number: 2053

Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2675

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database

9:00AM-11:00AM: Abstract Number: 2273

Risk of Serious Infections in Offspring According to TNFi Subtypes

9:00AM-11:00AM: Abstract Number: 2393

Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials

9:00AM-11:00AM: Abstract Number: 2697

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2619

Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies

9:00AM-11:00AM: Abstract Number: 2131

Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2141

Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients

9:00AM-11:00AM: Abstract Number: 2521

Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

9:00AM-11:00AM: Abstract Number: 2045

RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets

9:00AM-11:00AM: Abstract Number: 2238

Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach

9:00AM-11:00AM: Abstract Number: 2154

Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1927

Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy

9:00AM-11:00AM: Abstract Number: 2420

Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 2424

RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells

9:00AM-11:00AM: Abstract Number: L12

Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study

9:00AM-11:00AM: Abstract Number: 2093

Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 2375

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports

9:00AM-11:00AM: Abstract Number: 2360

Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2529

Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2152

Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2547

Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use

9:00AM-11:00AM: Abstract Number: 2530

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome

9:00AM-11:00AM: Abstract Number: 2574

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters

9:00AM-11:00AM: Abstract Number: 2175

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study

9:00AM-11:00AM: Abstract Number: L05

Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA

9:00AM-11:00AM: Abstract Number: 2177

Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study

9:00AM-11:00AM: Abstract Number: 2710

Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study

9:00AM-11:00AM: Abstract Number: 2124

Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?

9:00AM-11:00AM: Abstract Number: 2100

Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients

9:00AM-11:00AM: Abstract Number: 2589

Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index

9:00AM-11:00AM: Abstract Number: 2709

Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index

9:00AM-11:00AM: Abstract Number: 2272

Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1982

Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain

9:00AM-11:00AM: Abstract Number: 2116

Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data

9:00AM-11:00AM: Abstract Number: 2496

Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers

9:00AM-11:00AM: Abstract Number: 2428

Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience

9:00AM-11:00AM: Abstract Number: 2198

Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2271

Sexual Health, Intimacy and Rheumatology Practices

9:00AM-11:00AM: Abstract Number: 2358

Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials

9:00AM-11:00AM: Abstract Number: 2476

Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

9:00AM-11:00AM: Abstract Number: 2397

Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer

9:00AM-11:00AM: Abstract Number: 2577

SLE Disease Activity May Be Associated with Choroidal Thickness

9:00AM-11:00AM: Abstract Number: 2192

Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA

9:00AM-11:00AM: Abstract Number: 2165

Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults

9:00AM-11:00AM: Abstract Number: 2030

Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption

9:00AM-11:00AM: Abstract Number: 2453

Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2236

Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations

9:00AM-11:00AM: Abstract Number: 2209

Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls

9:00AM-11:00AM: Abstract Number: 2321

Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2721

Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome

9:00AM-11:00AM: Abstract Number: 2608

Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions

9:00AM-11:00AM: Abstract Number: 2194

Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers

9:00AM-11:00AM: Abstract Number: 2646

Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data

9:00AM-11:00AM: Abstract Number: 2669

Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2001

Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin

9:00AM-11:00AM: Abstract Number: 2111

Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies

9:00AM-11:00AM: Abstract Number: 2246

Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews

9:00AM-11:00AM: Abstract Number: 2225

Systematic Osteoporosis Screening in Chronic Obtructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis

9:00AM-11:00AM: Abstract Number: 2035

Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell

9:00AM-11:00AM: Abstract Number: 2699

Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

9:00AM-11:00AM: Abstract Number: L08

Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2274

Targeted Education Improves Awareness of Reproductive Health Issues Among Women with Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 2662

Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?

9:00AM-11:00AM: Abstract Number: 1990

Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor

9:00AM-11:00AM: Abstract Number: 2019

Tenosynovitis at the Metatarsophalangeal Joints, a Novel Feature of RA: Results from an Anatomical and Large Magnetic Resonance Imaging Study of Tendon Sheaths of the Forefoot

9:00AM-11:00AM: Abstract Number: 2174

Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials

9:00AM-11:00AM: Abstract Number: 2506

The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2252

The #Worldlupusday 2019 Across Twitter: An Explorative Analysis of Spreading Concepts and Sentiment Perceptions on Social Media

9:00AM-11:00AM: Abstract Number: 2645

The Anteromedial Ultrasound Examination of the Large Supraaortic Vessels Identifies Higher Rates of Large Vessel Involvement Than Previous Reported in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2425

The anti-Ro52 Prevalence in the Sjögren’s Syndrome Picture: A Single Center Cross Sectional Study

9:00AM-11:00AM: Abstract Number: 2657

The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2323

The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2501

The Association Between Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2267

The Association Between Non-restorative Sleep and Diurnal Patterns of Cognitive Function and Fatigue in People with Fibromyalgia and Matched Controls

9:00AM-11:00AM: Abstract Number: 2188

The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2073

The Association of Serum Uric Acid Levels and the Risk of Lower Urinary Tract Symptoms in Korean Healthy Adults

9:00AM-11:00AM: Abstract Number: 2703

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices

9:00AM-11:00AM: Abstract Number: 2105

The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids

9:00AM-11:00AM: Abstract Number: 2596

The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure

9:00AM-11:00AM: Abstract Number: 2299

The Course of Disability in Early Rheumatoid Arthritis over 10 Years of Follow-up in Women and Men – Comparison with the General Population

9:00AM-11:00AM: Abstract Number: 2638

The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2060

The Current State of Big Data Use and Artificial Intelligence in RMDs: A Systematic Literature Review Informing EULAR Recommendations

9:00AM-11:00AM: Abstract Number: 2490

The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype

9:00AM-11:00AM: Abstract Number: 2722

The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes

9:00AM-11:00AM: Abstract Number: 2400

The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry

9:00AM-11:00AM: Abstract Number: 2367

The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2392

The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2265

The Effects of Message Framing on Patients’ Perceptions and Willingness to Switch to a Biosimilar

9:00AM-11:00AM: Abstract Number: 1943

The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis

9:00AM-11:00AM: Abstract Number: 1936

The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2081

The Health-promoting Potential of Everyday Activities: Preliminary Results from an Exploratory Study of Adults with and Without Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2091

The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients

9:00AM-11:00AM: Abstract Number: 2507

The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab

9:00AM-11:00AM: Abstract Number: 2308

The Interaction Between Human Leukocyte Antigen Class II Alleles and Seroprotection to Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A post-hoc Analysis

9:00AM-11:00AM: Abstract Number: 1948

The Mechanism of DC-STAMP-Mediated Signaling in Cell-Cell Fusion and Osteoclast Maturation

9:00AM-11:00AM: Abstract Number: 2076

The Opioid Epidemic: The Rheumatology Response to Management of Chronic Pain

9:00AM-11:00AM: Abstract Number: 1949

The p.R321C Mutation in P62 Associated with Paget’s Disease of Bone Leads to a Change of Localization of the Protein in Human Osteoclasts

9:00AM-11:00AM: Abstract Number: 2450

The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center

9:00AM-11:00AM: Abstract Number: 2452

The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients

9:00AM-11:00AM: Abstract Number: 2427

The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjogren’s Syndrome : Data from a Prospective Korean Nation-wide Cohort

9:00AM-11:00AM: Abstract Number: 1938

The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study

9:00AM-11:00AM: Abstract Number: 2071

The Prevalence of 78 Autoimmune Diseases in Catalonia (MASCAT-PADRIS Big Data Project)

9:00AM-11:00AM: Abstract Number: 1974

The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection

9:00AM-11:00AM: Abstract Number: 2442

The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)

9:00AM-11:00AM: Abstract Number: 2472

The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis

9:00AM-11:00AM: Abstract Number: 2407

The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2436

The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention

9:00AM-11:00AM: Abstract Number: 2155

The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation

9:00AM-11:00AM: Abstract Number: 1977

The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment

9:00AM-11:00AM: Abstract Number: 2284

The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development

9:00AM-11:00AM: Abstract Number: 2254

The Urge for Mobile Apps in Rheumatology – a German Patient Perspective

9:00AM-11:00AM: Abstract Number: 2281

The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years

9:00AM-11:00AM: Abstract Number: 2656

The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy

9:00AM-11:00AM: Abstract Number: 2135

Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 2432

Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts

9:00AM-11:00AM: Abstract Number: 2129

Thyroperoxidase Antibodies in Patients with Positive ANA

9:00AM-11:00AM: Abstract Number: 2518

Time to Lupus Low Disease Activity State: Role of African-American Ethnicity

9:00AM-11:00AM: Abstract Number: 2047

Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain

9:00AM-11:00AM: Abstract Number: L10

Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2679

Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous

9:00AM-11:00AM: Abstract Number: 2681

Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone

9:00AM-11:00AM: Abstract Number: L14

Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance

9:00AM-11:00AM: Abstract Number: 2418

Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2085

Too Soon to Say: Promising Results from a Community-Delivered RCT Examining Work-Related Outcomes of the Chronic Disease Self-Management Program

9:00AM-11:00AM: Abstract Number: 2322

Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness

9:00AM-11:00AM: Abstract Number: 2601

Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 1951

Transcriptomic Responses in CD4+ T Cells During Successful Therapy for Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2078

Transitions in Lumbar Spine Osteoarthritis: The Johnston County Osteoarthritis Project

9:00AM-11:00AM: Abstract Number: 2389

Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed

9:00AM-11:00AM: Abstract Number: 2337

Treat to Target Is Not Linked to Best Myocardial Strain Indices: Is There Really a Myocardial Dysfunction Directly Associated with Disease Activity?

9:00AM-11:00AM: Abstract Number: 2383

Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed

9:00AM-11:00AM: Abstract Number: 2340

Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2520

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial

9:00AM-11:00AM: Abstract Number: 2369

Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2691

Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2266

Treatment Preferences in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2343

Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease

9:00AM-11:00AM: Abstract Number: 2202

Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014

9:00AM-11:00AM: Abstract Number: 1934

Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2097

Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1933

Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1944

Two Biomarkers with Predictive Capacity to Diagnosis Pre-Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2373

Two Decades of Changes in RA Treatment and Disease Outcomes from the United States

9:00AM-11:00AM: Abstract Number: 2672

Ultrasonography in the Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2607

Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2644

Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2083

Understanding Knee Function and Symptom Management in Individuals with Risk Factors for Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2037

Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity

9:00AM-11:00AM: Abstract Number: 2251

Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 2479

Unmet Treatment Needs in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2629

Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2637

Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2059

Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2394

Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit

9:00AM-11:00AM: Abstract Number: 2462

Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2412

Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2410

Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable

9:00AM-11:00AM: Abstract Number: 2711

Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2481

Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center

9:00AM-11:00AM: Abstract Number: 2338

Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2510

Validation of the Modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) as a Tool to Assess Axial PsA

9:00AM-11:00AM: Abstract Number: 2551

Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2456

Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis

9:00AM-11:00AM: Abstract Number: 2104

Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process

9:00AM-11:00AM: Abstract Number: 2683

Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2534

Vitamin D Reduces Cardiovascular Risk Factors in SLE

9:00AM-11:00AM: Abstract Number: 2211

What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT- scan in Patients with Ankylosing Spondylitis?

9:00AM-11:00AM: Abstract Number: 2244

What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?

9:00AM-11:00AM: Abstract Number: 2511

What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study

9:00AM-11:00AM: Abstract Number: 2186

What Is an Important Difference in Gait Speed in Adults with Knee Osteoarthritis?

9:00AM-11:00AM: Abstract Number: 1979

What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling

9:00AM-11:00AM: Abstract Number: 2088

When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis

9:00AM-11:00AM: Abstract Number: 2402

Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 1962

Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs

9:00AM-11:00AM: Abstract Number: 2084

Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017

9:00AM-11:00AM: Abstract Number: 2351

Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis

9:00AM-11:00AM: Abstract Number: 2525

Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2384

Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2429

Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae

11:00AM-12:30PM: Abstract Number: 2731

Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid

11:00AM-12:30PM: Abstract Number: 2730

Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease

11:00AM-12:30PM: Abstract Number: 2728

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

11:00AM-12:30PM: Abstract Number: 2729

Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial

11:00AM-12:30PM: Abstract Number: 2727

Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis

11:00AM-12:30PM: Abstract Number: 2732

The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations

2:30PM-4:00PM: Abstract Number: 2776

5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort

2:30PM-4:00PM: Abstract Number: 2760

A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

2:30PM-4:00PM: Abstract Number: 2771

A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate

2:30PM-4:00PM: Abstract Number: 2778

Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)

2:30PM-4:00PM: Abstract Number: 2784

Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients

2:30PM-4:00PM: Abstract Number: 2744

Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis

2:30PM-4:00PM: Abstract Number: 2765

Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2755

Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy

2:30PM-4:00PM: Abstract Number: 2754

AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria

2:30PM-4:00PM: Abstract Number: 2785

Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications

2:30PM-4:00PM: Abstract Number: 2761

Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial

2:30PM-4:00PM: Abstract Number: 2768

Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2743

Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis

2:30PM-4:00PM: Abstract Number: 2772

Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet

2:30PM-4:00PM: Abstract Number: 2757

Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)

2:30PM-4:00PM: Abstract Number: 2774

Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort

2:30PM-4:00PM: Abstract Number: 2782

Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications

2:30PM-4:00PM: Abstract Number: 2748

Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk

2:30PM-4:00PM: Abstract Number: 2750

Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis

2:30PM-4:00PM: Abstract Number: 2738

Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis

2:30PM-4:00PM: Abstract Number: 2746

Dimethyl Fumarate Ameliorates the GATA6 Deficiency-Induced Pulmonary Hypertension by Normalizing Oxidative and ER Stress

2:30PM-4:00PM: Abstract Number: 2799

Does Early Anterior Cruciate Ligament Reconstruction Prevent Further Meniscal Damage? Secondary Analysis of a Randomized Controlled Trial

2:30PM-4:00PM: Abstract Number: 2803

Efficacy of a 3-Month Wearable-enabled Physical Activity Counselling Program for People with Knee Osteoarthritis

2:30PM-4:00PM: Abstract Number: 2797

Exploring Possible Predictors of Physical Activity in Knee Replacement Patients

2:30PM-4:00PM: Abstract Number: 2800

Five Year Structural Changes in Patients with Meniscal Tear and Osteoarthritis from an RCT of Arthroscopic Partial Meniscectomy vs. Physical Therapy

2:30PM-4:00PM: Abstract Number: 2737

HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2802

High Intensity Interval Training for Knee Osteoarthritis: A Pilot Study

2:30PM-4:00PM: Abstract Number: 2779

Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors

2:30PM-4:00PM: Abstract Number: 2783

Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous

2:30PM-4:00PM: Abstract Number: 2747

Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis

2:30PM-4:00PM: Abstract Number: 2780

Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation

2:30PM-4:00PM: Abstract Number: 2745

Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop

2:30PM-4:00PM: Abstract Number: 2767

Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed

2:30PM-4:00PM: Abstract Number: 2773

Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier

2:30PM-4:00PM: Abstract Number: 2733

Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus

2:30PM-4:00PM: Abstract Number: 2741

Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States

2:30PM-4:00PM: Abstract Number: 2749

Long Non-coding RNA HOTAIR Induces Myofibroblast Activation in Systemic Sclerosis Through EZH2 Dependent De-repression of NOTCH Signalling Pathway Activation

2:30PM-4:00PM: Abstract Number: 2788

Longitudinal Changes in the Nasal Microbiome and Disease Activity in Patients with Granulomatosis with Polyangiitis

2:30PM-4:00PM: Abstract Number: 2753

Major Salivary Gland Ultrasound: Pilot Study of Findings and Feasibility in Childhood-Onset Systemic Lupus Erythematosus (cSLE)

2:30PM-4:00PM: Abstract Number: 2764

Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2793

Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives

2:30PM-4:00PM: Abstract Number: 2736

Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus

2:30PM-4:00PM: Abstract Number: 2789

Neutrophil Extracellular Traps Induce Tissue-Invasive Macrophages in Granulomatosis with Polyangiitis Dominated by Ear, Nose and Throat Manifestations

2:30PM-4:00PM: Abstract Number: 2758

Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis

2:30PM-4:00PM: Abstract Number: 2801

Optimal Threshold of Walking Speed Predictive of Mortality Risk over 9 Years in Knee Osteoarthritis: Data from Osteoarthritis Initiative

2:30PM-4:00PM: Abstract Number: 2766

Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Discrete-Choice Experiment

2:30PM-4:00PM: Abstract Number: 2795

Patterns of Ambulatory Health Care Utilization and Medication Adherence Among Transition-Age Youth with Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2790

Platelet Mediates Neutrophil Extracellular Traps Formation via TLR Signaling in ANCA-associated Vasculitis

2:30PM-4:00PM: Abstract Number: 2794

Predictors of Incident and Worsening Lumbar Spine Degeneration: The Johnston County Osteoarthritis Project

2:30PM-4:00PM: Abstract Number: 2787

Predictors of Renal Involvement in ANCA-Associated Vasculitis

2:30PM-4:00PM: Abstract Number: 2775

Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort

2:30PM-4:00PM: Abstract Number: 2786

Renal Histopathological Classifications Predict the Renal Outcomes of Plasma Exchange-Treated ANCA-Associated Vasculitides with Renal Failure

2:30PM-4:00PM: Abstract Number: 2735

Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis

2:30PM-4:00PM: Abstract Number: 2781

Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study

2:30PM-4:00PM: Abstract Number: 2734

Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2739

Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis

2:30PM-4:00PM: Abstract Number: 2759

Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy

2:30PM-4:00PM: Abstract Number: 2756

Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

2:30PM-4:00PM: Abstract Number: 2752

Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging

2:30PM-4:00PM: Abstract Number: 2740

Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex

2:30PM-4:00PM: Abstract Number: 2796

The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort

2:30PM-4:00PM: Abstract Number: 2792

The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis

2:30PM-4:00PM: Abstract Number: 2769

The Pre-Treatment Gut Microbiome Predicts Early Response to Methotrexate in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2762

The Preparation and Recovery Experience from Total Knee Replacement of Patients with Osteoarthritis: A Qualitative Study

2:30PM-4:00PM: Abstract Number: 2742

Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures

2:30PM-4:00PM: Abstract Number: 2770

Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission

2:30PM-4:00PM: Abstract Number: 2798

Trajectories of Opioid Filling Patterns After Total Knee Replacement

2:30PM-4:00PM: Abstract Number: 2791

Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review

2:30PM-4:00PM: Abstract Number: 2751

Very Low Prevalence of Ultrasound Determined Tendon Abnormalities in Healthy Subjects Throughout the Age Range: An Outcome Measures in Rheumatology (OMERACT) Ultrasound Minimal Disease Study

2:30PM-4:00PM: Abstract Number: 2763

What Disease Do You Have? – Assessment and Predictors of Accurate Illness Naming in Rheumatology

2:30PM-4:00PM: Abstract Number: 2777

What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts

4:00PM-6:00PM: Abstract Number: L20

A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks

4:00PM-6:00PM: Abstract Number: L18

A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study

4:00PM-6:00PM: Abstract Number: L17

Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

4:00PM-6:00PM: Abstract Number: L19

Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

4:00PM-6:00PM: Abstract Number: L21

Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study

4:00PM-6:00PM: Abstract Number: L22

Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study

4:30PM-6:00PM: Abstract Number: 2835

A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout

4:30PM-6:00PM: Abstract Number: 2841

A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis

4:30PM-6:00PM: Abstract Number: 2812

A New Role for Selectins in Systemic Lupus Erythematosus

4:30PM-6:00PM: Abstract Number: 2807

Activation of the STING Pathway Is a Shared Feature of Salivary Gland and Lung Inflammation in Sjogren’s Syndrome

4:30PM-6:00PM: Abstract Number: 2816

An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium

4:30PM-6:00PM: Abstract Number: 2824

Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)

4:30PM-6:00PM: Abstract Number: 2834

Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study

4:30PM-6:00PM: Abstract Number: 2839

Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts

4:30PM-6:00PM: Abstract Number: 2837

Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes

4:30PM-6:00PM: Abstract Number: 2820

Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production

4:30PM-6:00PM: Abstract Number: 2855

Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program

4:30PM-6:00PM: Abstract Number: 2821

Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease

4:30PM-6:00PM: Abstract Number: 2831

Cracks in Your Referral Process? Find Your Sustainable Solution Here

4:30PM-6:00PM: Abstract Number: 2857

Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors

4:30PM-6:00PM: Abstract Number: 2854

Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort

4:30PM-6:00PM: Abstract Number: 2822

Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women

4:30PM-6:00PM: Abstract Number: 2818

Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 2836

Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank

4:30PM-6:00PM: Abstract Number: 2810

Does Loss-of-function Variants in SAT1 Cause X-linked Pediatric Lupus?

4:30PM-6:00PM: Abstract Number: 2856

Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register

4:30PM-6:00PM: Abstract Number: 2850

Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry

4:30PM-6:00PM: Abstract Number: 2828

Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams

4:30PM-6:00PM: Abstract Number: 2829

Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk

4:30PM-6:00PM: Abstract Number: 2851

Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations

4:30PM-6:00PM: Abstract Number: 2808

Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block

4:30PM-6:00PM: Abstract Number: 2815

Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus

4:30PM-6:00PM: Abstract Number: 2817

Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 2814

Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE

4:30PM-6:00PM: Abstract Number: 2805

Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls

4:30PM-6:00PM: Abstract Number: 2804

Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration

4:30PM-6:00PM: Abstract Number: 2846

Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)

4:30PM-6:00PM: Abstract Number: 2845

Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)

4:30PM-6:00PM: Abstract Number: 2842

Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control

4:30PM-6:00PM: Abstract Number: 2813

Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis

4:30PM-6:00PM: Abstract Number: 2844

Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease

4:30PM-6:00PM: Abstract Number: 2823

Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting

4:30PM-6:00PM: Abstract Number: 2825

Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use

4:30PM-6:00PM: Abstract Number: 2849

Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR

4:30PM-6:00PM: Abstract Number: 2840

Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy

4:30PM-6:00PM: Abstract Number: 2826

Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study

4:30PM-6:00PM: Abstract Number: 2843

Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects

4:30PM-6:00PM: Abstract Number: 2848

Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)

4:30PM-6:00PM: Abstract Number: 2852

Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies

4:30PM-6:00PM: Abstract Number: 2833

Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients

4:30PM-6:00PM: Abstract Number: 2806

Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis

4:30PM-6:00PM: Abstract Number: 2809

Single-Cell RNA Sequencing of Murine Neutrophils Identifies a Transcriptional Continuum (“Neutrotime”) Across Biological Compartments

4:30PM-6:00PM: Abstract Number: 2847

Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA

4:30PM-6:00PM: Abstract Number: 2838

The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout

4:30PM-6:00PM: Abstract Number: 2811

The IRE1α Pathway Mediates Neutrophil Stress and NETosis in Lupus

4:30PM-6:00PM: Abstract Number: 2853

The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound

4:30PM-6:00PM: Abstract Number: 2819

The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells

4:30PM-6:00PM: Abstract Number: 2830

Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study

4:30PM-6:00PM: Abstract Number: 2832

Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target

4:30PM-6:00PM: Abstract Number: 2827

Weight Fluctuation and Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 2869

Access to Care and Diagnostic Delays in Juvenile Dermatomyositis

9:00AM-10:30AM: Abstract Number: 2871

Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study

9:00AM-10:30AM: Abstract Number: 2885

An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases

9:00AM-10:30AM: Abstract Number: 2873

Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland

9:00AM-10:30AM: Abstract Number: 2865

Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States

9:00AM-10:30AM: Abstract Number: 2868

Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study

9:00AM-10:30AM: Abstract Number: 2887

Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 2859

Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA

9:00AM-10:30AM: Abstract Number: 2884

Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years

9:00AM-10:30AM: Abstract Number: 2874

Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry

9:00AM-10:30AM: Abstract Number: 2891

Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs

9:00AM-10:30AM: Abstract Number: 2888

Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions

9:00AM-10:30AM: Abstract Number: 2881

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

9:00AM-10:30AM: Abstract Number: 2875

Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs

9:00AM-10:30AM: Abstract Number: 2864

Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies

9:00AM-10:30AM: Abstract Number: 2879

Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients

9:00AM-10:30AM: Abstract Number: 2866

Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus

9:00AM-10:30AM: Abstract Number: 2889

From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications

9:00AM-10:30AM: Abstract Number: 2876

Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients

9:00AM-10:30AM: Abstract Number: 2862

Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner

9:00AM-10:30AM: Abstract Number: 2863

Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation

9:00AM-10:30AM: Abstract Number: 2893

Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation

9:00AM-10:30AM: Abstract Number: 2861

Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA

9:00AM-10:30AM: Abstract Number: 2892

Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients

9:00AM-10:30AM: Abstract Number: 2867

Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 2870

Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response

9:00AM-10:30AM: Abstract Number: 2860

Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease

9:00AM-10:30AM: Abstract Number: 2886

Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries

9:00AM-10:30AM: Abstract Number: 2882

Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life

9:00AM-10:30AM: Abstract Number: 2878

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

9:00AM-10:30AM: Abstract Number: 2872

Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database

9:00AM-10:30AM: Abstract Number: 2877

Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis

9:00AM-10:30AM: Abstract Number: 2880

Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial

9:00AM-10:30AM: Abstract Number: 2883

Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases

9:00AM-10:30AM: Abstract Number: 2890

The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study

9:00AM-10:30AM: Abstract Number: 2858

The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model

11:00AM-12:30PM: Abstract Number: 2911

A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy

11:00AM-12:30PM: Abstract Number: 2901

Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience

11:00AM-12:30PM: Abstract Number: 2916

Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population

11:00AM-12:30PM: Abstract Number: 2928

Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease

11:00AM-12:30PM: Abstract Number: 2929

Cannabis Use Among Patients in a Large US Rheumatic Disease Registry

11:00AM-12:30PM: Abstract Number: 2894

CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity

11:00AM-12:30PM: Abstract Number: 2907

Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response

11:00AM-12:30PM: Abstract Number: 2923

Clinical Subsets in Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2920

Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2895

Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis

11:00AM-12:30PM: Abstract Number: 2903

Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission

11:00AM-12:30PM: Abstract Number: 2927

Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative

11:00AM-12:30PM: Abstract Number: 2906

DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial

11:00AM-12:30PM: Abstract Number: 2924

Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?

11:00AM-12:30PM: Abstract Number: 2909

Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

11:00AM-12:30PM: Abstract Number: 2919

Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

11:00AM-12:30PM: Abstract Number: 2898

Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis

11:00AM-12:30PM: Abstract Number: 2917

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017

11:00AM-12:30PM: Abstract Number: 2921

High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2922

Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis

11:00AM-12:30PM: Abstract Number: 2910

Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning

11:00AM-12:30PM: Abstract Number: 2897

Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials

11:00AM-12:30PM: Abstract Number: 2900

Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20

11:00AM-12:30PM: Abstract Number: 2926

Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach

11:00AM-12:30PM: Abstract Number: 2915

Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway

11:00AM-12:30PM: Abstract Number: 2918

Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis

11:00AM-12:30PM: Abstract Number: 2912

Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study

11:00AM-12:30PM: Abstract Number: 2914

Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early DiagnOsis of Systemic Sclerosis (VEDOSS)

11:00AM-12:30PM: Abstract Number: 2908

Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study

11:00AM-12:30PM: Abstract Number: 2905

Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial

11:00AM-12:30PM: Abstract Number: 2904

Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD

11:00AM-12:30PM: Abstract Number: 2913

Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)

11:00AM-12:30PM: Abstract Number: 2925

The Effects of Leisure Time Sitting and Sitting at Work on Worsening Radiographic Knee Osteoarthritis over Two Years: Data from the Osteoarthritis Initiative

11:00AM-12:30PM: Abstract Number: 2896

The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?

11:00AM-12:30PM: Abstract Number: 2902

The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease

11:00AM-12:30PM: Abstract Number: 2899

Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].